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Kindlin-1 is a focal adhesion (FA) protein and the founding member of the Kindlin 
family of proteins (Kindlins 1-3), which all have an important role in integrin signalling. 
Loss of functional Kindlin-1 has been associated with a congenital disease called 
Kindler syndrome that is characterised by a number of skin abnormalities including 
atrophy and blistering. Increased or decreased expression of the Kindlin family of 
proteins has been linked to a number of tumour types and Kindlin-1 is specifically 
associated with pulmonary metastasis in basal-like breast cancer. The mechanisms 
by which Kindlin-1 mediates metastasis to the lungs in breast cancer remain relatively 
unknown and this study aimed to investigate the role of Kindlin-1 in breast cancer. In 
line with previous reports, we have shown that Kindlin-1 regulates primary breast 
tumour formation. Our data suggest that the interaction of Kindlin-1 with integrins is 
specifically important for tumour initiation. 
The Kindlins have also been shown to have roles independent of integrin and have 
been found outside of focal adhesions; Kindlin-2 has been shown to have a nuclear 
localisation signal (NLS) and initial studies have identified a nuclear role for Kindlin-2 
in the promotion of breast cancer, however, nuclear roles of the Kindlins remain 
mostly unexplored. We explored a potential nuclear role for Kindlin-1 and revealed a 
novel cellular location for Kindlin-1 in cancer cells. We show that Kindlin-1 is present 
in the nucleus of breast cancer and squamous cell carcinoma cells and that Kindlin-1 
has an NLS that can be altered to prevent protein localisation to the nucleus. 
Furthermore, we show that presence of Kindlin-1 in the nucleus is important for 
primary tumour growth and mice inoculated with cells that express mutant Kindlin-1 
that cannot localise to the nucleus, have significantly lower tumour growth compared 
to mice inoculated with cells expressing wild-type Kindlin-1. We also provide 
evidence that the immune system impacts on the Kindlins ability to regulate tumour 
growth. Specifically, Kindlin-1 was shown to inhibit IL-6 production, which promotes 
differentiation of naïve CD4+ T cells into Tregs and results in tumour development 




are particularly interesting as the FA protein FAK has previously been reported to 
have an immune-modulatory role in the nucleus of squamous cell carcinoma cells 
through regulation of the transcription of inflammatory cytokines and chemokines. 
Our data suggest that Kindlin-1 may also have similar important roles in the nucleus 
that warrants further investigation. As Kindlin-1 does not have catalytic activity, 
further studies are warranted to investigate the nuclear roles of Kindlin-1 and the 
interaction of Kindlin-1 with the immune system, as understanding these roles may 
offer new avenues for therapeutic intervention. 
Very few binding partners have been identified for the Kindlin family and known 
binding partners include phosphoinositides and some focal adhesions proteins such 
as integrin-linked kinase (ILK) and migfilin. We carried out proteomic analyses and 
identified a number of novel binding partners of Kindlin-1 in different breast cancer 
cell models. Our findings suggest that Kindlin-1 is an adaptor protein in the cell that 
regulates a number of key signalling hubs, which control several cellular processes 
















Lay Reader Summary  
 
Breast cancer is the most common type of cancer diagnosed in women worldwide. 
Most breast cancer deaths are a result of the spread of cancer from the breast to 
other parts of the body. Increased levels of Kindlin-1, a protein involved in cell 
contacts with their environment, has been associated with breast cancer and its 
spread to the lungs. How Kindlin-1 promotes breast cancer is mostly unknown. The 
aim of our study was to explore the role of Kindlin-1 in breast cancer.  
We wanted to understand when Kindlin-1 is important in breast cancer growth and 
spread. We found when the production of Kindlin-1 was stopped, tumour growth was 
reduced. Our research has shown that when tumours are first growing, Kindlin-1 
helped tumours to grow by interacting with other proteins involved in cell to cell 
contacts called integrins. However, once tumours were established Kindlin-1 helped 
tumours to grow without using integrins. We also found evidence that Kindlin-1 may 
be involved in controlling the immune system. The immune system is important for 
slowing or preventing tumour growth and so this interaction is important.  
Kindlin-1 has not been shown to interact with many proteins other than integrins. We 
aimed to identify new interactions that might be important in the progression and 
spread of breast cancer. We identified a number of proteins that interact with 
Kindlin-1 in breast cancer cells. Our findings suggest Kindlin-1 interacts with a number 
of different proteins, linking Kindlin-1 to cellular processes including cell movement, 
death and proliferation of cells. 
Another protein that has similar roles to Kindlin-1, Kindlin-2, has been found in the 
nucleus in breast cancer. We identified that Kindlin-1 contains a signal that tags it for 
transportation into the nucleus and that Kindlin-1 was able to move into the nucleus 
of cancer cells. We demonstrated that cancer growth reduces when Kindlin-1 was 
prevented from moving to the nucleus. We, therefore, suggest that Kindlin-1 might 
control which genes are used by tumour cells in order to grow. Further studies should 




system. Understanding these roles may identify specific targets for drugs to be more 
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1.1 Breast Cancer 
Breast cancer is the most common type of cancer diagnosed in women worldwide 
and is responsible for 7% of all cancer related deaths in the UK (1). The disease can 
be ductal or lobular in origin and 80% of invasive ductal carcinoma accounts for 
diagnosed breast cancer cases (2). Invasive breast cancer has been classified into both 
histological and intrinsic molecular subtypes, owed to the complexity and 
heterogeneity of the disease (3). Broadly, breast cancer has been classified into four 
molecular subtypes and these include: luminal A, luminal B, HER2-enriched, basal-
like (Table 1), which have been identified by techniques such as 
immunohistochemistry (IHC) and gene expression profiling (4–6). Treatment for 
patients with cancer has been stratified using a number of factors including tumour 
morphology and grade classification, tumour size, presence of lymph node 
metastases, and expression of estrogen (ER), progesterone (PR) and human 
epidermal growth factor receptor 2 (HER2) receptors. 
 
Table 1. Intrinsic molecular subtypes of invasive breast cancer 
Intrinsic Subtype Protein Expression Profile 
Luminal A ER+ and/or PR+, HER2-, Ki67- 
Luminal B ER+ and/or PR+, HER2±, Ki67+ 
HER2 over-expression ER-, PR-, HER2+ 
Basal-like or Triple Negative ER-, PR-, HER2-, basal marker + 
ER- oestrogen receptor; HER2- human epidermal growth factor receptor 2; PR- progesterone receptor 
  
The ER and PR hormone receptors have been known to drive progression of cancer 
for some time and up to 80% of breast cancers are identified as ER-positive (7) 
whereas, 55-65% are PR-positive (8). The luminal A and B subtypes display hormone 




negative subtypes because hormone therapy can be used to treat these tumour types 
(1). As well as receptor status, the marker of cell proliferation, Ki67 is used to 
categorise luminal A and B tumours and high levels of Ki67 are associated with worse 
outcome (9,10). Luminal A has been associated with 30-40% of invasive breast 
cancers and luminal B HER2- with 20-30% of cases (11).  
 
The HER2 subtype, which accounts for 15-20% of breast cancers (2,12), is 
characterised by high levels of a transmembrane tyrosine kinase receptor that 
regulates cell growth, proliferation and survival via signalling pathways including 
mTOR and RAS/RAF/MEK/ERK (13). Tumours of this molecular subtype respond to 
anti-HER2 therapy and agents that target HER2 and these include: receptor tyrosine 
kinase inhibitors and humanised monoclonal antibodies that bind to the extracellular 
domain of HER2 receptors. 
 
The basal-like or triple negative subtype of breast cancer (TNBC) is characterised by 
lack of expression of hormone receptors or HER2 and high expression of basal 
markers (e.g. keratins 5, 6, 14, 17) (4,14). These account for 15-20% of breast cancer 
cases and have the worst survival rates compared with other subtypes (11). A study 
showed that the 5-year survival rate for patients in the TNBC subgroup was 77% 
whilst the 5-year survival was 93% for non-TNBC patients (15). While treatments exist 
for receptor positive subtypes of breast cancer, there are no treatments to 
specifically target TNBC. Treatment is limited to surgery, radiation and 
chemotherapy, however, some breast cancers with the BRCA 1 or 2 mutation have a 
basal/TNBC pathology and respond better to cisplatin-based chemotherapy and 
breast cancer poly(ADP-ribose) polymerase (PARP) inhibitors when compared to 
BRCA wild-type tumours (16,17). 
 
Although there have been advances in diagnosis and treatment as a result of our 




and other complications related with breast cancer are a result of the development 
of incurable metastatic disease (18). In fact, over 90% of cancer-related death is a 
result of metastatic disease (19). Breast cancer typically metastasises to the brain, 
bones, liver or lungs (20). Approximately 30% of breast cancer patients develop 
recurrences in distant organs despite successful treatment of the primary tumour 
(21). Recurrences often occur years after the primary tumour is diagnosed, which 
suggests that patients carry dormant tumour cells that later progress to become 
metastases (Fig. 1A) (21). There have been several hypotheses to describe how 
tumour cells survive and remain in a dormant state then later become reactivated 
and form macrometastases. The mechanisms of dormancy include cellular dormancy 
(Fig. 1B), insufficient angiogenic potential (Fig. 1C), active immune surveillance (Fig. 
1D), lack of tumour cell adhesion to the extracellular matrix (ECM) and interaction 
with stromal cells, which secrete anti-proliferative factors (22,23).  
 
 
Figure 1. Mechanisms of cancer cell dormancy. (A) Cell that acquire genetic and epigenetic changes 
form a primary tumour (solid blue line), which regresses following treatment. A very small number of 
cancer cells that remain in the body after treatment (dashed blue line) and tumours can remerge again 
in a distant organ (dashed red line) months, years or even decades after remission. Cancer cell 
dormancy can manifest as a result of (B) Cellular dormancy, where cells enter G0–G1 arrest and are 
quiescent. (C) Angiogenic dormancy. Pro- and anti-angiogenic factors such as vascular endothelial 
growth factor (VEGF) and thrombospondin (TSP) can result in insufficient angiogenic potential. 
Oncogenic Ras can induce VEGF and repress TSP, whereas, the stress-activated kinase p38 and the 




by to cytotoxic CD8+ T lymphocytes or anti-idiotypic antibodies against the B-cell receptor can prevent 
cancer cell proliferation. Adapted from (24). 
 
 
1.2 Cancer stem cells  
The cancer stem cell theory suggests that a small subpopulation of tumour cells (1-
5%) described as cancer stem cells (CSCs), are the origin of most human tumours (Fig. 
2A) (25). The CSC concept is based on the idea that the subpopulation of tumour cells 
(CSCs) have the ability to self-renew, differentiate and sustain the population of 
cancer cells in the same way that normal stem cells (NSCs) renew tissues and organs 
in the body (Fig. 2B). This concept stems from studies in acute myeloid leukaemias 
(26). A minority of human leukaemia cells expressing markers similar to normal 
hematopoietic stem cells have been shown to give rise to acute myeloid leukaemia 
in non-obese diabetic severe combined immune deficient (NOD SCID) mice whilst 
after transplantation, a large proportion of the population of tumour cells failed to 
engraft and initiate disease (Fig. 2B) (26,27). It has also been shown that cells which 
initiate leukaemias, have the ability to generate cells that lose their capacity to 
initiate disease, which recaptures the cellular heterogeneity of leukaemia and 
demonstrates a functional hierarchy (26). CSC or tumour-initiating activity has been 
illustrated in multiple tumour types including breast, lung and colon (25,28,29). In a 
breast cancer model, engrafted mesenchymal stem cells (MSCs) cause otherwise 
weakly metastatic human breast cancer cells to enhance their metastatic potential 








Figure 2. The cancer stem cell theory. (A) A subpopulation of tumour cells (CSCs) have the ability to 
self-renew and differentiate. (B) This population of CSCs has the capacity to generate a tumour across 
a number of serial passages in mice. Reproduced from (31). 
 
The CSC theory assumes the population of CSCs are responsible for sustained tumour 
growth and that cancer stem cells are accountable for relapse following cancer 
treatment. CSCs may have increased drug and chemotherapy resistance compared to 
differentiated tumour cells and may also express anti-apoptotic genes unlike 
differentiated cells (32). Although surgery, radiation, chemotherapy and anti-cancer 
drugs may either eliminate the signs of cancer or shrink tumour size, if the cancer 
stem cells are not eradicated, the tumour may remerge or grow back and CSCs may 
also drive the formation of metastases at distant sites due to their self-renewal 
capabilities (33). Hence, metastatic breast cancer mortality also remains high due to 






1.2.1 Markers of breast cancer stem cells 
Several markers that have been characterised for breast CSCs have high overlap with 
markers of normal mammary stem cells (MaSCs). The cell surface markers of breast 
CSCs have been determined through in vivo experiments in which human breast 
cancer cells are grown in immunocompromised mice. One study showed that the 
oncogenic subpopulation of cells expressed CD24-/CD44+ and only this minority of 
tumour cells could initiate new tumours (25). This population of cells were able to 
generate more CD24-/CD44+ cells as well as a population of non-oncogenic cells 
across a number of serial passages, demonstrating the ability to self-renew and also, 
generate a heterogeneous population of tumour cells (25).  
 
Cells with the cell surface markers CD24+/CD29h have been shown to expand in the 
mouse mammary tumour virus (MMTV)-Wnt-1 mouse model (35) and the Mouse 
mammary tumour virus-polyoma middle tumour-antigen (MMTV-PyMT) mouse 
model (36). Furthermore, cells with CD24+/CD49fh markers were also identified as 
responsible for generating outgrowths following mammary fat pad transplantation 
(37). Breast cancer cell lines with the BRCA1 mutation have also been shown to have 
a subpopulation of cells with CD24+/CD29h or CD24+/CD49fh cell surface markers and 
these cells displayed amplified proliferation, colony forming capacity in vitro, and 
heightened oncogenic ability in vivo (38).  
 
The markers Lgr5+ and Procr+ have been identified in CD44+ breast CSC populations 
and these are also found on the cell surface of MaSCs (39–43). Leucine-rich repeat-
containing G-protein coupled receptor 5 (LGR5)  and protein C receptor (PROCR) are 
target genes of the Wnt pathway, a pathway that is significant for initiation of 
mammary organogenesis, subsequent generation of the mammary gland and in 
breast tumorigenesis through regulation of stem cell self-renewal, expansion and 
differentiation (44,45). Overexpression of LGR5 in breast cancer is significantly linked 




catenin signalling, LGR5 promotes breast CSC self-renewal and epithelial-
mesenchymal transition (EMT) to promote carcinogenesis (Fig. 3) (42,46). EMT is a 
process which is important during development but has been linked with cancer 
progression (Fig. 4) (47). In EMT, basal epithelial cells undergo biochemical 
modifications that enable the cell to adopt a mesenchymal phenotype (47). Epithelial 
cells become motile and this leads to an invasive phenotype (47). Similarly, research 
has shown that PROCR expression also induces tumour formation and is important 
for breast CSC maintenance (48). Moreover, procr+ MaSCs have EMT signatures, 
which possibly suggests that procr+ MaSCs are precursors of breast CSCs (41).  
 
 
Figure 3. Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) promotes breast cancer 
stem cell (CSC) self-renewal and epithelial-mesenchymal transition (EMT) to promote carcinogenesis 
by activating Wnt-β-catenin signalling. Lgr5 is activated by R-spondin and has been proposed to 
recruit the LRP-frizzled receptor complex. LRP5/6 are phosphorylated and the LRP-frizzled receptor 
complex binds to Wnt ligands. Wnt signalling leads to the accumulation of β-catenin, which is 
translocated to the nucleus and binds with transcription factors (including members of the T cell-factor 
(TCF) and lymphoid enhancer-binding factor (LEF) family) to induce expression of Wnt target genes 
(including C-myc, Cyclin D1, Lgr5). This promotes tumorigenesis by activation of the cell cycle and cell 







Figure 4. Epithelial and mesenchymal cell features. During epithelial-mesenchymal transition (EMT), 
epithelial cells lose their apical-basal polarity and connections to the basement membrane. The 
process is regulated by transcription factors including; ZEB, SNAIL and TWIST, which inhibit genes that 
are related to the epithelial state (47). Cells gain mesenchymal features including the expression of 
mesenchymal markers and display front-to-back polarity. Acquisition of focal adhesions and extensive 
actin cytoskeleton reorganisation results in increased migratory and invasive capacity. This is 
reversible process that occurs both during normal development and cancer progression. Reproduced 
from (50). 
 
ALDH+ activity has been identified as a stem cell marker in both MaSCs and breast 
CSCs and increased ALDH levels in breast malignancy is a predictor of poor patient 
outcome (51). Notably, a universal signature of CSC markers has not been clearly 
defined and there are many different mutational profiles across different subtypes of 
breast malignancies, which proposes that the CSC phenotype may be tumour-type 
dependent (52).  
 
1.3 Metastasis 
Metastasis describes the spread of cancer cells from the primary tumour to the 
regional lymph nodes, and distant organs within the body which consequently results 




changes in the tumour cells and the tumour environment enable cancer cells to 
detach from the primary tumour, invade local tissues and migrate into the tumour 
stroma (53,54). During local invasion, the basement membrane is broken down and 
tumour cells invade the surrounding ECM (55). Tumour cells then enter the blood 
circulation by intravasation to migrate to distant organs. Following entry into the 
blood circulation, the tumour cells are referred to as circulating tumour cells (CTCs). 
The CTCs must avoid immune destruction, endure mechanical stress and attach to 
endothelial cells in order to undergo subsequent extravasation and colonise distant 
organs (54,56). Tumour cells are termed disseminated tumour cells (DTCs) once 
settled at a distant site and may remain dormant as either single cells or 
micrometastases for several years before developing into macrometastases (57). The 
DTCs must establish a specialised microenvironment called the metastatic niche that 
permits angiogenesis and proliferation in order to form larger macrometastases (56). 
The metastatic niche is formed by a variety of different cell types and soluble factors 
secreted by the primary tumour and cancer associated fibroblasts. The ECM is also 
thought to be important in this context as it is frequently transformed in tumours and 
is essential for development patterning, tissue reorganisation as well as the stem cell 
niche (23,58). In addition to distal metastasis or hematogenous metastasis, which has 
been described here and is defined by the dissemination of the tumour cells via the 
blood circulation, the tumour cells may enter and spread through the lymphatic 





Figure 5. The stages of metastasis. Multiple steps lead to metastasis of tumour cells. Tumour cells 
firstly undergo local invasion whereby, the basement membrane is broken down and tumour cells 
migrate into the surrounding extracellular matrix (ECM) of adjacent tissues. Tumour cells then enter 
the circulation in a step termed intravasation and are known as circulating tumour cells (CTCs). The 
CTCs travel through the blood vessels coated in platelets as either single cells or clusters of cells. In 
order to spread successfully to distant organs, the CTCs must evade destruction by the immune 
systems and survive mechanical stress. Tumour cells then undergo subsequent extravasation and 
colonise the target organ by attaching to endothelial cells. Once settled in the metastatic organ, 
tumour cells are termed disseminated tumour cells (DTCs). It is essential that the DTCs survive the 
foreign environment and form a microenvironment that permits angiogenesis and proliferation in 
order to establish micrometastases and later, form large macrometastases. Created using Inkscape 
and Servier Medical Art. 
 
1.3.1 Treating metastasis in breast cancer 
Even though the mortality rate of breast cancer has substantially declined over the 




patients with primary tumour growth and not those suffering from metastatic disease 
(19). It has been proposed that preventing metastasis may be a more effective 
strategy compared to targeting existing metastatic lesions. In order to reduce existing 
metastatic lesions, millions of tumour cells need to be targeted with radiation or a 
cytotoxic therapy, which results in cell death and tumour shrinkage. On the other 
hand, to prevent metastasis, fewer tumour cells need to be targeted and in addition 
to cytotoxic agents, cytostatic agents that inhibit tumour growth without direct 
cytotoxicity can be used (61).   
 
Adjuvant therapy has shown some success for the treatment of metastasis in breast 
cancer. Examples include the use of tamoxifen or aromatase inhibitors that treat 
hormone receptor positive breast cancer (62,63). Adjuvant therapy using these 
agents has been shown to improve disease-free survival and overall survival in 
patients (62,63). In addition, continuing the use of adjuvant tamoxifen from five to 
ten years has been shown to approximately half the mortality rate of breast cancer 
patients (64) and prolonged use was also shown to decrease tumour recurrence (65). 
Mechanistically, tamoxifen has been hypothesised to influence the 
microenvironment of tumour cells to promote dormancy and prevent metastasis 
(65). The drug trastuzumab that is used for treatment of the HER2 subtype of cancer 
is another example of adjuvant therapy which has improved overall survival and 
significantly decreased cancer recurrence in breast cancer patients (66–68). 
However, although some patients may benefit in the short-term from adjuvant 
therapies, adjuvant treatment is not always effective due to differences in the biology 
of disseminated cancer cells and the primary tumour. The disseminated tumour cells 
are able to remain clinically asymptomatic as a result of dormancy (Fig. 1) and 
dormancy enables these cells to resist targeted therapy (24,69). Importantly, some 
studies have suggested that breast cancer cells disseminate from the breast to a 
distant organ 5-7 years before initial diagnosis (70). Therefore, it has been suggested 
that inducing or maintaining dormancy of DTCs could be potential therapeutic 




proposed include targeting either DTC survival or the mechanisms of DTC drug 
resistance (71). 
 
Aguirre-Ghiso, Bragado & Sosa (72) have proposed that DTC profiling should be 
trialled in the clinic. This would involve characterising the molecular and phenotypic 
profiles of DTCs to determine which and when patients might relapse and identify 
DTC-specific mechanisms to target. As patients with DTC-positive bone marrow 
frequently have worse prognosis compared to patients with DTC-negative bone 
marrow, Aguirre-Ghiso, Bragado & Sosa (72) proposed that DTC-negative bone 
marrow patients should be monitored for DTC appearance. Moreover, the authors 
suggested that DTCs from DTC-positive patients should be profiled for proliferative 
markers. If proliferation markers are found, patients should be targeted with 
conventional anti-proliferative treatments in combination with a dormancy-inducing 
therapies (Table 2). However, if the DTCs from DTC-positive patients display 
dormancy markers then dormancy-inducing therapies could be used alone to extend 
dormancy (Table 2). There are several drugs already in the clinic that could be suitable 
to induce dormancy in DTCs (Table 2). The DNA methylation inhibitor 5-azacytidine 
has been shown to downregulate expression of cell cycle G0 to G1 exit genes 
including DNMT1 and FOXM1 (73,74). This was demonstrated in breast cancer and 
leukaemia lines and genes such as RARB and CDKN1A (genes that are upregulated in 
p38-induced dormancy) were also upregulated (73,75). This suggests that 
demethylating agents combined with RARα and RARβ agonists are a possible therapy 
for inducing tumour cell dormancy (Table 2). Retinoic acid coupled with 5-azacytidine 
has also been found to induce a dormancy phenotype in vivo similar to bone marrow 
and p38-induced dormancy (73,75,76). HDAC inhibitors have also shown promise for 







Table 2. DTC and niche markers and potential therapies for DTC-positive patients.  
Patients with disseminated tumour cell (DTC)-positive bone marrow are considered to have a poor 
prognosis (72) and therefore, DTCs from these patients could be profiled to test for proliferation 
markers (e.g. upregulation of COCO, fibronectin, periostin (POSTN), transforming growth factor-β1 
(TGFβ1) or phosphorylated ERK (P-ERK) and low expression of phosphorylated p38 (P-p38)) or 
dormancy markers (e.g. down-regulation of P-ERK, high expression of P-p38, TGFBR3, bone 
morphogenetic protein receptor type 2 (BMPR2), TGFβ2 or BMPs). If DTCs display proliferative 
markers, then DTCs could be targeted with conventional anti-proliferative drugs coupled with 
dormancy-inducing drugs. Conversely, if DTCs exhibit dormancy markers then dormancy-inducing 
drugs alone could be used. It is possible that expression profiles from DTCs might help to detect 
specific targets to eliminate DTCs. DTCs positive for interferon-γ (IFNγ) receptors may be sensitive to 
immune therapy,  chloroquine may eliminate autophagic dormant DTCs, and SRC and MEK inhibitors 
may cause the eradication of DTCs (as reviewed in (71)). 
Reproduced from (71).  
 
As previously described earlier in this chapter, tumours cells are thought to lie 
dormant until a cue within their microenvironment triggers proliferation to resume 
(Fig. 1) (78) and the term colonisation describes the outgrowth of disseminated 
tumour cells (Fig. 5). Some research into targeting metastasis has surrounded the 
colonisation stage as it is considered a promising window for treatment. By targeting 




state of dormancy is extended. There are several drugs that are either under 
development or in clinical trials that aim to target breast cancer metastasis and 
specifically, target the colonisation stage. These include inhibitors against a family of 
non-receptor tyrosine kinases called Src. Src activates a number of proteins called 
receptor tyrosine kinases, which have roles in motility survival, proliferation and 
angiogenesis (79). A role for Src in colonisation has been suggested as Src gene 
expression has been associated with onset of bone metastasis in all breast cancer 
sub-types (80). In addition, mice studies where Src expression has been depleted or 
mice have been treated with Src inhibitors has prevented the formation of breast 
cancer metastases in a range of different breast cancer mouse models (80–85). 
 
Drugs which block the ligand binding motifs of the integrin family have been shown 
to inhibit cancer cell invasion and metastasis in mouse models (86,87). The integrins 
are a family of heterodimeric cell surface transmembrane receptors formed by an 
alpha and beta subunit (Fig. 6). They participate in bidirectional signalling across the 
plasma membrane and regulate processes such as adhesion, migration and invasion 
(their role will be described in more detail later in this chapter, in 1.4.1.) (88,89). 
Cilengitide, a drug that targets αvβ3 and αvβ5 integrins may be suitable to treat bone 
metastasis as a mouse xenograft model demonstrated that osteolytic lesions form 
slower in mice treated with the drug  (90). Bone metastasis was also inhibited by a 
small molecule antagonist of αvβ3, S247, in a mouse model where mice received an 
intracardiac injection of MDA-MB-435 cells (91). 
 
Inhibitors of Focal Adhesion Kinase (FAK) are also under investigation as metastasis 
inhibitors. FAK is a non-receptor kinase that localises to focal adhesions and has 
important cell functions that are primarily through regulation of the cytoskeleton and 
through integrin mediated signalling pathways (92). Inhibition of FAK either through 
disruption of FAK expression or by using inhibitors, has been shown to prevent breast 




Fibrosis inhibitors have also shown potential for the treatment of metastasis. Fibrosis 
is a disease caused by the thickening of connective tissues due to inflammation and 
excessive production of ECM that is caused by the activation of myofibroblasts (97). 
Lysophosphatidic acid (LPA) induces fibrosis through binding to a G-protein coupled 
receptor and antagonists have been developed to target this receptor (98). Inhibition 
of the receptor for LPA, using an antagonist called Debio-0719, has also been shown 
to suppress breast cancer metastasis and induce tumour cell dormancy (99). Debio-
0719 reduced breast cancer metastasis to the liver and lungs in a 4T1 spontaneous 
metastasis model and similar results were also reported using an experimental 
pulmonary metastasis model using MDA-MB-231 cells (99). 
 
1.4 The Kindlin family  
The Kindlin family consists of three four-point-one, ezrin, radixin, moesin (FERM) 
domain-containing focal adhesion proteins, Kindlin 1-3, that share high sequence 
identity (Table 3)  (100).  Kindlin-1 and Kindlin-2 share the highest sequence similarity 
as they evolved from Kindlin-3 (Table 3) (100). Kindlin-1 is the founding member of 
the Kindlin family of proteins and was named after a loss-of-function mutation in the 
gene encoding Kindlin-1, FERMT1, was shown to cause Kindler Syndrome (101). 
Kindler syndrome is  a rare, autosomal recessive genodermatosis which causes skin 
atrophy, blistering, photosensitivity, hyper or hypo-pigmentation, increased light 
sensitivity and an enhanced risk of developing aggressive squamous cell carcinoma 
(SCC) (100,102,103).  
 
Following the finding that mutations in the FERMT1 gene cause Kindler syndrome 
(101), mutations in the FERMT3 gene that encodes Kindlin-3 were found to cause 
leukocyte adhesion deficiency (104). Kindlin-2 is not associated with inherited disease 
but loss of Kindlin-2 expression has been shown to cause embryonic lethality in mice, 
(105,106). All three of the Kindlin isoforms have been associated with acquired 




atherosclerosis (109), polycystic ovary syndrome (110), neuropathic pain (111), heart 
failure (112), osteoporosis (113) and immune deficiency (114). In addition, both 
increased and decreased expression of Kindlin proteins have also been shown to 
promote tumorigenesis in a range of different tumour types (reviewed in (115)). 
Table 3. Sequence similarity between the Kindlin family of proteins. 
 
Proteins Sequence Similarity (%) 
Kindlin-1 and Kindlin-2 62 
Kindlin-1 and Kindlin-3 49 
Kindlin-2 and Kindlin-3 53 
Kindlin-1 and Talin-1 28 
Sources: (100,116) 
 
The Kindlin proteins are differentially expressed in tissues, although, some cells may 
express more than one isoform. Kindlin-2 is ubiquitously expressed with the 
exception of haematopoietic cells and is predominantly enriched in skeletal and 
smooth muscle cells (Table 3) (117). It is also the only Kindlin isoform expressed in 
embryonic stem cells (Table 3) (106,117). Kindlin-1 is predominantly found in 
epithelial cells such as the skin, intestine and kidney whereas Kindlin-3 is primarily 
expressed in haematopoietic cells (100,117,118). Homologue-specific functions for 
each of the Kindlins in multiple signalling pathways have been identified as a result 
of differential expression in tissues and subcellular compartments (Table 4) 
(117,119). The Kindlins have conserved amino acid stretches that are presumed to 
facilitate the common functions of the family, whereas the variable regions of the 
Kindlin sequences are thought to enable the unique functions (100).  
 
 
Table 4. Expression of the Kindlin family in different cell types and tissues. 










1.4.1 Kindlin is a regulator of integrin activation  
Bladder + + - 
Brain - + - 
Colon + + - 
Embryonic stem cell - + - 
Endothelial cell - + + 
Epithelial cell + + - 
Fibroblast - + - 
Heart - + - 
Kidney + + - 
Leukocyte - - + 
Liver - + - 
Lung - + + 
Lymph node - + + 
Skeletal muscle - + - 
Skin + + - 
Small intestine + + - 
Spleen - + + 
Stomach + + - 




A number of studies have shown that loss of the Kindlin isoforms results in defective 
integrin activation and consequently, impaired integrin regulated cellular functions 
(18,29,31). The integrins are a family of heterodimeric transmembrane receptors, 
which are important for cell adhesion - they connect the cytoskeleton with the ECM 
(122,123). The integrins are composed of an α and β subunit and at least 18 α and 8 
β subunits are known (124). The α and β subunits have large extracellular domains 
that bind the ECM, a single membrane-spanning helix and a cytoplasmic tail (Fig. 6) 
(123). The cytoplasmic tail binds intracellular signalling molecules and adaptor 
proteins, which connects integirns to numerous signalling pathways and provides a 
link to the actin cytoskeleton (125).  
 
 
Figure 6. Kindlin and Talin mediate integrin activation and control integrin bidirectional signalling 
across the plasma membrane. Integrins partake in both inside-out an outside-in signalling across the 
plasma membrane, which enables many cellular processes such as ECM assembly, cell adhesion, 
migration and proliferation to occur. Kindlins cooperate with talin intracellularly to activate integrins 
by binding β-integrin tails via their four-point-one, ezrin, radixin, moesin (FERM) domains. Upon 
Kindlin and Talin binding to β-integrin tails, ‘inside-out signalling’ is initiated (left). The integrins change 
conformation from a bent inactive conformation (centre) into an extended, active high affinity state 




‘outside-in signalling’. ECM ligands such as fibronectin bind to the extracellular heads of integrins 
(right) and stimulate conformational changes which leads to integrin clustering. This triggers focal 
adhesion complex assembly of which Kindlins and Talin are key components of and leads to 
intracellular signalling. (Created using Adobe Illustrator CC 2018) 
 
Integrin activation describes the transformation of integrins from an inactive low 
affinity state to an active high affinity state and facilitates bidirectional signalling 
across the plasma membrane. Bidirectional signalling is important for diverse cellular 
processes including; ECM assembly, cell adhesion modulation, migration, 
proliferation and survival (Fig. 6) (reviewed in (126)). The integrins participate in 
‘outside-in signalling’ where ligands bind to integrin extracellular domains, 
stimulating integrin clustering and increasing integrin-ligand binding avidity 
(124,127). Subsequently, this stimulates assembly of large macromolecular 
complexes called focal adhesion (FA) complexes and activates numerous signalling 
pathways inside cells (126). The integrins also participate in ‘inside-out signalling’ 
where intracellular proteins such as Talin and Kindlin bind to β-integrin tails to 
facilitate integrin activation (128,129).  
 
A study in Caenorhabditis Elegans was the first study to propose the importance of 
the Kindlin-integrin interaction (129). A homozygous null mutation in unc-112, the 
worm ortholog of FERMT2 caused abnormal assembly of dense bodies and M lines in 
muscle cell basal membranes, which was similar to abnormalities observed for 
mutations in worm orthologues of β-integrin and an ECM component, perlecan (129). 
UNC-112 was shown to colocalise with the worm ortholog of β-integrin (PAT-3) and 
was required for localisation to the muscle membrane (129). In 2003, mutations in 
the FERMT1 gene, which encodes a human homolog of UNC-112, Kindlin-1, were 
shown to cause KS (100). However, studies that demonstrated that Kindlin was 
essential in integrin activation came much later, in 2008, when null mutations in 
FERMT3 were shown to decrease integrin activation in platelets, that still expressed 
Talin (a protein previously thought to be the only mediator of integrin activation) 
(128,130). Correspondingly, depletion of Kindlin-2 was shown to impair β-integrin 





1.4.2 Structure and function of Kindlin  
The Kindlins do not exhibit catalytic activity and have been identified as adaptor 
proteins, which bind to integrins (Fig. 6) and mediate additional protein-protein 
interactions via their FERM domains (Fig. 7) (reviewed in (131)). FERM domains are 
found in other proteins, which function to connect the plasma membrane of the cell 
with the cytoskeleton such as FAK and Talin (132). Unlike most FERM domains, which 
have subdomains F1-F3, the FERM domains of the Kindlin family have five 
subdomains; F0-F3 and a pleckstrin homology (PH) domain that transects the F2 
domain (Fig. 7) (101,133). The PH domain is a unique feature of the Kindlin FERM 
domain and binds to lipids (101). The PH domain targets the Kindlin proteins to the 
plasma membrane by binding to phosphoinositides and localises the Kindlin proteins 




Figure 7. Schematic of Kindlin FERM domain organisation and known Kindlin-binding proteins. The 
FERM domain consists of five subdomains: F0-F3 and a Pleckstrin homology (PH) domain. The coloured 
bars indicate the position where each of the known Kindlin-binding proteins bind Kindlin 1-3. Black 
lines indicate an unknown binding region. Figure created using Inkscape.    Sources:  Binding partners 
were previously reviewed in (115,131,136) and sources (137–139) were used to adapt the summary 
of the current literature surrounding the Kindlin interactors.   
 
It was previously believed that Talin was the only regulator of integrin activation but 




share a high level of sequence similarity (Table 3) and there is close sequence 
similarity between their FERM domains (Table 5) (133,141). Both Kindlin and Talin  
FERM domains have an F0 subdomain, which is important for effective integrin 
activation and has phospholipid binding sites (Fig. 8) (133,141). Mutation of F0 in 
Kindlin-2 disrupts membrane binding and prevents cooperative activation of integrin 
αIIbβ3 with Talin (142). Moreover, Chinese Hamster Ovary (CHO) cells that lack a 
Kindlin-1 F0 domain have impaired integrin activation (133). Kindlins 1-3 have similar 
F0 subdomain structures and their F0 subdomains contain a ubiquitin-like fold similar 




Table 5. Kindlin and Talin FERM domains share sequence similarity  
Domains Sequence Similarity (%) 
F0: Kindlin and Talin 36 
F1: Kindlin and Talin  55 
F2: Kindlin and Talin 50 
F3: Kindlin and talin 54 
Sources: (133,141)  
 
The F1 subdomain also has phospholipid binding sites (Fig. 8). The F1 subdomain has 
an unstructured loop with a membrane targeting motif, which is involved in targeting 
Kindlin to the focal adhesions (143). Notably, the loop in the F1 domain of Kindlin is 
at the same position as Talin (between strands of a ubiquitin-like fold) but the loop 
in the Kindlin F1 domain is much longer than the loop in the Talin F1 subdomain and 
there is little sequence similarity (143). The F1 loop is conserved between the Kindlin 
isoforms and species which, suggests an important role (143). The F1 loop has been 




Kindlin-1 and -2 were unable to activate αIIbβ3 integrin with loss of this loop with 
presence of functional Talin and conversely, Kindlin was unable to activate αIIbβ3 
integrin if Talin lacked the F1 loop (143).  
 
Both Kindlin and Talin directly interact with β-integrin cytoplasmic tails via a 
phosphotyrosine-binding (PTB)-fold located in the F3 subdomain (101,106,144,145). 
Kindlin-1 binds to β cytoplasmic tails via a conserved tryptophan and distal NxxY 
motif, whereas Talin binds via a proximal NxxY motif (Fig. 8) (146,147). Studies have 
suggested that Kindlin and Talin cooperatively regulate integrin activation as Talin 
without Kindlin or Kindlin without Talin is not sufficient to trigger integrin activation 
(Fig. 6) (104,106,148,149). 
 
Figure 8. Kindlin-1-integrin and cell membrane binding. The Kindlin proteins bind to the β-integrin 
cytoplasmic tail via the FERM F3 subdomain through a serine and/or threonine motif (1), the 
membrane distal NxxY motif (2) and the C-terminus (3). The Pleckstrin homology (PH) domain of the 
Kindlin FERM domain binds to phosphoinositides and the positively charged regions of the F0 and F1 





The F2 subdomain is fundamental to the differential functions of Kindlin-2 and 
Kindlin-3 (150). In particular, the C-terminal of the F2 subdomain supported 
localisation of Kindlin-2 but not Kindlin-3 to FAs (150). Functionally, Kindlin-3 deviates 
from Kindlin-1 and -2, which both have a key role for ECM adhesion through their 
interaction with integrins at FAs (151,152). Even though Kindlins 1-3 bind integrins, 
Kindlin-3 cannot localise to FAs, including when Kindlin-3 is present in adherent cells 
(130,145,148). Kindlin-3 does localise to podosomes, which are specialised transient 
adhesion structures in hematopoietic cells but only Kindlin-1 and -2 have been shown 
to localise to and function at FAs (117,119). The presence of a variable glycine-rich 
sequence in the C-terminal of the F2 subdomain in Kindlin-3 is partly responsible for 
differential subcellular localisation and the loss of targeting of Kindlin-3 to FAs (150). 
It has been postulated that this insertion may encode an extra site for protein binding 
or a flexible linker that inhibits its recruitment to FAs (150). This functionally may be 
important for the role of Kindlin-3 in haematopoietic cells (150). As the only Kindlin 
family member found in haematopoietic cells, it has been hypothesised that the loss 
of permanent association of Kindlin-3 at FAs might be required for Kindlin-3 to enable 
rapid adhesion in these cells (150). 
 
The Kindlins are differentially distributed when expressed in the same cell types, 
which suggests different roles within cells. For example, in endothelial cells, Kindlin-
3 was found at extending membrane areas in the cell whilst Kindlin-2 was found at 
the FAs (119). Kindlin-1 and -2 have also been shown to localise to different cell 
adhesion sites and so even though there are overlapping functions of this family of 
proteins, the Kindlin proteins have developed additional specific functional 
adaptations in different cells and tissues (117). Deletion of Kindlin-1 in a mouse model 
resulted in loss of epithelial cell adhesion to the basal membrane demonstrating that 
Kindlin-2 is unable to compensate for loss of Kindlin-1 (149). Furthermore, Kindlin-1 






Kindlin-2 has been found predominantly at FAs in epithelial cells, keratinocytes and 
breast cancer cells where its recruitment to FAs is connected to its role in cell 
spreading (153–155). In these studies Kindlin-1 does not compensate for cells 
deficient in Kindlin-2 as Kindlin-2 deficient cells have impaired spreading (153–155). 
Some of the functional differences of the Kindlin family have been associated with 
differential binding to β-integrin subunits, which connect the Kindlins with different 
cellular signalling pathways. Whilst all three of the Kindlin isoforms can bind to β1 
and β3 integrins, Kindlin-1 is the only isoform that binds β6 and it does not bind to 
β2 integrin like Kindlin-2 and -3 (Fig. 7) (106,130,145,148,149,153,156–158). Binding 
of Kindlin-1 to the β6-integrin tails is particularly important in disease, including; KS 
as epithelial cells lack Kindlin-1 and SCC as there are high levels of αvβ6 integrin and 
low levels of Kindlin-1 (153,156). Kindlin-2 cannot compensate for lack of Kindlin-1 
interaction with αvβ6 and less activation of this integrin leads to disease phenotypes 
(156). 
 
As well as functional differences, there are also functional similarities between the 
Kindlin family. In breast cancer cells, Kindlin-1 is predominantly found at the 
perinuclear region and Kindlin-2 was found in the cell periphery suggesting that 
Kindlin-2 is predominantly located at FAs (155). Kindlin-1 was shown to relocate with 
Kindlin-2 inactivation and may compensate for the functions of Kindlin-2 as 
simultaneous loss of Kindlin-1 and Kindlin-2 had severe effects on cell shapes, size 
and migration consistent with data in keratinocytes and fibroblasts (154,159), 
whereas loss of either Kindlin-1 or Kindlin-2 alone had little effect, emphasising 
redundancy (155).   
 
1.4.3 Kindlin binding partners 
In addition to binding to integrin, several other binding partners have been identified 
for the Kindlin isoforms (Fig. 7) and these interactions relate to the different Kindlin 




Kindlin-1 has been shown to bind to Sharpin and suppress β1-integrin activation in 
CHO cells (Fig. 9A) (138) and unsurprisingly, the Kindlins have been found to bind to 
other focal adhesion proteins. All three of the Kindlin isoforms bind to the focal 
adhesion protein, Integrin-Linked Kinase (ILK) (Fig. 9B) (160). Research has 
demonstrated that Kindlin-2 binds to the ILK complex through a linker region located 
within its F2 PH subdomain and this, in addition to integrin-binding (via its F3 
subdomain), is necessary for optimal Kindlin-2 accumulation at FAs (Fig. 3) (160). 
Notably, Kindlin-3 does not localise at FAs and was found to bind to ILK differently 
when compared to Kindlin-2 (160). ILK, like the Kindlin family of proteins is required 
for effective integrin signalling; mice embryos that do not express ILK are unable to 
polarise their epiblast and fail to form cavities, which leads to death at the peri-
implantation stage (161). ILK, although initially thought to have kinase activity, lacks 
key catalytic residues in its kinase domain and has therefore been coined a 
pseudokinase (162). The interaction of Kindlin with ILK will covered in more detail in 
chapter 4.  
 
Kindlin-1 and Kindlin-2 have both also been reported to bind to Migfilin (Fig. 9B) 
(118,163), a focal adhesion protein that regulates cell shape and is important in cell 
spreading (164). Interaction of Kindlin and Migfilin is thought to be important for 





Figure 9. Kindlin-1 binds focal adhesion proteins. (A) Sharpin directly binds to Kindlin-1 and β1 integrin 
cytoplasmic tails and competitively inhibits the Talin head. This leads to negative regulation of α5β1 
activation in Chinese Hamster Ovary cells. (B) Upon integrin activation, Kindlin binds to Migfilin (left) 
and Integrin-Linked Kinase (ILK) (right), which connects the integrin to the cytoskeleton and enables 
cell spreading. Adapted from (121,138). 
 
Co-immunoprecipitation experiments have confirmed binding of Kindlin-1 with Smad 
anchor for receptor activation (SARA), Smad3 and to the TGF-β receptor I (TβRI) in 
colorectal cancer cells and has linked Kindlin-1 to transforming growth factor β (TGF-
β) signalling (Fig. 10A) (165). The TGF-β pathway normally has tumour suppressor 
functions as it is involved in regulation of  the cell cycle and apoptosis but in cancer, 
its activation has been shown to promote metastasis and chemoresistance by 
inducing EMT (166,167). The interaction of Kindlin-1 with SARA, Smad3 and TβRI was 
found to mediate Smad3 phosphorylation and nuclear translocation. This resulted 





Figure 10. The Kindlins regulate a number of different signalling pathways. (A) Kindlin and TGFβ 
signalling. Kindlin-2 binds directly to TGFβ receptor I (TβRI) and promotes Smad3 phosphorylation and 
TGFβ signalling. Kindlin-1 has been shown to form a complex with TβRI, Smad3 and SARA to regulate 
TGFβ signalling. (B) Kindlins and Wnt signalling. Kindlin-1 regulates Wnt independent of integrin and 
may transcriptionally inhibit Wnt signalling by retaining transcriptional cofactors in the cytoplasm. 
Ablation of Kindlin-1 increases Wnt ligand transcription, induction of canonical Wnt signalling and 
upregulation of Wnt target genes. Kindlin-2 directly binds β-catenin, which inhibits its degradation. 
Kindlin-2 forms a complex with active β-catenin and T-cell factor 4 (TCF4), to form a transcriptional 
complex that binds to the promoter of Wnt target genes and stimulates gene expression. (C) Kindlin-
1 has been shown to be required for full activation of ERK signalling and this protect cells from 
oxidative. Kindlin-2 expression is upregulated by EGFR signalling and Kindlin-2 also forms a complex 
with Y-box binding protein-1 (YB-1) and β-catenin, and binds EGFR promoter to increase transcription 
of EGFR. Adapted from (115,131). 
 
In keratinocytes, Kindlin-1 has also been shown to bind to the cyclin-dependent 




This interaction was shown to be important to regulate cell cycle arrest in response 
to oxidative stress (137). Kindlin-1 also interacts with Polio-like kinase (Plk-1) in breast 
cancer cells and this is important for its role in mitosis (briefly discussed later in this 
chapter (1.4.5) and in more detail in chapter 4) (168).  
 
1.4.4 Integrin independent roles 
The role of the Kindlin proteins in integrin activation is most established, however, 
the Kindlins also have integrin-independent roles, which have more recently been 
recognised and these roles are still being discovered. Studies have explored integrin-
independent functions of the Kindlin family by using mutants that contain mutations 
to the QW motif that binds integrin, which is located in the F3 subdomain of the FERM 
domain. This has linked the Kindlins to a number of signalling pathways independent 
of integrin binding and these include roles in the Wnt, TGF-β and Epidermal growth 
factor receptor (EGFR) pathways.  
 
Kindlin-1 and Kindlin-2 have been shown to regulate Wnt signalling, a signalling 
pathway that regulates a number of cellular processes including angiogenesis and cell 
growth (156,169,170). The transcription of Wnt ligands and receptors was enhanced 
in keratinocytes from floxed Kindlin-1 mice and it has been hypothesised that 
mechanistically, Kindlin-1 may transcriptionally inhibit Wnt signalling by retaining 
transcriptional cofactors in the cytoplasm (Fig. 10B) (156). Re-expression of an 
integrin binding-deficient Kindlin-1 mutant demonstrated that the mechanism which 
Kindlin-1 inhibits Wnt signalling does not require integrin binding (171). Conversely, 
Kindlin-2 has been shown to enhance Wnt signalling in the nucleus and contains a 
nuclear localisation signal (NLS) that tags the protein for nuclear import (117). 
Kindlin-2 promotes Wnt signalling in breast cancer cells by binding active β-catenin 
and T-cell factor 4 (TCF4), to form a transcriptional complex that binds to the 




Interestingly, an NLS has not yet been identified for Kindlins 1 and 3 but they have 
been shown to localise to the nucleus in keratinocytes (Kindlin-1) and human 
umbilical vein endothelial cells (Kindlin-3) (118,119,156). Therefore, it is possible that 
all three Kindlin isoforms have integrin independent roles within the nucleus, which 
are yet to be recognised.   
 
In addition to Wnt, Kindlin-2 has an integrin independent role in the TGF-β signalling 
pathway, a pathway that has been linked to disease including cancer when 
deregulated (166). Kindlin-2 has also been shown to mediate TβRI and Smad3 binding 
in kidney tubular epithelial cells (Fig. 10A) (107). Reduction of Kindlin-2 expression 
suppressed the interaction of TβRI with Smad3, preventing TGF-β/Smad3 signalling 
and expression of target genes whilst overexpression of Kindlin-2 amplified TGF-β-
induced Smad3 activation (107). The regulation of TGF-β1-induced Smad3 activation 
by Kindlin-2 is integrin-independent as expression of a Kindlin-2 mutant that cannot 
bind to β1 integrin did not rescue the phenotype and knockdown of β1 did not 
recapitulate the effect that reduction of Kindlin-2 expression had (107). In 
accordance, in pancreatic ductal adenocarcinoma (PDAC) cells, a positive feedback 
loop occurs with Kindlin-2 and TGF-β expression that regulates PDAC progression 
(172). Kindlin-2 has been identified as a TGF-β target gene in PDAC and therefore, 
increased TGF-β signalling results in increased Kindlin-2 protein expression (172). 
Conversely, TβRI is upregulated by Kindlin-2, which is important for TGF-β signalling 
(172). HoxB9 and E-cadherin were downregulated as a result of TGF-β1-induced 
Kindlin-2 expression, which promoted PDAC progression (172).  
 
The EGFR signalling pathway is also promoted by Kindlin-2 and Kindlin-1 (Fig. 10C). 
Kindlin-2 forms a complex with Y-box binding protein-1 (YB-1) and β-catenin, which 
binds to the EGFR promoter to increase transcription and this also promotes 
expression of YB-1 and β-catenin (Fig. 10C) (173). In breast cancer, Kindlin-2 has also 
been shown to bind the EGFR kinase domain and prevent ubiquitination and 





In addition to roles in cellular signalling pathways, Kindlin-2 has been shown to 
control clathrin-dependent trafficking of endothelial cell-surface enzymes by directly 
interacting with clathrin via the F3 subdomain of its FERM domain (175). This 
interaction was shown to be important for haemostasis as loss of Kindlin-2 in a mouse 
model caused increased expression of adenosine triphosphate diphosphohydrolase 
and ecto-5’-nucelotidase at the surface of endothelial cells preventing platelet 
aggregation (175).  
 
1.4.5 Roles of Kindlin-1 in Kindler syndrome and the skin 
Specific cellular roles have been identified through depletion of Kindlin-1 expression 
or by using Kindlin-1 mutants that have impaired function. Loss of Kindlin-1 has been 
shown to impair integrin activation in vitro (101) and in vivo; in KS skin (176) and the 
intestinal epithelium of mice with deletion of Kindlin-1 (149). Defective integrin 
activation resulted in reduced adhesion to the integrin ligands; fibronectin and 
laminin 322 in cultivated KS keratinocytes (176–178) and caused significant adhesion 
defects in intestinal epithelial cells of mice with deletion of Kindlin-1 (149). Adhesion 
defects are likely to be connected to the skin abnormalities in KS patients such as 
atrophy, fragility and the tissue separation found within or below the basal 
keratinocyte layer (177). In addition to lethal intestinal epithelial dysfunction due to 
epithelial detachment, mice with deletion of Kindlin-1, had a severe inflammatory 
reaction, which resembled ulcerative colitis that is observed in KS patients (149). 
Kindlin-1 has also been shown to regulate the inflammatory response in the skin. In 
response to cellular stress, KS-deficient keratinocytes were found to increase the 
expression of the cytokines: IL-20, IL-24, TGF-β2, IL1F5, PDGFB, and CTGF in the 
dermis (179). Progressive fibrosis of the dermis follows inflammation in KS and 
activation of TGF-β, CTGF and IL-6 are thought to causal factors (180). These cytokines 
are important for extracellular matrix synthesis by fibroblasts and have been linked 





As well as adhesion, Kindlin has also been shown to regulate a number of other 
cellular roles in keratinocytes. Kindlin-1 was shown to regulate proliferation, polarity 
and motility (177) and defective β1-integrin function was connected to abnormal cell 
morphology, focal adhesion assembly and cell migration (178). In addition, cell 
spreading defects have been observed in cultured KS keratinocytes (178) and in 
human immortalised keratinocytes with knockdown of Kindlin-1 (101). Kindlin-1 has 
also been identified as important for regulation of mitosis although, this was reported 
in breast cancer cells not keratinocytes (168). Kindlin-1 is phosphorylated by Plk-1 at 
the centrosomes of mitotic cells and regulates mitotic spindle formation and 
orientation  (168). 
 
Research has also suggested that Kindlin-1 is linked to regulation of stem cells in the 
skin. Loss of Kindlin-1 has been shown to reduce stem cell markers in KS skin and 
lower the colony-forming capacity of keratinocytes (176). Clonogenic activity is a 
sensitive indicator of undifferentiated stem cells suggesting that Kindlin-1 is involved 
in regulation of stem cells (176). Other studies found that KS keratinocytes exhibit 
precocious senescence, decreased clonogenic activity and reduced stem cell markers 
(181). This was linked to Kindlin-1 deficiency as a similar phenotype was observed in 
normal keratinocytes with Kindkin-1 targeting siRNA (181). In addition, Kindlin-1 has 
been shown to regulate the proliferation and differentiation of cutaneous epithelial 
stem cells through two different mechanisms (156). Kindin-1 was shown to activate 
the release of TGF-β via αvβ6 integrin (Fig. 11) and also inhibit Wnt-β-catenin 
signalling through regulation of the expression of Wnt ligand via a mechanism that is 
independent of integrin (156).  It has been suggested that KS skin atrophy may be 
caused by loss of the regulation of cell stemness by Kindlin-1.  
 
KS patients have an increased risk of developing squamous cell carcinoma (SCC), 
however, little is known about the mechanisms that lead to increased risk of KS 




accelerated tumour onset and greater tumour burden, which is thought to be 
connected to the important role that Kindlin-1 has in regulating skin homeostasis 
(156).  
 
Figure 11. Kindlin-1 activates TGFβ signalling by mechanism dependent on integrin and regulate the 
proliferation and differentiation of cutaneous epithelial stem cells. Activation of αvβ6 integrin 
through Kindlin-2 binding, causes binding of αvβ6 integrin to the RD motif of the latency-associated 
peptide (LAP). LAP is associated with the latent TGFβ-binding protein (LTBP), and stimulates release of 
TGFβ, which binds to the transforming growth factor beta receptors I and II (TβRI and TβRII). 
Consequently, Smad3 is phosphorylated and forms a complex with Smad4. This complex is 
translocated to the nucleus and together with cofactors, stimulates the transcription of TGFβ target 
genes.  
 
 1.4.6 Kindlin-1 in cancer progression  
Deregulation of Kindlin expression has been reported in cancers from different 
organs and abnormal expression has been shown to inhibit and promote different 
tumour types. Kindlin-1 expression has been shown to inhibit progression of 
oesophageal cancer (182) and lung cancer (183) but promote the progression of 
pancreatic cancer (184), colorectal cancer (165) and early pulmonary breast cancer 
metastasis (185,186). Mutation of Kindlin-1 or reduction of Kindlin-1 expression has 




Kindlin-1 has also been reported as a prognostic factor for overall and disease free 
survival in hepatocellular carcinoma (188) and osteosarcoma (189).  
 
1.4.6.1 The Kindlins and breast cancer 
The Kindlin-2 isoform was the first Kindlin isoform to be associated with breast cancer 
and was linked to increased breast cancer invasion (190). Subsequently, there have 
been conflicting studies with reports of both upregulation and downregulation of 
Kindlin-2 linked to breast tumorigenesis (164,170,191–193). Interestingly, although 
Kindlin-3 is not expressed in epithelial cells, a study demonstrated a tumour 
suppressive role for FERMT3 in breast cancer (194). FERMT3 mRNA expression was 
downregulated in breast cancer tissues compared to normal breast tissues and 
knockdown of Kindlin-3 in mice was also shown to enhance breast cancer metastasis 
(194). Azorin et al (155) identified that Kindlin-3 localisation is confined to infiltrating 
immune cells of normal breast tissue and found that Kindlin-3 expression was highly 
correlated with immune marker levels in breast tumours. Upregulation of Kindlin-3 
was shown to correlate with ER status and molecular subtype with HER2 and TNBC 
tumours containing the highest levels of Kindlin-3 transcripts (155).  
 
A potential role for Kindlin-1 in primary tumour growth has also been suggested for 
Kindlin-1. Kindlin-1 overexpression has been reported in human breast tumours that 
were compared to normal breast tissues (155). In addition, the gene encoding 
Kindlin-1, FERMT1, was identified in a six gene signature predictive of breast cancer 
metastasising to the lungs and this signature was significantly linked to the triple-
negative basal-like subtype (195,196). Clinical data in human breast tumours 
supported this finding as increased expression of Kindlin-1 was significantly 
associated with breast cancer that metastasises to the lungs (186). Furthermore, 
breast tumours that expressed high levels of FERMT1 transcripts were identified as 
predominantly hormone receptor negative, with the highest levels of Kindlin-1 




suggested that Kindlin-1 could be a predictive marker for the identification of breast 
cancer patients that are more at risk of development of metastatic disease.  
 
Little is known mechanistically about the role of Kindlin-1 in breast cancer lung 
metastasis although it has been reported that Kindlin-1 may control breast cancer 
invasion and metastasis by regulating TGFβ signalling and initiating EMT (186). Sin et 
al. (186) showed that silencing of Kindlin-1 reduced tumour growth and prevented 
lung metastasis in an orthotopic mouse model. Kindlin-1-depleted primary tumours 
had increased levels of E-cadherin compared to tumours that expressed Kindlin-1 
(186). As loss of E-cadherin in cancer cells leads to activation of EMT transcription 
factors and has been shown to promote metastatic dissemination (197), decreased 
E-cadherin expression in Kindlin-1 expressing tumours was associated with EMT. 
Regulation of EMT by Kindlin-1 was associated with activation of the growth 
regulatory protein, TGFβ and Sin et al. (186) showed increased Smad-2 and Smad-3 
activation, and upregulated expression of TGFβ target genes in the presence of 
Kindlin-1. Genes that were upregulated by Kindlin-1 included: connective tissue 
growth factor, endothelin 1, early growth response 1, TGFβ2 and matrix 
metalloproteinase 9, which are known to promote tumorigenesis (186). 
 
Using the MMTV-PyMT-driven mouse model of mammary tumourigenesis, recent 
work by the Brunton group has shown that loss of Kindlin-1 significantly delayed 
tumour onset and reduced lung metastasis (185). Additionally, loss of Kindlin-1 
reduced metastatic colonisation in experimental metastases assays using Kindlin-1 
deficient cells. Mechanistically, Kindlin-1 enhanced metastatic growth in an integrin-
dependent manner through integrin-dependent adhesion to endothelial cells in the 
metastatic niche. Furthermore, loss of β1-integrin decreased the outgrowth of 






Proteomic analysis showed that Kindlin-1 regulated the secretion of a number of 
factors associated with metastasis including tenascin-C (185). Tenascin-C is a large 
hexameric ECM glycoprotein protein that has a multimodular structure enabling the 
protein to bind a number of diverse ligands including: fibronectin (198), periostin 
(199), integrins (200), and a range of soluble growth factors such as vascular 
endothelial growth factor (VEGF), TGF-β and fibroblast growth factor (FGF) (201). 
Tenascin-C is abundantly expressed in embryos at sites of morphogenesis (202), 
however, little is found in the adult, where it is restricted to tissues bearing high 
tensile stress and at sites of inflammation or tissue injury (203). Additionally, it is most 
prominently expressed in stem cell niches in the adult  (204,205), at sites of EMT and 
is concentrated in the stroma of solid tumours (206). Particular interest in the 
involvement of tenascin-C in breast cancer stemmed from research which identified 
tenascin-C in a gene set that mediates breast cancer metastasis to the lung (207). 
Cancer cell-derived tenascin-C is important in the ECM of the metastatic niche and 
enables breast cancer cells to colonise the lungs through positive regulation of stem-
cell signalling pathways (205). Regulation of the Notch and Wnt pathways by 
tenascin-C was shown to support breast CSC fitness and promote micrometastatic 
outgrowth (205). Bioinformatic analysis by the Brunton group found a positive 
correlation between TNC and FERMT1 expression in MDA-MB-231 breast cancer cell 
line subpopulations predisposed to lung metastasis and in primary breast tumours 
associated with lung metastasis (185). This further suggests that Kindlin-1 has a role 












1.5 Hypothesis and project aims  
Pulmonary metastatic breast cancer presents a major clinical challenge: patients with 
pulmonary breast cancer metastasis have a median survival rate of less than 2 years 
after diagnosis (208). Studies have demonstrated that Kindlin-1 is a mediator of 
pulmonary breast cancer metastasis and that its expression may also impact primary 
tumour growth (Fig. 12) (185,186,207,209). Silencing of Kindlin-1 has been shown to 
significantly reduce mammary primary tumour growth and prevent lung metastasis 
in mice (186), which suggests that targeting Kindlin-1 could present an effective 
strategy for targeting both primary tumour growth and metastasis. Translating these 
findings to the clinic provides a challenge as Kindlin-1 is an adaptor protein that does 
not exhibit catalytic activity. Therefore, an understanding of the mechanisms by 
which Kindlin-1 promotes breast cancer is imperative to uncover targets that may be 






Figure 12. The role of Kindlin-1 in Breast Cancer. (A) The first studies connecting Kindlin-1 to breast 
cancer suggested a role for Kindlin-1 in the promotion pulmonary breast cancer metastasis (195,196). 
High levels of FERMT1 transcripts and high Kindlin-1 protein levels were confirmed in breast tumours 
metastasising to the lungs (155,186). (B) Furthermore, when compared with normal breast tissue, 
breast tumour tissues have higher Kindlin-1 protein levels suggesting a potential role for Kindlin-1 in 
primary tumour growth (155). (C) Disruption of Kindlin-1 expression has been shown to prevent 
primary tumour growth and metastasis in an orthotopic mouse model of breast cancer (186). Primary 
tumours were found to have increased levels of E-cadherin with loss of Kindlin-1 and therefore, 
Kindlin-1 was suggested to promote EMT and tumour dissemination (186).  
(D) Metastatic burden is reduced in a genetically modified mouse model of Kindlin-1 loss and an 
experimental metastasis mouse model of Kindlin-1 loss (185). Mechanistically, Kindlin-1 regulates α4 
integrin-dependent adhesion of tumour cells to endothelial cells via VCAM-1 and activates β1-integrin 
to promote metastasis (185). As β1-integrin is required for outgrowth of micrometastases, this raised 
the question: is Kindlin-1 required for micrometastatic outgrowth? And in addition to integrin, what 
does Kindlin-1 bind to promote tumorigenesis? 
(E) In vitro studies have shown that ectopic expression of Kindlin-1 increases proliferation (186), 
clonogenicity (186) and breast cancer cell invasion (155,186). High Kindlin-1 levels have been 
associated Kindlin-1 with TGF-β signalling, and activation of TGF-β was suggested to induce EMT (186). 
Kindlin-1 was also shown to promote the secretion of metastasis-associated proteins and regulate the 
expression of a protein called tenascin-C (185), which has been shown to support pulmonary 
micrometastatic outgrowth in breast cancer (205). Tenascin-C supports breast cancer cell fitness 
through its role in the regulation of stem cell signalling pathways (205), which leads to the question: 
does Kindlin-1 promote the fitness of breast cancer cells through stem cell signalling? And does 
Kindlin-1 localise to the nucleus to regulate factors associated with metastasis?  
 
From the existing literature on Kindlin-1, which is demonstrated in Figure 12, the 
following hypothesis was formed: 
Kindlin-1 regulates micrometastatic outgrowth by 1.) Supporting the fitness of breast 
cancer cells through regulation of stem cell signalling, and 2.) Localising to the nucleus 
of cancer cells to regulate factors associated with metastasis in breast cancer cells.  
 
The aims of this project were to: 
 Determine if Kindlin-1 regulates outgrowth of micrometastases by developing 
and characterising a pulmonary metastatic mouse model of human Kindlin-1 
loss using human MDA-MB-231 cells (with inducible shRNA Kindlin-1). 
 Establish if Kindlin-1 affects breast cancer stem cell activity by using the in 
vitro mammosphere assay in mouse Met-1 and human MDA-MB-231 cells 
(with inducible shRNA Kindlin-1). 
 Identify binding partners of Kindlin-1 in different breast cancer cell models 




in Met-1 cells and metastatic and non-metastatic variants of MDA-MB-231 
cells.  
 Explore a nuclear role for Kindlin-1 in breast cancer. Establish if nuclear 
Kindlin-1 has an important role in breast cancer cells by developing a Kindlin-
1 mutant that cannot localise to the nucleus of mouse Met-1 cells and 





























































2.1 Cell culture 
2.1.1 Cell lines and maintenance  
Murine Met-1 Clone A1 Kindlin-1 Null (Kin1-Null), Kindlin-1 WT (Kin1-WT) and Kindlin-
1 AA (Kin1-AA) cells and the Met-1 Clone 3B Kindlin-1 Null cell line used to generate 
a Kindlin-1 NLS (Kin1-NLS) cells as described in 2.1.4 were previously generated by 
the Brunton Group (185). Murine SCC Kindlin-1 Null (Kin1- Null), Kindlin-1 WT (Kin1-
WT) and Kindlin-1 AA (Kin1-AA) cells were obtained from I. Stavrou (ECRC, Edinburgh) 
(210). Human MDA-MB-231 cells (parental and the lung metastatic variant, 4173) 
were obtained from B. Qian (QMRI, Edinburgh). Human MDA-MB-231 cells used for 
generation of the Kindlin-1 shRNA cell line were obtained from ATCC). Cell lines were 
cultured in Dulbecco’s Modified Medium (DMEM) high glucose (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) (Gibco by Life Sciences). Met-1 and 
SCC cells were also supplemented with hygromycin B (200 μg/mL) (Invitrogen). The 
cell lines were maintained in a humidified incubation at 37 °C with 5% CO2. Cell lines 
were mycoplasma tested every month and were used within three months of 
recovery from frozen.  
 
2.1.2 Generation of MDA-MB-231 inducible Kindlin-1 knockdown cell line  
MDA-MB-231 cells were transfected with a doxycycline inducible TRIPZ FERMT1 
shRNA vector (shRNA Kin1)  (Fig. 9A) and a TRIPZ non-targeting (NT) shRNA vector 
(for use as a negative control) as described previously by Dodd (211). Doxycycline 
(dox) (1 μg/mL) (Sigma Aldrich) was added to cells in order to induce transcription of 
the shRNA and knockdown the FERMT1 gene. Knockdown of FERMT1 expression was 
confirmed by western blot and real-time quantitative reverse transcription PCR (RT-







2.1.3 Generation of Kindlin-1 knockout in MDA-MB-231 lung metastatic cell line 
MDA-MB-231 cells were infected with a double nickase CRISPR/Cas9 knockout 
plasmid (Santa Cruz; sc-412553-NIC) or a control double nickase plasmid (Santa Cruz; 
sc-437281) (for use as a negative control) according to manufacturer's protocol 
except X-tremeGENE HP DNA Transfection Reagent was used as the transfection 
reagent (Roche; XTG360-RO) and opti-MEM reduced serum medium (ThermoFisher 
Scientific; 31985062) used as the transfection medium.  
 
2.1.4 Generation of a Kindlin-1 nuclear localisation mutant cell line   
The pWZL-Kindlin-1 WT vector previously generated by the Brunton group (185) was 
used to generate the pWZL-Kindlin-1 NLS mutant using the Q5® Site-Directed 
Mutagenesis Kit (New England BioLabs; E0554) as per manufacturers protocol. The 
primers used for mutagenesis are listed in Table 6. Plasmids containing mutations to 
the Kindlin-1 sequence were sequenced after each transformation before proceeding 
using the primers in Table 7. A retroviral infection protocol was used to infect the 
mutant Kindlin-1 NLS vectors into Met-1 3B Kindlin-1 Null cells previously generated 
by the Brunton group. The pWZL-Kindlin-1 WT and an empty pWZL vector were also 
infected into Met-1 3B Kindlin-1 Null cells. Phoenix ECO cells were seeded into 10cm 
plates 24 hours prior to transfection. A plasmid (10µg) and opti-MEM (0.5mL) 
reduced serum media mix was made and incubated at room temperature for 10 
minutes. A lipofectamine mastermix was also made containing 20µL Lipofectamine 
2000 (ThermoFisher Scientific; 11668030) and 0.5mL opti-MEM (ThermoFisher 
Scientific; 31985062) for each sample and incubated at room temperature for 10 
minutes. Both mastermixes were combined and incubated for 15 minutes at room 
temperature. The media of Phoenix ECO cells was replaced with 5mL opti-MEM and 
the cells were transfected with lipofectamine/DNA mixes dropwise whilst swirling. 
The media was removed after 6 hours and replaced with DMEM 10% FBS. The media 
of Phoenix cells was replaced with DMEM 20% FBS (Viral induction media) after 24 




(day 3) the media was harvested from the phoenix ECO cells and passed through a 
0.45µM filter and added to Met-1 Kindlin-1 Null plates with polybrene transfection 
reagent (Sigma-Aldrich; TR-1003-G) at a concentration of 1:2000. Harvesting of the 
virus was repeated a second time the following day. The infected cells were left to 
grow until 50-60% confluency before selecting with puromcyin (100µg/mL). Cells 
were supplemented with fresh antibiotic every two days and passaged once 
confluency was reached. Western blot analysis was used to confirm that plasmids 
were successfully introduced into the Met-1 Kindlin-1 Null cell line and nuclear 
fractionation performed followed by western blot to confirm that Kindlin-1 NLS 
mutants were successful (Fig. 49C). 
 
Table 6. Mutagenesis primers used to generate Kindlin-1 nuclear localisation mutants 
Name (F/R) Oligo (Uppercase = target-specific primer) Tm Ta * 
R131A_F GCTGAATATCgcaAGACCAGAAGAAC 57°C 58°C 
R131A_R ACTTTGCAGATATCAGCG 59°C 
R132A_F GAATATCAGAgcaCCAGAAGAACTTTC 55°C 56°C 
R132A_R AGCACTTTGCAGATATCAG 59°C 
K131/132A_F GCTGAATATCgcagcaCCAGAAGAACTTTCATTG 56°C 57°C 
K131/132A_R ACTTTGCAGATATCAGCG 59°C 
K147/148A_F TGACTACTGTgccgcgAAAAAAAAGAAAGAAAAAAATAG 56°C 56°C 
K147/148A_R CTAGAAGGCTTTAACAATG 55°C 
K149/150A_F CTGTGCCGCGgccgccAAGAAAGAAAAAAATAG 60°C 61°C 
K149/150A_R TAGTCACTAGAAGGCTTTAAC 59°C 
K151/152A_F CGCGGCCGCCgccgccGAAAAAAATAG 57°C 59°C 
K151/152A_R GCACAGTAGTCACTAGAAG 60°C 
 
 
Table 7. Sequencing primers for mutagenesis  
Primer Description Sequence 
Kindlin-1 NLS sequencing forward CTTCGCCTGCCCAATGCC 






Experiments were performed in compliance with UK Home Office guidelines by 
Morwenna Muir. Animals were sacrificed as determined by UK Home Office 
regulations. The mice were weighed and monitored twice weekly. On cull, tissue was 
removed, weighed and stored in formalin for embedding or flash frozen in liquid 
nitrogen and stored at -80°C for further analysis. Fixed tissues were processed by the 
histology department at the Institute of Genetics and Molecular Medicine. 
Hematoxylin and eosin (H&E) staining was also carried out by the histology 
department. 
 
2.2.1 Experimental metastasis assay 
Female NOD SCID mice were inoculated intravenously via the tail vein with 0.5x106 
MDA-MB-231 shRNA Kin-1 (2 groups, n=4). The diet of one of the groups receiving 
MDA-MB-231 shRNA K1A cells lines was changed from a control diet (RM1 diet made 
by blending wheat, barley, wheatfeed, de-hulled extracted toasted soya, soya protein 
concentrate, macro and micro minerals, soya oil, whey powder, amino acids, and 
vitamins) to a doxycycline containing diet (RM1 + 625ppm Doxy (P) 25kGy) after 24 
hours. The mice were culled 2 weeks post-implantation (carried out by M. Muir). 
QuPath v.0.2.0 was used to analyse the area of micrometastases in the lungs of mice. 
 
2.2.2 Subcutaneous implantation 
2.2.2.1 MDA-MB-231 cells 
Ten female CD-1 Nude mice were inoculated subcutaneous bilaterally with 4x106 
MDA-MB-231 shRNA Kin1 cells. Group A (n=5) received the control RM1 diet and 
group B (n=5) received doxycycline containing diet (RM1 + 625ppm Doxy (P) 25kGy) 





Female NOD SCID mice were implanted subcutaneous bilaterally with MDA-MB-231 
shRNA Kin1 fragments. Group A (n=5) received the control RM1 diet, group B (n=5) 
received the doxycycline containing diet (RM1 + 625ppm Doxy (P) 25kGy) from day 0 
and group C (n=5) received the doxycycline containing diet (RM1 + 625ppm Doxy (P) 
25kGy) from day 7. The mice were culled at the maximum end point (carried out by 
M. Muir).  
 
2.2.2.2 Met-1 Clone A1 cells 
Female FVB/NHanHSD mice were implanted subcutaneous bilaterally with 1x106 
Met-1 cells per implant. Group A (n=8) were inoculated with Met-1 Kin1-WT cells, 
group B (n=8) with Met-1 Kin1-Null cells and group C (n=8) with Kin1-AA cells. The 
mice from each group were culled for tissue on day 21. 
 
Female CD-1 Nude mice were implanted subcutaneous bilaterally with 0.5x106 Met-
1 cells per implant. Group A (n=6) were inoculated with Met-1 Kin1-WT cells, group 
B (n=7) with Met-1 Kin1-Null cells and group C (n=7) with Kin1-AA cells. The mice from 
each group were culled for tissue at the maximum end point.  
 
2.2.2.3 Met-1 Clone 3B cells 
FVB/NHanHSD female mice were implanted subcutaneous bilaterally with 1x106 Met-
1 cells per implant. Group A (n=8) were inoculated with Met-1 Kin1-WT cells, group 
B (n=8) with Met-1 Kin1-Null cells and group C (n=8) with Kin1-NLS cells. Five mice 
from each group were culled for tissue on day 10, the remaining 3 mice continued for 
the growth curve. 
 
2.3 Western Blotting 
Cells were washed twice with cold PBS and lysed in RIPA buffer (50 mM Tris-HCl pH 




sodium deoxycholate (Thermo Fisher Scientific), 0.1% SDS (Sigma-Aldrich) 
supplemented with 1.25 mM PMSF (complete ULTRA tablet, Roche), 1.7 μg/mL 
aprotinin (Sigma-Aldrich), 0.5 mM NaF (Sigma-Aldrich) and 0.1 mM sodium 
orthovanadate (Sigma-Aldrich). The lysed cells were centrifuged at 13,000 rpm for 15 
minutes at 4 °C and the pellet discarded. Cell lysate protein concentration was 
determined by a bicinchoninic acid (BCA) assay (Invitrogen) and 20μg protein was 
added to 1x sample buffer (10 mM Tris-HCl pH6.8 (Sigma-Aldrich), 20% glycerol 
(ThermoFisher Scientific), 8% SDS (Sigma-Aldrich), 0.008% bromophenol blue 
(BioRad), 6% β-mercaptoethanol (Sigma-Aldrich)) and made up to 13μL with RIPA 
buffer. The samples were boiled at 65°C for 5 minutes and lysates resolved by gel 
electrophoresis. The gels were transferred to nitrocellulose (BioRad) and probed with 
primary antibodies in 5% BSA (Table 8) and membranes were then probed with anti-
rabbit (1:5000; Cell Signaling Technology; 7074) or anti-mouse (1:5000; Cell Signaling 
Technology; 7076) for detection by chemiluminescence using a Bio-Rad ChemiDoc 
system. Blots were washed 3x 15 minutes with 1x Tris-buffered saline containing 
0.1% Tween 20 (Sigma) detergent (T-BST) before imaging. A colorimetric image was 
a taken after the chemiluminescence image and the images merged to determine the 
molecular weight of the bands. Fiji was used to quantify protein levels and statistical 
analysis performed using GraphPad Prism v.8.0.2. 
 
2.4 Real-Time Quantitative Reverse Transcription PCR 
Reverse transcription and quantitative real-time PCR Total RNA isolation (Invitrogen) 
and cDNA synthesis (Superscript III RT-PCR kit, Invitrogen) were performed according 
to manufacturer's protocols. A NanoDrop2000 spectrophotometer was used to 
measure the concentration of RNA and cDNA. cDNA was mixed with 2X Mastermix 
(Applied Biosystems) and primers for the target gene or endogenous control (Table 
9). Quantitative real-time PCR was performed in triplicate using an Applied 
Biosystems StepOne System (Applied Biosystems, Carlsbad, CA USA). SybrGreen 




normalised to the housekeeping gene, Gapdh/GAPDH. The cycling parameters used 
were as follows: 95°C for 5 seconds, 60°C for 10 seconds then 72°C for 10 seconds, 
for 40 cycles. The relative DNA expression was calculated using the Applied 
Biosystems StepOne software. The experiment was carried out on three independent 
occasions for each primer set unless otherwise stated. Analysis was performed using 
excel and GraphPad Prism v.8.0.2. 
 
Table 8. Antibodies and dilutions used for western blotting. 
Protein Supplier Catalogue Number Dilution 
Kindlin-1 Abcam ab68041 1:1000 
β-actin Cell Signalling Technology 3700 1:5000 
FAK Cell Signalling Technology 3285 1:1000 
ILK Cell Signalling Technology 611802 1:2000 
Kindlin-1 Movarian Biotech - 1:500 
GM130 BD Transduction Laboratories 610822 1:1000 
α-tubulin Cell Signalling Technology 2144 1:1000 
Histone H4 Cell Signalling Technology 2592 1:1000 
Kindlin-2 EMD Millipore MAB2617 1:1000 
p65 Cell Signalling Technology 8242 1:1000 
 
2.5 Immunostaining   
2.5.1 Immunohistochemistry  
Paraffin sections were dewaxed with 2 x 5 minute washes of xylene (Fischer 
Scientific), and then rehydrated with 2 minute washes in decreasing concentrations 
of ethanol (100%, 100%, 80% and 50%). Sections were rinsed in water and then boiled 
for 5 minutes using a pressure cooker in pre-warmed 10 mM sodium citrate buffer 
(pH 6.0) (Fisher Scientific). Sections were cooled and washed in tap water followed 
by 2 x 5 minute washes in 0.0025% Tween in TBS (TBS-T). A hydrophobic pen (DAKO) 




15 minutes at room temperature. Sections were subsequently washed with water 
and incubated with serum free protein block (DAKO) for 2 hours at room 
temperature. Sections were incubated overnight at 4 °C with primary antibodies 
(Table 10) diluted in antibody diluent buffer (DAKO). A negative control was included 
in all experiments, in which a section was incubated with serum free protein block 
(DAKO) overnight. Following overnight incubation, sections were washed twice in 
0.0025% TBS-T and incubated with either a mouse or rabbit Envision (DAKO) 
secondary antibody for 1 hour at room temperature. Sections were then washed 3 x 
5 minutes with TBS-T and treated with DAB-DAB chromagen (DAKO) for 10 minutes 
at room temperature before counterstaining with haematoxylin (Pioneer Research 
Chemicals) for 2 minutes. Sections were rinsed with water and incubated for 2 
minutes with Scott’s tap water (0.35% sodium bicarbonate (Sigma-Aldrich) and 2% 
magnesium sulphate (Sigma-Aldrich) in distilled water). Sections were washed with 
water and dehydrated with 2 minutes washes in a series of solutions of increasing 
ethanol concentrations (50%, 80%, 100% and 100%). Finally, sections were washed 
twice for 2 minutes in xylene before being mounted in DPX mounting medium 
(Fisher). Sections were scanned using NanoZoomer-XR Digital slide scanner 
(Hamamatsu) and visualised using NDP.view 2 software U12388-01 (Hamamatsu).  
 
2.5.2 Immunofluorescence  
Cells were seeded onto glass coverslips in 6 well plates 24 hours in advance. Cells 
were fixed in PEM (80mM PIPES pH6.8, 5mM EGTA, 2mM MgCl2) with 4% 
formaldehyde for 37°C for 15 minutes and then washed twice with PEM. Cells were 
then incubated with 2mL 0.1M glycine in PEM for 5 minutes at room temperature. 
Cells were permeabilised with 0.2% Triton X-100 in PEM for 5 minutes at room 
temperature. Cells were washed twice with PEM and then blocked with 2% BSA in 
PEM for 1 hour at room temperature. Coverslips were then incubated with primary 
antibodies (FAK Cell Signalling Technology; 3285 or ILK Santa-Cruz; sc-137221) 




times with 0.05% Tween-20 in PEM for 5 minutes at room temperature. The 
coverslips were incubated with 100μL of 1:400 secondary antibody (Alexa Fluor; 488 
goat anti-rabbit IgG (H&L); Invitrogen; A11008 or Alexa Fluor; 488 goat anti-mouse 
IgG (H&L); Invitrogen; A11005) in 0.05% Tween 20 in PEM for 45 minutes at room 
temperature in the dark. Coverslips were then washed three times with 0.05% Tween 
20 in PEM for 5 minutes at room temperature in the dark. The coverslips were 
washed with PEM and then fixed in PEM with 4% formaldehyde for 15 minutes. The 
coverslips were washed twice with PEM and incubated in 2mL 0.1M glycine in PEM 
for 5 minutes. The coverslips were washed with PEM and then water before 
mounting with fluoroshield containing DAPI (Sigma-Aldrich; F6057-20ML). Images of 
cells were taken using an Olympus FV3000 using a 60x 1.42 NA oil immersion 
objective with appropriate excitation and filter sets used. 
 
2.6 Mammosphere Assay 
Mammospheres were grown by plating 5000 cells per well on ultra-low-adhesive 
plates (Costar) as described by Shaw et al. (212) (Fig. 5A). Mammospheres were 
cultured in phenol red free DMEM/F12 medium (Invitrogen) supplemented with 
5μg/mL insulin (Invitrogen), 20ng/mL epidermal growth factor (EGF) (Sigma-Aldrich), 
10ng/mL basic fibroblast growth factor (FGF) (Preprotech) and 2% vol/vol B27 
(Invitrogen). Mammospheres were cultivated for 5 days and imaged using an 
ImageExpress Micro (Molecular Devices) before passaging and reseeding to quantify 
their self-renewal. Secondary mammospheres were reseeded at the same density as 
the primary mammospheres and cultivated for 5 days. For experiments using the 
gamma secretase inhibitor, dibenzazepine (DBZ), 10µM of DBZ inhibitor (73092; Stem 
Cell Technologies) or an equal volume of Dimethyl sulfoxide (DMSO) was added to 
the media of the plates. Spheroids were counted using CellProfiler 3.0.0 (213) and 
calculations performed for analysis as described by Shaw et al. (212). GraphPad Prism 







Table 10. Antibodies and concentrations used for immunohistochemistry  
Protein Supplier Catalogue 
Number 
Dilution 
Kindlin-1 Abcam ab68041 1:200 
B220 Biolegend 103202 1:500 
CD3 Abcam ab16669 1:100 
Kindlin-1 Movarian Biotech N/A  1:100 
Tenascin C Abcam ab108930 1:2000 
RFP Abcam ab62341 1:400 
Lamin A+C Abcam ab8984 1:500 
 
2.7 Immunoprecipitation 
2.7.1 Immunoprecipitation-mass spectrometry 
Cells (Met-1 Kin1-Null, Met-1 Kin1-WT, Met-1 Kin1-AA, MDA-MB-231 4173 and MDA-
MB-231 parental cells) were plated onto 15 cm dishes. Cells were cultured until they 
reached the desired confluency and lysed in 350μL RIPA buffer. 1mg of lysate was 
diluted in RIPA buffer with protease and phosphatase inhibitors and made up to a 
final volume of 500μL. Either 1μL Kindlin-1 (abcam; ab68041) or control rabbit IgG 
antibody (CST; 7074) was added to the lysate and samples were rotated at 4°C and 
then aliquoted into a deep-welled 96-well plate. Protein G Mag Sepharose™ Xtra 
beads (GE Healthcare) were washed with RIPA buffer (10μL per sample) and then 
resuspended in 100μL and aliquoted directly into the deep-welled 96-well plate. The 
samples were loaded into the Thermo Kingfisher Duo robot and samples with beads 
were washed 2x with RIPA buffer and 3x with TBS (50 mM tris, 150 mM NaCl, pH 7.4). 
Then the samples were digested in trypsin working reagent (2 M urea, 100 mM tris, 
1 mM DTT, 6 ug/mL trypsin) at 27oC for 30 minutes to release beads and the released 
peptides then digested with 1µg of porcine trypsin MS-grade (Promega) for 9 hours 
at 37 oC. Peptides were next alkylated by adding iodoacetamide to 50 mM (room 




10ug of the resulting peptide solution was loaded onto an activated C18 STAGE tip, 
and washed with 100uL 0.1% TFA. Peptides were desalted and purified using STAGE 
tip protocol (214). Peptides were eluted in 80% Acetonitrile (v/v), 01% TFA (v/v) and 
lyophilized in a Concentrator Plus (Eppendorf). Peptides were resuspended in 7,5µl, 
0.1% TFA and analysed by LC-MS/MS on a Orbitrap Fusion™ Lumos™ Tribrid™ Mass 
Spectrometer (Thermo Fisher).  Protein identification and quantification was 
performed by label-free quantification using MaxQuant software, version 1.6.1.0 
(215,216) with trypsin as protease and carbamidomethyl cysteine set as a fixed 
modification by A. Bolado Carrancio. The mouse or human proteome file used was 
downloaded from Uniprot in August 2017. Other parameters were set as default. 
Statistical analysis was performed using Perseus (217). The values were transformed 
into log2 and the protein hits filtered to eliminate those which were not detected in 
at least 3 out of 4 replicates. A t-test was performed to determine potential 
interactors and the list was filtered by a 2-fold enrichment unless stated. Perseus 
version 1.6.10.50, R version 3.5.0 (218), STRING (219) and Venny (220) were used to 
present the data. 
 
2.7.2 Manual Immunoprecipitation 
One mg of protein was used per sample and samples made up to 500 μL with RIPA 
buffer. Magnetic beads (10μL per 1 mg sample) were washed twice with 100μL of 
0.2% TritonX in PBS using a bench top centrifuge. The beads were then resuspended 
in 200μL of PBS with 1 μL of Kindlin-1 antibody (Abcam; ab68041) or 1 μL of IgG 
control antibody (CST; 2729) and incubated for 30 minutes at room temperature on 
a roller. Beads were then washed twice with RIPA buffer before resuspending in 
200μL RIPA per sample. The coated beads were added to the protein samples and 
incubated for 45 minutes at room temperature on a roller. The samples were washed 
three times with lysis buffer and twice with PBS. As much liquid was removed as 
possible and samples resuspended in 10μL PBS with 4μL 6x loading buffer and 




2.9 Nuclear Fractionation 
Cells were plated on 15 cm dishes and cultured until reaching the desired confluency. 
Media was removed with cells on ice and cells washed with ice cold PBS. Cells were 
lysed very gently using a cell scraper and 500 μL Buffer A (20 mM Tris pH 7.5, 1 mM 
MgCl2, 1 mM EGTA) plus inhibitors (1.25 mM PMSF (complete ULTRA tablet, Roche), 
1.7 μg/mL aprotinin (Sigma-Aldrich), 0.5 mM NaF (Sigma-Aldrich) and 0.1 mM sodium 
orthovanadate (Sigma-Aldrich)) and detergent 0.05% NP-40 (Calbiochem). Samples 
were rotated at 4oC for 5 minutes and centrifuged at 4oC, 800 x g for 4 minutes. The 
supernatant was transferred into a new tube and NP-40 added to give a final 
concentration of 1%. Samples were vortexed vigorously, centrifuged at 4oC, 14,000 
rpm for 10 minutes and the supernatant collected as the cytoplasmic fraction. The 
pellet was washed twice with 200 μL of Buffer A with inhibitors and detergent and 
centrifuged at 4oC, 800 x g, 3 minutes. The pellet was washed with 200 μL of Buffer A 
with inhibitors but no detergent and centrifuged at 4oC, 800 x g, 3 minutes. The pellet 
was gently resuspended in two volumes of Buffer B (10 mM Tris-HCl pH 7.4, 2.5 mM 
MgCl2, 1.5 mM KCl, 0.2 M LiCl) with inhibitors (1.25 mM PMSF (complete ULTRA 
tablet, Roche), 1.7 μg/mL aprotinin (Sigma-Aldrich), 0.5 mM NaF (Sigma-Aldrich), 
0.1% Triton X-100 and 0.1% sodium deoxycholate and rotated at 4oC for 15 minutes 
and then centrifuged at 4oC, 2,000 x g for 5 minutes. The supernatant was transferred 
to a fresh microfuge tube (keeping the pellet) and centrifuged at 14,000 rpm for 10 
minutes and collected as the perinuclear fraction. The pellet was then washed twice 
with 200 μL Buffer B plus inhibitors and detergents and once with 200 μL Buffer B 
plus inhibitors but no detergents and centrifuged 4oC 2000 x g, 3 minutes. The pellet 
was then resuspended in two volumes of RIPA buffer (50 mM Tris-HCl pH 8.0 (Sigma-
Aldrich), 150 mM NaCl (Sigma-Aldrich), 1 mM EDTA (Sigma-Aldrich), 0.5% sodium 
deoxycholate (Thermo Fisher Scientific), 0.1% SDS (Sigma-Aldrich) supplemented 
with 1.25 mM PMSF (complete ULTRA tablet, Roche), 1.7 μg/mL aprotinin (Sigma-
Aldrich), 0.5 mM NaF (Sigma-Aldrich) and 0.1 mM sodium orthovanadate (Sigma-
Alrich) and sonicated at 4oC on high power (5 cycles: 30 seconds on; 30 seconds off) 




14,000 rpm for 10 minutes and the supernatant collected as the nuclear fraction. 
Samples were analysed by western blot using the antibodies in Table 8. The purity of 
each fraction was confirmed using controls as described in chapter 5. 
 
2.9 Statistical Analysis 
All p values below 0.05 were considered as statistically significant and statistical 
analysis was performed using GraphPad Prism software, version 8.0.2 (GraphPad 
Software Inc., La Jolla, CA, USA) except for the mass spectrometry data, which was 
analysed in Perseus version 1.6.10.50 (as stated above). Data is presented as mean ± 
standard error (SEM) and statistically analysed by using either a Student’s t-test, a 
one-way ANOVA or two-way ANOVA. A Shapiro-Wilk test of normality was not 





























The mechanisms by which Kindlin-1 mediates metastasis to the lungs in breast cancer 
remain relatively unknown. Recent work from the Brunton group showed that 
Kindlin-1 regulates the secretion of a number of factors linked to metastatic spread 
including tenascin-C, a protein which promotes metastatic outgrowth of DTCs (185). 
Mechanistically, Tenascin-C regulates stem cell signalling by controlling expression of 
musashi homolog 1 (MSI1), a positive regulator of Notch signalling and LGR5, a WNT 
pathway target gene (205). Tenascin-C was shown to enhance Notch signalling and 
promote metastasis by inhibiting JAK2-STAT5 signalling in breast cancer cells (205). 
Inhibition of JAK2-STAT5 deters inhibition of the positive regulator of both Notch and 
Wnt pathways, MSI1, and thus, increases stem cell signalling activity (205).  
 
The Kindlin proteins are highly expressed in the mouse and human embryo during 
early stage events (193) suggesting that their expression may correlate with stem-
like characteristics of cells and several studies have supported this idea (156,165). For 
example, Kindlin-1 expression has been shown to increase expression of the stem cell 
marker LGR5 in colorectal cancer. In this study, Kindlin-1 promoted EMT (a pathway 
that has been linked with stem cell properties of cancer cells) (165). Kindlin-1 
downregulated epithelial markers such as E-cadherin and ZO-1 through TGF-β-
mediated regulation of Snail, Slug and Twist (165). 
 
To date, the role of Kindlin-1 in stem cell regulation in breast cancer has not yet been 
addressed and therefore, we sought to define a role for Kindlin-1 in stem cell activity 
both in vitro and further define its role in breast cancer in vivo.  
 
Specific aims of this chapter include: 
1. Use of the in vitro mammosphere assay and gene expression analysis to investigate 
breast cancer stem cell activity in vitro.  




3. To establish whether Kindlin-1 regulates primary tumour growth and outgrowth of 


























3.1 Regulation of mammosphere growth by Kindlin-1 in a mouse model 
As Kindlin-1 regulates secretion of tenascin-C, which is known to be prominent in 
stem cell niches (221–223) and required for pulmonary micrometastatic outgrowth 
(205,207), we used a mouse model of Kindlin-1 loss to investigate effects on stem cell 
activity. The Fermt1 gene was excised from the Met-1 cell line using the CRISPR-Cas9 
method to generate Kindlin-1 Null cells (Kin1-Null) (185). The Met-1 cell line has a 
metastatic phenotype and was derived from the transgenic MMTV-PyMT mouse 
mammary gland carcinoma model of breast cancer (185). Wild-type (WT) Kindlin-1 
was re-expressed into Kin1-Null cells to generate Kindlin-1 WT cells (Kin1-WT) (185). 
Loss of Kindlin-1 expression was not found to have an effect on the formation of 
primary mammospheres in the mouse Met-1 cell model (Fig. 13), which suggests that 
Kindlin-1 does not affect stem cell or early progenitor activity. However, loss of 
Kindlin-1 significantly decreased the generation of secondary mammospheres, which 
represents mammosphere self-renewal (Fig. 13C) and suggested that Kindlin-1 has a 
role in stem cell self-renewal. 
 
3.2 Inhibition of Notch signalling does not alter mammosphere formation 
To test the functional implications of this finding, we performed gene expression 
analysis in secondary mammospheres (Fig. 14). Loss of Kindlin-1 expression did not 
change expression of the mammary differentiation marker, Gata3, or components of 
the Wnt pathway; Lgr5 and Wnt5, but significantly increased expression of Nanog, a 
factor that is essential for the maintenance of pluripotency in stem cells (224,225). 
Kindlin-1 loss significantly decreased expression of Msi1 (Fig. 14), an inhibitor of a 
negative regulator of the Notch pathway, NUMB (Fig. 15A) (205). Kindlin-1 loss also 
resulted in significantly decreased expression of Tnc (Fig. 14), which is in line with 
what we previously reported in Met-1 cells grown in adherent 2D monolayers (185). 
As expression of TNC in CSCs has also been shown to enhance expression of MSI1 
(205), we investigated whether Kindlin-1 regulates self-renewal in this model through 




(226) to assess whether inhibition of Notch signalling in cells expressing Kindlin-1 
would reduce mammosphere self-renewal to that of Kin1-Null cells. GSIs inhibit the 
Notch pathway by preventing proteolytic cleavage of the Notch receptor by γ-
secretase (Fig. 15A). This prevents the release of the Notch intracellular domain, 
which upon cleavage, enters the cell nucleus to modify gene expression (Fig. 15A) 
(227). To confirm that DBZ was inhibiting the Notch pathway and select a 
concentration to use in the mammosphere assay, cells were treated with different 
concentrations of DBZ for 3 days alongside a DMSO control (Fig. 15B). Increasing the 
concentration of DBZ reduced cleaved Notch1 but did not impact Kindlin-1 expression 
in Met-1 Kin1- WT cells (Fig. 15B). Addition of 10 μM DBZ inhibitor significantly 
reduced the expression of the Notch pathway target gene, Dtx1, in Met-1 Kin1-WT 
cells but had no significant effect on Dtx1 expression in Kin1-Null cells (Fig. 15C). 
Notch inhibition did not alter the size of the mammospheres formed or decrease 
mammosphere formation (Fig. 16A-B), a result which has been previously reported 
with the use of GSIs in human breast cancer models (228), and there was no 
significant effect on mammosphere self-renewal (Fig. 16B). Inhibition of Notch had 
no significant effect on expression of Fermt1 and Tnc in both Met-1 Kin1-Null and 
Kin1-WT cells (Fig. 16C). 
 
Notably, we did not find a significant difference in mammosphere self-renewal 
between DMSO control Met-1 Kin1-Null cells and Met-1 Kin1-WT cells in the 
mammosphere assay using the GSI (Fig. 16B) as previously found in Figure 13C for 
untreated cells. Following this finding, the mammosphere assay was repeated with 
addition of an untreated control as well as the GSI, DBZ, and a DMSO control to 
ensure that addition of DMSO was not affecting mammosphere formation (Fig. 16D). 
Repetition of the assay with each of these conditions did not result in a significant 
difference between Met-1 Kin1-Null and Kin-1-WT cells secondary mammospheres 





Figure 13. Regulation of mammosphere growth by Kindlin-1. (A) Schematic of the mammosphere 
assay (B) Kindlin-1 expression in mammospheres derived from Met-1 cells with genetic deletion of 
Fermt1 (Kin1-Null) and re-expression of WT Kindlin-1 (Kin1-WT). Expression was analysed by qRT-PCR; 
values are mean ± SEM of triplicate experiments. The expression in Met-1 Kin1-Null cells was 
normalised to Met-1 Kin1-WT cells. (****p<0.0001). P values were obtained by a two-tailed Student’s 
t test. (C) Quantitative analysis of mammosphere formation in primary and secondary spheroids in 
Kindlin-1 deficient Met-1 cells comparative to Met-1 Kin-WT. Combined data (average±SEM) from 3 
independent experiments is shown for cell lines (*p<0.05). P values were obtained by two-tailed 





Figure 14. Gene expression analysis in Kindlin-1-deficient secondary mammospheres. Expression 
was analysed by qRT-PCR; values are mean ± SEM of triplicate experiments. For all genes, the 
expression in Met-1 Kin1-Null cells was normalised to Met-1 Kin1-WT cells. (*p<0.05, ***p<0.001, 








Figure 15. Inhibition of Notch signalling in Met-1 cells. (A) Working model of Musashi-1 (MSI1) in stem 
cell signalling. MSI1, is an RNA binding protein and stem cell regulator that positively regulates the 
Notch and Wnt signalling pathways by binding to the 3’ untranslated region of target mRNAs and 




include NUMB, adenomatous polyposis coli (APC) and cyclin-dependent kinase inhibitor/p21WAF-1 
(CDKN1A) and their downregulation promotes cell cycle progression through Wnt and Notch signalling 
pathways. The Notch pathway can be inhibited by targeting the enzyme complex, γ-secretase, with γ-
secretase inhibitors. γ-secretase proteolytically cleaves the Notch receptor to release the intracellular 
domain, which subsequently translocates to the nucleus where it controls gene expression 
predominantly by binding to a ubiquitous transcription factor, CBF1, suppressor of hairless, Lag-1 
(CSL). Transcription activators are recruited upon binding to the CSL complex and converts it from a 
transcriptional repressor into an activator, which turns on several downstream effectors. Figure 
created using Inkscape and Servier Medical Art. (B) Reduction of Notch signalling with addition of the 
γ-secretase inhibitor, dibenzazepine (DBZ). Western blot analysis for cleaved Notch1 expression and 
Kindlin-1 expression in Met-1 Kin1-Null and Kin1-WT cells after 3 days of treatment with DBZ or 
dimethyl sulfoxide (DMSO) as a control (left). β-actin was used as a loading control. (C) Expression of 
Dtx1 after 3 days of treatment with 10 μM DBZ or DMSO was analysed by qRT-PCR; values are mean 
± SEM of triplicate experiments. Gene expression in Met-1 Kin1-Null cells was normalised to Met-1 



















Figure 16. Inhibition of Notch signalling in Met-1 cells does not impact mammosphere formation. 
(A) Representative images illustrating the appearance of mammospheres treated with dimethyl 
sulfoxide (DMSO) or dibenzazepine (DBZ) after 3 days. Objective magnification: ×4. Scale bar 
represents 50μm. (B) Quantitative analysis of mammosphere formation in primary and secondary 
mammospheres in Kindlin-1 deficient Met-1 cells comparative to Met-1 Kin1-WT treated with 10 μM 
DBZ inhibitor or DMSO as a control for 7 days. Combined data (average ± SEM) from 3 independent 
experiments is shown for cell lines and a two-way ANOVA performed to test for statistical significance. 
(C) Gene expression analysis in Kindlin-1-deficient secondary mammospheres treated with DBZ 
inhibitor. Expression was analysed by qRT-PCR; values are mean ± SEM of two experiments. The 
expression in Met-1 Kin1-Null cells was normalised to Met-1 Kin1-WT cells. (D) Quantitative analysis 
of mammosphere formation in primary and secondary mammospheres in Kindlin-1 deficient Met-1 
cells comparative to Met-1 Kin1-WT untreated, treated with 10μM DBZ inhibitor, or treated with 
DMSO as a control for 7 days. Combined data (average ± SEM) from 3 independent experiments is 
shown for cell lines and a two-way ANOVA performed to test for statistical significance. 
 
3.3 Generation of an inducible human model of Kindlin-1 loss using shRNA 
To understand further whether Kindlin-1 is involved in mammosphere formation, we 
generated another model of Kindlin-1 loss using human MDA-MB-231 cells with an 
inducible shRNA against Kindlin-1 (shRNA Kin1) (Fig. 17). The shRNA against Kindlin-
1 is induced in the presence of doxycycline (Fig. 17C-D) and this also induces 
expression of red fluorescent protein (RFP) (Fig. 17A-B,D). A non-targeting shRNA 
(shRNA NT) was used as a control and upon treatment with doxycycline, significant 
reduction of Kindlin-1 was confirmed at the protein level in shRNA Kin1 cells (Fig. 
17C). Gene expression analysis also confirmed significant reduction of FERMT1 










Figure 17. Knockdown of Kindlin-1 in MDA-MB-231 cells in vitro. (A) Vector map of TRIPZ Inducible 
Lentiviral shRNA. The vector is tetracycline (Tet)-inducible, which enables reversible control of gene 
silencing. shRNA expression is induced in the presence on doxycycline (Tet-On) alongside expression 
of turbo red fluorescent protein (tRFP). (B) Representative images of MDA-MB-231 shRNA Kin1 cells –
dox and +dox after 24 hours. Cells express RFP upon addition of dox. Objective magnification: 10x. 
Scale bar represents 100μm. (C) Western blot analysis for Kindlin-1 expression in MDA-MB-231 shRNA 
Kin1 cells +/– doxycycline (dox) to induce knockdown of Kindlin-1 compared to a non-targeting shRNA 
(NT) control. 𝜷-actin was used as a loading control. Kindlin-1 protein expression was significantly lower 
with addition of doxycycline in shRNA Kin1 cells. Expression was analysed by Fiji; values are mean ± 
SEM of three replicates. Protein expression was normalised to shRNA NT -dox cells. (*p<0.05). P values 
were obtained by a two-way ANOVA. (D) Gene expression analysis of FERMT1, RFP, TNC and IL-6 in 
MDA-MB-231 shRNA Kin1 cells –dox and +dox to induce knockdown of Kindlin-1 compared to a shRNA 
NT control for FERMT1 and RFP expression. Expression was analysed by qRT-PCR; values are mean ± 
SEM of three experiments. Gene expression was normalised to NT -dox cells for FERMT1 and RFP 
expression and Kin1 –dox cells for TNC and IL-6 expression. (*p<0.05). P values were obtained by a 






Figure 18. Kindlin-1 does not regulate mammosphere growth in MDA-MB-231 cells. (A) Quantitative 
analysis of mammosphere formation in primary and secondary mammopsheres in Kindlin-1 deficient 
MDA-MB-231 cells. Combined data (mean ±SEM) from 3 independent experiments is shown for cell 
lines and a one-way ANOVA performed. (B) Gene expression analysis in Kindlin-1-deficient secondary 
mammospheres. Expression was analysed by qRT-PCR; values are mean ± SEM of triplicate 





3.4 Characterisation of the effect of Kindlin-1 on stem cell activity in MDA-MB-231 
cells  
We next used the inducible Kindlin-1 shRNA model to investigate Kindlin-1 loss on 
stem cell activity in MDA-MB-231 cells. Loss of Kindlin-1 did not have a significant 
effect on the formation of primary mammospheres and although there was a small 
reduction in secondary mammospheres with Kindlin-1 loss, this was not significant 
(Fig. 18). Furthermore, TNC expression was also unaltered by Kindlin-1 loss in 
secondary mammospheres (Fig. 18B).  
 
3.5 Kindlin-1 and Tenascin C are highly expressed in human lung metastatic MDA-
MB-231 cells 
In order to explore further the role of Kindlin-1 in breast cancer, protein levels of 
Kindlin-1 in a lung metastatic variant of the human breast cancer cell line, MDA-MB-
231, were compared to its parental counterpart (Fig. 19A). The lung metastatic 
variant was shown to have increased Kindlin-1 expression compared to its parental 
counterpart (Fig. 19A). Previously, the lung metastatic variant MDA-MB-231 cell line 
has been shown to have increased mammosphere secondary formation that has 
been linked to a greater TNC expression (205) and we were also able to confirm 
increased TNC expression (Fig. 19B). As we have previously shown that Kindlin-1 
regulates Tnc in the Met-1 model, we hypothesised that Kindlin-1 may be important 
in the lung metastatic MDA-MB-231 variant, which is dependent on TNC for 
mammosphere formation. In order to investigate this hypothesis, CRISPR-cas9 
technology was used to knock out Kindlin-1 in the lung metastatic variant of the 
human breast cancer cell line, MDA-MB-231 as it was shown to have increased 
Kindlin-1 expression compared to its parental counterpart (Fig. 19A,C). The pool of 
lung metastatic MDA-MB-231 CRISPR-Kindlin-1 cells generated, had a distinct 
decrease in expression of Kindlin-1 in comparison to the control cell lines generated 





Figure 19. Kindlin-1 and tenascin-C expression is significantly higher in a human breast cancer cell 
line that has high capacity to colonise the lungs in mice. (A) Western blot analysis for Kindlin-1 
expression in a lung metastatic variant of MDA-MB-231 cells compared to their parental counterpart 
(left). 𝜷-actin was used as a loading control. Kindlin-1 protein expression quantification in the lung 
metastatic variant compared to their parental counterpart (right). Expression was analysed by Fiji; 
values are mean ± SEM of five replicates. Protein expression in lung metastatic cells was normalised 
to parental cells. (**p<0.01). P values were obtained by a two-tailed Student’s t test. (B) Tenascin-C 
expression in the lung metastatic variant compared to their parental counterpart. Expression was 
analysed by qRT-PCR; values are mean ± SEM of five experiments. Gene expression in lung metastatic 
cells was normalised to parental cells. (**p<0.01). P values were obtained by a two-tailed Student’s t 
test. (C) Western blot analysis demonstrating loss of Kindlin-1 expression in the lung metastatic variant 
of MDA-MB-231 cells. 𝜷-actin was used as a loading control. 
 
complete knockout of Kindlin-1, however, due to problems with the specificity of new 
batches of the Kindlin-1 antibody, confirmation of complete knockdown was difficult 




Biotech before proceeding. Time delays due to Covid-19 has meant that this has not 
been pursued further. 
 
3.6 Characterisation of the effect of Kindlin-1 on the outgrowth of 
micrometastases  
As the Brunton group previously demonstrated that pulmonary metastatic burden is 
reduced with loss of Kindlin-1 in the Met-1 model (185), we set out to establish 
whether Kindlin-1 regulates outgrowth of micrometastases in the MDA-MB-231 
model.  Mice were inoculated intravenously with MDA-MB-231 shRNA Kin1 tumour 
cells and the cells allowed to seed in the lungs for one day before knockdown of 
Kindlin-1 was induced. H&E were used to stain sections (Fig. 20A) and the area 
covered by metastases was confirmed by lamin A+C immunohistochemistry (Fig. 
20C). Stained H&E sections were used to quantify the area covered by metastasis and 
after 14 days, there was no significant difference in percentage area of metastases 
found (Fig. 20B), however, IHC using a Kindlin-1 antibody showed that there was no 
reduction in Kindlin-1 expression (Fig. 20C). We also observed RFP staining in the 
metastases in the presence and absence of doxycycline suggesting that the promoter 
was leaky (Fig. 20C). Similar expression of tenascin C was observed in the two 
different groups (Fig. 20C). 
 
In the previous experiment (Fig. 20C), IHC suggested that knockdown of Kindlin-1 was 
not achieved and we had concerns with regards to the specificity of the Kindlin-1 
antibody and decided to confirm knockdown using RT-qPCR. The metastases formed 
in the lungs were too small to remove from the lungs to extract only RNA 
corresponding to the tumour cells and perform RT-qPCR for Kindlin-1 expression. 
Therefore, to assess whether sufficient knockdown of Kindlin-1 could be achieved in 
vivo, MDA-MB-231 shRNA Kin1 cells were injected into the mammary fat pad (Fig. 
21). RNA was extracted from the tumour cells and RT-qPCR was performed for 




1 expression was significantly reduced and RFP expression significantly increased in 
mice receiving doxycycline compared with the control group (Fig. 21C). 
 
Staining showed an increase in RFP expression with the addition of doxycycline, 
however, similar levels of Kindlin-1 expression were observed in both groups 
suggesting that the antibody was binding non-specifically (Fig. 22). The levels of 
tenascin-C expression in the mice receiving the doxycycline diet were similar to those 
receiving the control diet (Fig. 22). Tumours from the CD-1 nude mice receiving the 
doxycycline diet had a reduced growth rate compared to those receiving the normal 
diet suggesting that Kindlin-1 may regulate primary tumour growth in this model, 
however, only one time point in the experiment reached significance (Fig. 21A). 
Statistical analysis of the final tumour volume showed a significant reduction in 
volume at day 25 with loss of Kindlin-1 (Fig. 21B). The experiment was repeated to 
establish if the data was reproducible using SCID mice and MDA-MB-231 shRNA Kin1 
tumour fragments were implanted into the mice to reduce the time taken for 
tumours to appear (Fig. 23). In this experiment, two of the groups received 
doxycycline to induce knockdown of Kindlin-1. One group received doxycycline at day 
zero to evaluate if knockdown of Kindlin-1 affects tumour initiation in this model and 
one group at day seven to evaluate if Kindln-1 knockdown affects the outgrowth of 
the tumour once it has been established (Fig. 23). There was no significant difference 
between the growth rates of either of these groups compared to mice receiving the 
control diet and the growth rates followed a similar trend (Fig. 23A). We also did not 
find a significant difference between the final tumour volumes of the groups (Fig. 
23B). Analysis of mRNA confirmed that the knockdown had been successful as 
expression of Kindlin-1 was significantly reduced and RFP expression significantly 









Figure 20. Pulmonary metastasis was not altered in mice inoculated with MDA-MB-231 shRNA Kin1 
cells. (A) Representative haematoxylin and eosin staining of lung metastases from mice inoculated 




magnification: ×2.5. Scale bar represents 100μm. (B) Total area covered by metastatic lesions in lungs 
after injection of MDA-MB-231 shRNA Kin1 cells –dox and +dox. Values are means ± SEM (n=4 mice 
per group, p=ns, Student’s t test). Quantification was performed using QuPath. (C) 
Immunohistochemistry staining of Lamin A+C, RFP, Kindlin-1 and Tenascin-C protein expression in 
lungs of MDA-MB-231 shRNA Kin1 cells –dox and +dox mice. Objective magnification: ×20. Scale bar 
represents 100μm. 
 
3.7 Tumour growth is significantly reduced with loss of Kindlin-1 in Met-1 cells in 
immunocompetent and immunodeficient mouse models and Kin1-Null tumours 
have significantly reduced regulatory T cells  
We then proceeded to establish whether loss of Kindlin-1 affected primary tumour 
growth in a subcutaneous Met1 model. As described earlier in this chapter, a model 
of Kindlin-1 loss was previously generated in Met-1 cells and WT-Kindlin-1 re-
expressed into Met-1 Kin1-Null cells to generate Met-1 Kin1-WT cells (185). 
Additionally, a mutant Kindlin-1, in which glutamine 611 and tryptophan 612 was 
mutated to alanine was also re-expressed into Met-1 Kin1-Null cells to generate 
Kindlin-1 AA cells (Kin1-AA) (185). Tryptophan 612 is critical for integrin binding and 
its mutation to alanine, renders it unable to bind β-integrin tails (145). The Kin-1 AA 
cell line enables the role of Kindlin-1 and integrin activation to be investigated in the 
cell line. Mice were inoculated with Met-1 cells subcutaneously and loss of Kindlin-1 
reduced the growth rate in the immunocompetent FVB mice (Fig. 24A) and in the 
immunodeficient CD-1 nude mice (Fig. 24C). The final tumour volume was 
significantly reduced in both FVB (Fig. 16B) and CD-1 mice (Fig. 24D) that were 
inoculated with Met-1 Kin1-Null cells compared to mice inoculated with Kin1-WT and 
Kin1-AA cells. There was an initial time delay in the growth rate of tumours from mice 
inoculated with Met-1 Kin1-AA cells, which expressed a mutant Kindlin-1 that is 
unable to bind to integrin (Fig. 24A,C). The growth rate of Met-1 Kin1-AA tumours 
initially mirrored Kin1-Null tumours but Kin1-AA tumours later caught up to the 
growth rate of Kin1-WT cell tumours (Fig. 24A,C). This suggests that integrin 
activation by Kindlin-1 is required for tumour initiation but once the tumour has been 










Kin1 cells. (A) Mean (±SEM) tumour growth from mice inoculated with MDA-MB-231 shRNA Kin1 cells 
–dox or +dox to induce knockdown of Kindlin-1 (n=8 tumours per group, *p<0.05, two-way ANOVA). 
(B) Mean (±SEM) tumour volume at day 25 (n=8 tumours per group, *p<0.05, student’s t test). (C) 
FERMT1 and RFP expression in MDA-MB-231 shRNA Kin1 cells –dox or +dox tumours. Expression was 
analysed by qRT-PCR; values are mean ± SEM of 3 tumours for –dox cells and 4 tumours for +dox cells. 
Gene expression in lung metastatic cells was normalised to -dox cells. (**p<0.01). P values were 
obtained by a two-tailed Student’s t test.  
 
Figure 22. Immunohistochemistry staining of MDA-MB-231 shRNA Kin1 cells –dox and +dox 
subcutaneous tumours. Representative images of immunohistochemistry staining of RFP, Kindlin-1 
and Tenascin-C in MDA-MB-231 shRNA Kin1 cells –dox and +dox subcutaneous tumours from CD1 








Figure 23. Kindlin-1 knockdown in SCID mice subcutaneously inoculated with MDA-MB-231 shRNA 
Kin1 cells. (A) Mean (±SEM) tumour growth from mice inoculated with MDA-MB-231 shRNA Kin1 cells 
–dox or +dox at day 0 or day 7 to induce knockdown of Kindlin-1 (n=10 tumours per group, p=ns, two-
way ANOVA). (B) Mean (±SEM) tumour volume at day 21 (n=10 tumours per group, one-way ANOVA). 
(C) Analysis of FERMT1, RFP and IL-6 expression in MDA-MB-231 shRNA Kin1 cells –dox or +dox 
tumours. Expression was analysed by qRT-PCR; values are mean ±SEM of 4 tumours for –dox cells, 5 
tumours for +dox day 0 cells and 4 tumours for +dox day 7 cells. Gene expression was normalised to -
dox cells. (*p<0.05,**p<0.01, one-way ANOVA). 
 
Interestingly, whereas loss of Kindlin-1 in the immunocompetent, FVB mice resulted 
in complete reduction in growth rate and clearance of the tumour (Fig. 24A-B), in the 
CD-1 nude immunocompromised mouse model, the growth rate was reduced but the 
tumour was not completely cleared (Fig. 24C-D). CD-1 nude mice lack T cells (229), 
which suggests that Kindlin-1 may regulate T cell responses. 
 
Data from our group showed that in vitro, Met-1 Kin1-Null cells express IL-6 whereas 
Kin1-WT cells do not (Fig. 25A). This is important as Tregs actively supress the anti-
tumour immune response (230). IL-6 is an important cytokine in pushing the 
differentiation of naïve CD4+ T cells away from regulatory T cells (Tregs) and towards 
T helper 7 (Th17) cells (Fig. 25B) (231). Data from our group also showed that tumours 
from Met-1 Kin1-Null mice have significantly reduced Tregs, which is demonstrated 
by significantly reduced levels of the transcription factor, FoxP3, a specific marker of 
Tregs (Fig. 25C) (230). In addition, in vitro conditioned media from Kin-1 Null cells 
caused naïve CD4+ T cells to differentiate into Th17 cells, which is demonstrated by 
higher levels of the transcription factor RoRgammaT, a marker of Th17 cells (Fig. 25D) 
(232). As IL-6 protein levels were significantly increased in Kin1-Null cells, we also 
examined IL-6 mRNA expression, however, IL-6 mRNA did not significantly differ 
between Kin1-Null and Kin1-WT cells suggesting that Kindlin-1 does not 
transcriptionally regulate IL-6 (Fig. 25E).  
 
As differential tumour growth with Kindlin-1 loss in the immunocompetent and 




Figure 24. Tumour growth is significantly reduced with loss of Kindlin-1 in Met-1 cells in FVB and CD1 
mice models. (A) Mean (±SEM) tumour growth of FVB mice inoculated with Met-1 Kin1-Null, Kin1-WT 
or Kin1-AA cells (n=16 tumours per group). (B) Mean (±SEM) tumour volume at day 16 of FVB mice 
inoculated with Met-1 Kin1-Null, Kin1-WT or Kin1-AA cells (n=16 tumours per group, ***p<0.001, 
****p<0.0001, one-way ANOVA). (C) Mean (±SEM) tumour growth of CD-1 nude mice inoculated with 




Null and Kin1-AA cells). (D) Mean (±SEM) tumour volume at day 14 of CD-1 nude mice inoculated with 
Met-1 Kin1-Null, Kin1-WT or Kin1-AA cells (n=12 tumours for Kin1-WT cells and n=14 tumours for Kin1-
Null and Kin1-AA cells, ****p<0.0001, one-way ANOVA).  
 
 
Figure 25. Met-1 Kin1-Null cells produce IL-6 and have an increased population of T helper 17 cells. 
(A) Quantitative analysis of IL-6 expression by ELISA assay in concentrated media of Met-1 Kin1-Null, 
Kin1-WT and parental cells. Combined data (average±SEM) from 6 independent experiments is shown 
for cell lines and a one-way ANOVA performed to test for statistical significance (***p<0.001). (Data 




away from T regulatory (Tregs) cells and towards T helper 17 (Th17) cells. This is important as Tregs 
are regulatory T cells and actively supress the immune response to tumour cells. (Data from Emily 
Webb) (C) Quantitative analysis of T cell markers by flow cytometry in Met-1 Kin1-Null and Met-1 Kin-
1 WT tumours. Combined data (average±SEM) from 5 tumours is shown for each cell line (**p<0.01). 
P values were obtained by a two-tailed Student’s t test. (Schematic produced by Emily Webb) (D) Flow 
cytometry analysis of transcription factor RoRgammaT in CD4+ T cells in Met-1 Kin1-Null and Kin1-WT 
cells treated with Met-1 Kin1-Null conditioned media (Data from Emily Webb) (E) Expression of Il-6 
was analysed by qRT-PCR; values are mean ± SEM of triplicate experiments. Gene expression in Met-
1 Kin1-Null cells was normalised to Met-1 Kin1-WT cells and a two-tailed Student’s t test was 
performed to test for statistical significance. 
 
performed IHC with the immune markers B220 and CD3 (Fig. 26). B220 is commonly 
used as a pan B cell marker in mice but is only expressed by a subset of B cells in 
humans (233). It may act as differentiation-specific marker in human B cells, marking 
mature naïve B cells (233). Tumours from Met-1 Kin1-WT and Kin1- AA cells had some 
diffuse B220 staining whereas, Kin1-Null tumours were largely negative for B220 (Fig. 
26A). In order to look at the T cells, tumours were stained with CD3, which is a highly 
effective T cell marker as it is present at all stages of T cell development and is 
exclusive to the T cell lineage (234). Met-1 Kin1-WT and Kin1-AA tumours were 
mostly negative for CD3 staining compared to Kin1-Null tumours (Fig. 26B).  
 
As data from the Met-1 model showed that Kindlin-1 regulated IL-6 at the protein 
level, we looked at IL-6 expression in the MDA-MB-231 model, however, IL-6 did not 
significantly differ between the groups in vitro or in vivo (Fig. 27).  To further 
investigate if Kindlin-1 has a role in regulating T cells, we also performed IHC with 
immune markers in the tumours from the CD1 nude mice to evaluate if Kindlin-1 
affects the immune system in a human model (Fig. 28). The mouse tissues (Fig. 26) 
were run alongside the human tissues as a positive control, however, tumours from 
shRNA Kin-1 –dox and +dox stained negatively for B220 (Fig. 28A) and CD3 (Fig. 28B) 












Figure 26. Presence of immune markers in tumours from FVB mice inoculated with Met-1 cells. 
Representative images of immunohistochemistry staining of (A) B220 and (B) CD3 in Met-1 Kin1-Null, 
Kin1-WT and Kin1-AA cells. Objective magnification: 5x (left) and 20x (right). Scale bar represents 






Figure 27. Analysis of IL-6 expression in the MDA-MB-231 model. (A) Analysis of IL-6 expression in 
MDA-MB-231 shRNA Kin1 cells –dox or +dox cells. Expression of Il-6 was analysed by qRT-PCR; values 
are mean ± SEM of triplicate experiments. Gene expression in +dox cells was normalised to –dox cells 
and a two-tailed Student’s t test was performed to test for statistical significance. (B) Analysis of IL-6 
expression in MDA-MB-231 shRNA Kin1 cells –dox or +dox tumours from SCID mice. Expression was 
analysed by qRT-PCR; values are mean ±SEM of 4 tumours for –dox cells, 5 tumours for +dox day 0 
cells and 4 tumours for +dox day 7 cells. Gene expression was normalised to -dox cells. 
(*p<0.05,**p<0.01, one-way ANOVA).  
 
3.8 Characterisation of a Kindlin-1 antibody generated by Movarian-Biotech 
Due to problems with the specificity of the Abcam Kindlin-1 antibody (Fig. 24), a 
polyclonal Kindlin-1 antibody was designed by our group and generated by Movarian-
Biotech. The epitopes used to generate the Kindlin-1 antibody were designed to react 
with both mouse and human Kindlin-1 sequences at the C-terminus (Fig. 29A). The 
Abcam antibody is a polyclonal antibody that has been raised to react with mouse 
and human Kindlin-1 sequences at the C-terminus (Fig. 29B). The Movarian Biotech 





Figure 28. Presence of immune markers in tumours from CD-1 nude mice inoculated with MDA-MB-
231 shRNA Kin1 cells. Representative images of immunohistochemistry staining of (A) B220 and (B) 
CD3 in MDA-MB-231 shRNA Kin1 cells –dox and +dox subcutaneous tumours. Objective magnification: 










Figure 29. Evaluation of Kindlin-1 antibody generated by Movarian-biotech. (A) Alignment of 
epitopes raised against the Kindlin-1 sequence for generation of the Movarian-Biotech Kindlin-1 
antibody (B) Alignment of the epitope raised against the Kindlin-1 sequence for the generation of the 
Abcam Kindlin-1 antibody (C) Western blot analysis for Kindlin-1 expression in Met-1 A1 Kin1-Null, 
Kin1-WT and Kin1-AA cells using the Movarian-Biotech and Abcam Kindlin-1 antibodies. 𝜷-actin was 
used as a loading control. (D) Immunohistochemistry staining of Kindlin-1 protein expression in Met-1 
A1 Kin1-Null, Kin1-WT and Kin1-AA cells and MDA-MB-231 shRNA Kin1 cells –dox and +dox cells. 





line (Fig. 29C). Both antibodies specifically bound to Kindlin-1 in Met-1 Kin1-WT and 
Kin1-AA cells and a band was not detected in Kin1-Null cells (Fig. 29C). 
Immunohistochemistry staining of Met-1 cell pellets using the Movarian Biotech 
antibody demonstrated that the antibody stained Met-1 Kin1-WT and Kin1-AA cells 
but did not stain cells from Met-1 Kin1-Null cell line (Fig. 29C). The Movarian Biotech 
antibody stained both MDA-MB-231 shRNA Kin1 –dox and +dox cells, suggesting that 
the antibody might non-specifically stain human cells (Fig. 29D).  
 
3.9 Discussion 
3.9.1 Regulation of mammosphere formation by Kindlin-1 
As we previously showed that Kindlin-1 regulates Tnc (185) and tenascin-C has a 
defined role in regulating cancer stem cell self-renewal through the regulation of the 
Notch and Wnt pathways via MSI1 and LGR5, respectively (205), we sought to 
establish if Kindlin-1 has a role in regulating stem cell activity. The in vitro 
mammosphere assay can be used to define early stem cell or early progenitor activity 
through the generation of primary mammospheres and investigate stem cell self-
renewal through the generation of secondary mammospheres (212). The first results 
from the mammosphere assay suggested that FERMT1 expression significantly 
increased secondary formation of mammospheres and therefore, Kindlin-1 may have 
a role in cancer stem cell self-renewal (Fig. 13). Previous data from the Brunton group 
using the PyMT murine model of breast cancer, showed that loss of Kindlin-1 has an 
effect on tumour initiation, which is suggestive of an effect on stem cells. 
Furthermore, integrins, including β1 integrin, which Kindlin-1 is known to bind, have 
been associated with the differentiation (235,236) and self-renewal properties of 
stem cells (237,238). For example, it has been shown that in PyMT mice, β1 integrin 
is necessary for the generation or amplification of CD24highCD29lowCD61high 
cancer cells (239,240). Collectively, this suggests that Kindlin-1 may have a role in 




assay, we did not see the same effect on mammosphere self-renewal with loss of 
Kindlin-1 and saw a large variation between the replicates of each experiment 
(Compare Fig. 13C with Fig. 16C and 16D).  
 
There are a number of methodological difficulties with the in vitro mammosphere 
assay and several limitations to the assay, which may affect accuracy of results and 
account for the variation in results we obtained when performing the assay. The key 
principle of the mammosphere assay is that each mammosphere is derived from a 
single cell and is therefore clonal. Fusion or aggregation of mammospheres can either 
occur as a result of plating density or movement of plates during the culture period, 
or when examining cultures under the microscope and this can result in problems 
with interpretation of results. Furthermore, cell loss can happen when dissociating 
primary mammospheres for generation of secondary mammospheres, which can also 
affect the results produced. Additionally, the protocols that are used by different 
groups vary, which can mean that the results are inconsistent. The mammosphere 
assay performed in this project involved counting the number of mammospheres in 
the whole well, whereas some research groups take several random images of the 
wells and perform calculations using the number of mammospheres per field, which 
may not be a true representation of the results. We have analysed and displayed the 
primary and secondary mammospheres as mammosphere forming efficiency 
percentage and mammosphere self-renewal percentage, whereas some groups 
present the data as spheres/10,000 cells or the number of mammospheres per field, 
which makes it difficult to compare the results from different studies.  
 
As well as mammosphere assays, colony forming assays have been used as an in vitro 
quantitative technique to study cancer stem cells. The colony forming assay is an 
agarose-based assay that examines the capability of a single cell to grow into a large 
colony through clonal expansion (241). This assay could be a useful alternative to the 
mammosphere assay and may provide a solution to some of the issues with the 




In addition, to explore if the conflicting results that we obtained from the 
mammosphere assay are a result of the variability of the assay, comprehensive 
analysis of stem cells markers in vitro could be carried out as only a small selection of 
these markers were evaluated in this study (Fig. 14). The cell surface markers of 
breast CSCs have been determined through in vivo experiments in which human 
breast cancer cells are grown in immunocompromised mice. One study showed that 
the oncogenic subpopulation expressed CD24-/CD44+ surface markers and only this 
minority of tumour cells could initiate new tumours (25). Therefore, it would be 
beneficial to analyse CD24-/CD44+ cell populations in the mammospheres by FACs in 
order to detect whether the mammosphere assay selects for breast CSCs.  
 
Although in vitro mammosphere assays may demonstrate the capability of cells to 
display stem cell traits, they are not a read out of in vivo stem cell frequency as they 
do not capture the complexity of CSC formation or behaviour in vivo (242). 
Mammosphere assays lack the niche components such as the immune and stromal 
components that can be provided by xenograft transplantation experiments (243). 
Lineage tracing experiments rely on using markers to identify the CSC subset and 
enable the dynamic in vivo formation of CSCs to be traced (242). Thus, in vivo 
transplantation paradigms or in vivo lineage tracing experiments are required to 
complement the mammosphere assay and provide a more informative view of the 
CSC properties of a cell line.  
 
We also explored breast stem cell activity in a human model of breast cancer but 
despite obtaining sufficient knockdown of Kindlin-1 in a human breast cancer model 
(Fig. 17C-D), we did not observe an effect on mammosphere formation in the MDA-
MB-231 model (Fig. 18A) as observed in the initial mammosphere experiment in the 
Met-1 model (Fig. 13C). Although mammosphere self-renewal percentage was lower 
with knockdown of Kindlin-1, mammosphere self-renewal was not significantly lower 
(Fig. 18A). We saw some variation between the replicates of the mammosphere self-




made it difficult to identify small changes, however, the expression of TNC was also 
unaltered upon Kindlin-1 knockdown (Fig. 18B), which may correlate with the non-
significant mammosphere self-renewal result that we observed in the MDA-MB-231 
model. This suggests that the phenotype observed in the Met-1 model is not universal 
and cell type specific.  
 
A fundamental hypothesis of the CSC theory is that CSCs drive the formation of 
metastases. One area of research that explicitly implicates CSCs as metastasis-
initiating cells which, in association with the metastatic niche, generate metastatic 
nodules, is work on tenascin-C in breast CSCs by Oskarsson et al. (205). We have 
shown that Kindlin-1 expression correlates with TNC expression in a human breast 
cancer cell line that was used by Oskarsson et al. (205) for their research on tenascin-
C and pulmonary breast cancer metastasis (Fig. 21A-B). This finding correlates with 
previous data from the Brunton group, which showed a strong correlation between 
FERMT1 and TNC and the lung metastatic capacity of MDA-MB-231 variants (185). 
We used CRISPR-cas9 technology to knock out Kindlin-1 in the lung metastatic variant 
of the human breast cancer cell line (Fig. 19C), however, we were unable to confirm 
knockout in single cell clones due to issues with the specificity of a batch of the Abcam 
Kindlin-1 antibody by western blot. A Kindlin-1 antibody was designed by the Brunton 
group and generated by Moravian Biotech in order to overcome this problem (Fig. 
29), however, even though specificity of antibody for Kindlin-1 was demonstrated by 
western blot (Fig. 29C), we did not have time to pursue this further. As Kindlin-1 may 
be important for TNC expression in this model, future work to generate a Kindlin-1 
knockout cell line would be a useful tool to explore if loss of Kindlin-1 has an effect 
on mammosphere formation and stem cell signalling.   
 
As previous in vivo data from our group demonstrated that loss of Kindlin-1 
significantly reduced metastatic growth in the lungs of mice and we have shown here 
that Tnc is significantly increased in Met-1 mammospheres that express Kindlin-1 (Fig. 




metastatic human breast cancer cell line (Fig. 19A-B), this strongly suggests that 
Kindlin-1 has a role in stem cell regulation and further research needs to be carried 
out to explore the role of Kindlin-1 in regulation of stem cells. 
 
3.9.2 The role of Kindlin-1 in the regulation of signalling pathways that control 
stem cells. 
Expression of cancer cell-derived tenascin-C has been shown to promote breast 
cancer pulmonary metastasis by positively regulating two stem cell signalling 
pathways; Notch and Wnt (205) and as we found Kindlin-1 regulates Tnc expression 
(185), we explored expression of stem cell markers in the Met-1 mammospheres (Fig. 
14). Kindlin-1 has been previously reported to regulate the proliferation and 
differentiation of cutaneous epithelial stem cells through two different mechanisms; 
by activating the release of TGF-β via αvβ6 integrin and by inhibiting Wnt-β-catenin 
signalling through regulation of the expression of Wnt ligand via a mechanism that is 
independent of integrin (156). Our results suggested that loss of Kindlin-1 does not 
affect the Wnt pathway but instead suggested that Kindlin-1 may regulate stem cell 
self-renewal through the Notch pathway by regulating expression of a positive 
regulator of the Notch pathway, Msi1 (Fig. 14). As expression of tenascin-C in breast 
CSCs was previously linked to enhanced expression of MSI1 and regulation of the 
Notch pathway (205), we chose to investigate the Notch pathway. We did not follow 
up the implications of the differential expression of Nanog, which was significantly 
decreased in Kin1-WT secondary mammospheres (Fig. 14). Nanog is a master 
transcription factor that controls self-renewal and also, pluripotency of stem cells, 
however, it has been previously reported that disruption of TNC expression in 
secondary mammospheres does not affect expression of NANOG (205). In addition, 
it has been shown that overexpression of Nanog in adult mammary tissues of a 





We expected that inhibition of Notch signalling in both Met-1 Kin1-Null and Kin1-WT 
cells would result in decreased mammosphere formation. However, inhibition of 
Notch signalling did not negatively affect mammosphere formation in Kin1-Null or 
Kin1-WT cells (Fig. 16B,D) suggesting that the Notch pathway is dispensable for the 
induction of pluripotent stem cells in this model. Notably, studies using the GSI DBZ 
were in human breast cancer cell models, and these studies have shown that with 
addition of the inhibitor, the mammospheres generated are much smaller (228). The 
size of the Met-1 mammospheres generated in the presence of the inhibitor were 
not affected (Fig. 16A), further strengthening the argument that the Notch pathway 
is not essential for stem cell signalling in this murine breast cancer model. 
 
 In glioma, it has been reported that the intracellular domain of the Notch2 receptor 
can also bind to the Tnc promoter and as a result, a positive feedback loop may be 
established with Tnc expression and Notch signalling (245). We therefore expected 
Notch inhibition may decrease expression of Tnc, however, Tnc expression was not 
significantly altered with Notch inhibition in Kin1-Null and Kin-1 WT mammospheres 
(Fig. 16C). In addition, a higher level of cleaved Notch1 was found in Kin1-Null cells 
compared to Kin1-WT cells, suggesting that expression of Kindlin-1 inhibits cleavage 
of Notch1 (Fig. 15B). Our results appear to contradict the literature as we find 
significantly increased expression of Msi1, a positive regulator of the Notch pathway, 
and tenascin-C in Kin1-WT cells (Fig. 14) yet, we find less expression of cleaved Notch 
in Kin1-WT cells compared to Kin1-Null cells (Fig. 15B). Our results suggest that the 
Notch pathway does not have a general effect on mammosphere formation or 
expression of Tnc in this cell model. Kindlin-1 may regulate formation of 
mammospheres in the secondary generation through regulation of tenascin-C 
expression; however, the results suggest that Kindlin-1 does not engage in the Notch 
pathway to support the fitness of tumour-initiating cells in the Met-1 model.   
 
A multitude of signalling pathways which control normal stem cell self-renewal and 




CSC signalling. When dysregulated following mutation; Janus-activated kinase/signal 
transducer and activator of transcription (JAK/STAT) (246), WNT (247,248), Sonic 
Hedgehog (SHH) (249,250), Notch (251–253), phosphatidylinositol 3-
kinase/phosphatase and tensin homolog (PI3K/PTEN) (254,255), nuclear factor-κB 
(NF-κB) (256) and BMI1 (257,258) have all been linked to neoplastic proliferation in 
breast cancer. Therefore, it is possible that Kindlin-1 has a role in regulating of stem 
cells via a stem cell signalling pathway other than Notch. We have shown that Kindlin-
1 regulates the protein levels of the cytokine IL-6 (Fig. 13A) and as this protein has 
been linked to  NF-κB signalling (259), this could be an avenue to explore next.  
 
3.9.3 Regulation of tumour formation by Kindlin-1 
Previous research has shown that Kindlin-1 is a mediator of pulmonary breast cancer 
metastasis (185,186,207,209) and breast tumorigenicity (155,186). Clinical data has 
shown that kindlin-1 potentially mediates lung metastasis in breast cancer (186) and 
has also highlighted a potential role for Kindlin-1 in primary breast tumorigenesis as 
breast tumour tissues had significantly upregulated Kindlin-1 protein levels compared 
to normal adjacent breast tissue (155). Genes that promote metastasis are generally 
not associated with primary tumour growth, however, our data is consistent with 
previous research showing that Kindlin-1 loss decreases primary tumour growth (Fig. 
24). Sin et al. (186) showed that silencing of Kindlin-1 using an orthotopic mouse 
model prevented tumour growth and lung metastasis, however, these effects could 
be linked. As this is a spontaneous metastasis model, decreased metastasis could be 
a result of the reduced primary tumour growth observed with the suppression of 
Kindlin-1. Experimental metastases assays bypass this issue as cells are inoculated via 
the tail vein of mice and cells that survive the circulation, accumulate in the lungs and 
form micrometastases. Previous data from the Brunton group showed that 
metastatic burden was reduced with loss of Kindlin-1 in an experimental metastasis 
assay (185). In this study, in addition to the experimental metastasis model, the 




This model had no effect on primary tumour growth but delayed tumour onset and 
reduced metastasis demonstrating that the different models can give rise to different 
effects (185). Genetically engineered mouse models have spontaneous 
autochthonous tumour development, which may be important. Tumours from 
genetically engineered mouse models of metastasis develop in a normal context and 
in a system that possesses a functional immune system (260). 
 
Sin et al. (186) also investigated overexpression of Kindlin-1 and showed that these 
cells had increased  proliferation, clonogenicity, and invasion in vitro. These are 
hallmarks that are important for initiation and  progression of primary tumours from 
metastasis (19,56). Ectopic Kindlin-1 expression was also shown to induce EMT and 
this was associated with increased TGF-β signalling  (186). Several TGF-β target genes 
that have previously been linked to breast cancer progression were upregulated in 
Kindlin-1 overexpressing cells  (186). TGF-β signalling has been shown to promote 
lung metastasis formation in several transgenic mouse models suggesting that 
mechanistically, regulation of TGF-β signalling by Kindlin-1 may promote breast 
cancer progression (186,261,262). It has been speculated that Kindlin-1-mediated 
activation of αvβ6 integrin is responsible for increased TGF-β signalling in breast 
cancer as Kindlin-1 has been shown to activate αvβ6 integrin and promote TGF-β 
signalling in keratinocytes (131,171).  
 
We also demonstrate that activation of integrin by Kindlin-1 is required for tumour 
initiation in primary tumours as loss of Kindlin-1-integrin binding caused a distinct lag 
in tumour growth (Fig. 24A,C). Once the tumour has been established, tumours 
expressing a mutant Kindlin-1 that is unable to bind integrin grow to a similar volume 
as tumours that express Kin1-WT (Fig. 24A,C). This provides evidence that after 
tumour initiation has occurred, the interaction of Kindlin-1 with integrin is no longer 
necessary for tumour growth (Fig. 24A,C) and suggests that Kindlin-1 has roles 
independent of integrin that are important for tumour growth. Kindlin-1 has been 




suggested that Kindlin-1 may inhibit Wnt signalling at the transcriptional level by 
retaining transcriptional cofactors in the cytoplasm (171). As the integrin 
independent roles of Kindlin-1 are largely unknown and remain entirely unexplored 
in breast cancer, this study further highlights that these roles should be further 
scrutinised.  
 
To our knowledge, this is the first study to show evidence that the immune system 
impacts on the Kindlin’s ability to regulate tumour growth. Our results demonstrate 
that loss of Kindlin-1 in an immunocompetent mouse model results in complete 
clearance of the tumour (Fig. 24A-B), whereas loss of Kindlin-1 in an 
immunocompromised mouse model that has a reduced amount of T cells (229), does 
not result in complete clearance of the tumour by the immune system (Fig. 24C-D). 
We show that mechanistically, loss of Kindlin-1 post-transcriptionally upregulates 
production of the cytokine IL-6 (Fig. 25A,E), which causes differentiation of naïve 
CD4+ T cells into Th17 cells or differentiation of Tregs into Th17 cells (Fig. 25C-D). IL-
6 is responsible for moderating the balance between IL-17 secreting Th17 cells and 
Treg cells, which secrete TGFβ and IL-10 (Fig. 25B) (reviewed in (263)). IL-6 promotes 
the generation of Th17 cells from naïve CD4+ T cells together with TGFβ or 
contrastingly, inhibits generation of Tregs by TGFβ (Fig. 25B). Tregs are responsible 
for suppressing the anti-tumour immune response and stimulating immunological 
ignorance to tumour cells by limiting effector T cell responses (reviewed in (264)). 
Loss of Kindlin-1 decreases the numbers of Tregs in tumours (Fig. 25C) and increases 
the population of Th17 cells (Fig. 25D). Th17 cells produce the pleiotropic cytokine IL-
17, which in turn activates secretion of numerous pro-inflammatory cytokines and 
chemokines and results in tissue inflammation (reviewed in (265)). IL-17 has also be 
shown to induce neutrophil and macrophage recruitment and this has been shown 
to protect against microbes (266). Some studies have shown that Th17 cells can 
promote tumour growth but there is also evidence from murine tumour models that 
Th17 cells have anti-tumour effects, which correlates with our data. Th17 cells have 




(267) and also recruit immune cells and anti-tumour immune responses by triggering 
cytolytic CD8+ T cell responses (268). In addition, Th17 cells have been shown to 
positively predict patient outcome by activating the Th1-type chemokines CXCL9 and 
CXCL10 in ovarian cancer patients, which recruits effector T cells (269). Th17 cells 
have also been shown to promote differentiation of CD4+ T cells into effector T cells, 
which effectively destroy tumour cells in lung cancer (270). 
 
Staining suggested that tumours from Met-1 Kin1-Null cells had more T cells, 
compared to Kin1-WT tumours, however, Kin1-Null cell tumours were much smaller 
than Kin1-WT, which may account for this finding (Fig. 26B). In line with the literature, 
our results suggest that loss of Kindlin-1 promotes secretion of IL-6, which leads to 
differentiation of naive CD4+ T cells into Th17 cells and this has a protective anti-
tumour function. In future studies, an IL-6 inhibitor could be used in mice inoculated 
with Met-1 Kin1-Null cells to establish if this leads to a tumour growth phenotype 
similar to Met-1 Kin1-WT cells. Furthermore, effector T cell populations could be 
investigated in the tumours. 
 
We also investigated Kindlin-1 loss in a human breast cancer model and interestingly, 
we did not observe an effect on metastases formation in the lungs of mice inoculated 
with the MDA-MB-231 shRNA-Kin1 cells via the tail vein (Fig. 20A-B), contrary to what 
has been reported in the literature and what we have previously reported in the Met-
1 model (185,186,207,209). It has been reported that Kindlin-1 mRNA transcripts are 
upregulated in the basal B subtype of breast cancer (186) and therefore, as MDA-MB-
231 cell line is a basal B, TNBC cell line, we would expect loss of Kindlin-1 to reduce 
tumorigenesis. However, our results suggest that knockdown was not achieved as we 
found expression of Kindlin-1 in mice receiving the doxycycline diet (Fig. 20C). It is 
possible that there may have been an issue with the doxycycline diet in this 
experiment as we were able to confirm that FERMT1 expression was significantly 
reduced in a subsequent experiment where mice were subcutaneously inoculated 




However, the subcutaneous tumours with Kindlin-1 knockdown also stained positive 
for Kindlin-1 by IHC (Fig. 22), suggesting that the Kindlin-1 antibody non-specifically 
stains tissues. As Kindlin-1 expression is not completely abrogated in this model, 
some Kindlin-1 staining may occur in tumours from mice that received doxycycline 
diet and perhaps the concentration of the antibody needs to be optimised further for 
IHC use.  
 
Interestingly, our initial experiment evaluating Kindlin-1 loss in primary tumour 
growth using the MDA-MB-231 model in CD1 nude mice showed a significantly 
decreased final tumour volume with Kindlin-1 loss (Fig. 21B). This result suggested 
that Kindlin-1 reduces tumour burden in a human and mouse model in vivo. Notably, 
in an SCC model of Kindlin-1 loss, loss of Kindlin-1 has the opposite effect on tumour 
growth compared to the breast cancer models discussed here and loss of Kindlin-1 
significantly increases tumour volumes (210). It is possible that this is due to the 
different driver mutations that promote cancer development in different tumour 
types. Because of time restraints the tail vein experiment using new doxycycline diet 
was not revisited and we decided to focus on the subcutaneous data as we had 
interesting results with the Met-1 model.  
 
Intriguingly, a subsequent subcutaneous tumour growth experiment in SCID mice 
using the MDA-MB-231 model of Kindlin-1 loss did not affect the final tumour volume 
(Fig. 23B). As it is difficult to establish tumours in mice using the MDA-MB-231 cell 
line in the CD1 nude mice, we chose to use SCID mice for our second primary tumour 
experiment using the MDA-MB-231 model. We also transplanted tumour fragments 
into the mice in order to speed up the process. SCID mice have a mutation that results 
in both T and B cell deficiency (271) whereas CD1 nude mice have depleted T cells 
but functional B cells (229). As SCID mice are more immunocompromised than CD1 
mice, tumours established from human cell lines grow more easily in SCID mice 
compared to CD1 nude mice. However, we did not expect a difference in the growth 




date that Kindlin-1 effects B cell populations and experiments in CD1 and SCID mice 
would need to be repeated with identical conditions to test for this. It is possible that 
we saw a difference in tumour growths in the SCID mice compared to the CD1 mice 
because tumour fragments were transplanted into the SCID mice. Tumour fragments 
may react differently with loss of Kindlin-1 as they are established tumours and would 
have bypassed the tumour initiation phase that cells would undergo. This may mean 
that tumours are able to cope better with Kindlin-1 loss and therefore, we do not see 
a difference in the final tumour volumes in the SCID mice. The data from the CD-1 
mice demonstrates a significant effect on the growth rate in the early stages of the 
experiment (at day 7) with knockdown of Kindlin-1, which conforms with this 
hypothesis. As we have shown that tumour initiation is affected with loss of Kindlin-
1-integrin binding in the Met-1 model, taken together, this data provides more 
evidence to suggest that Kindlin-1 is important for the initial establishment of the 
tumour.  
 
In order to establish whether the significant difference in tumour volumes in the CD1 
nude mice is reproducible, the experiment needs to be repeated using the CD1 nude 
mice. In addition, generating a Kindlin-1 knockout MDA-MB-231 cell line would be 
useful to directly compare loss of Kindlin-1 in this model with the Met-1 model. 
Knockdown of Kindlin-1 using shRNA is not a clean model of Kindlin-1 loss, some 
Kindlin-1 expression will be present in the cell and this may account for smaller 
changes in tumour growth.  
 
3.9.4 Summary and Future Work 
In summary, our data strongly suggest that Kindlin-1 has a role in stem cell signalling, 
however, we have shown that Kindlin-1 does not act through the Notch pathway in a 
murine model of breast cancer and further experiments need to be carried out to 
investigate other pathways that Kindlin-1 may regulate. Further work to 




in vivo transplantation paradigms or in vivo lineage tracing experiments would 
provide a greater understanding into the role of Kindlin-1 in stem cell regulation. 
 
We have shown that Kindlin-1 regulates primary breast tumour formation and is 
important for the initial stages of tumour establishment in a mouse and human 
model. We have also demonstrated a novel role for Kindlin-1 in the regulation of T 
cells. We show that Kindlin-1 inhibits IL-6 production, which promotes differentiation 
of naïve CD4+ T cells into Tregs and results in tumour development due to 
suppression of the anti-tumour response of the immune system. For future studies, 
it would be valuable to further investigate the regulation of IL-6 by Kindlin-1 using an 









































It has already been shown that all three of the Kindlin isoforms bind to ILK. Kindlin-3 
was found to bind to ILK with the least affinity whilst Kindlin-2 was found to bind with 
the strongest affinity (160). ILK is an important regulator of integrin-mediated 
processes and its main function is as an adaptor protein partnering with the LIM 
domain protein, PINCH and the calponin homology domain protein, parvin to form 
the IPP complex, which is imperative for its function (162,272–276). ILK also binds to 
other FA proteins either directly or indirectly through either PINCH or parvin in order 
to mediate integrin-signalling and function as a scaffold protein at FAs (161,277–279). 
ILK has therefore been linked to numerous cellular processes, which include 
adhesion, differentiation, survival, migration and polarity, proliferation and invasion 
(as reviewed in (280)). 
 
Research has revealed that binding of Kindlin-2 to the IPP complex supports integrin 
activation (160). Binding of ILK to Kindlin also drives subcellular localisation of the 
Kindlins, however, work has focussed mainly on Kindlin-2 and Kindlin-3 and less is 
known about the role of Kindlin-1-ILK binding (160,281). Therefore, we wanted to 
establish if Kindlin-1 interacts with ILK similarly to Kindlin-2 at focal adhesions in a 
breast cancer and squamous cell carcinoma model. Furthermore, the importance of 
the role of Kindlin as an adaptor protein is clearly highlighted through its interaction 
with ILK. Therefore, we wanted to understand how the interaction of Kindlin-1 with 
other proteins may be significant and identify novel binding partners. 
 
Specific aims of this chapter include: 
1. Use immunofluorescence to identify if the subcellular localisation of ILK is 
dependent on Kindlin-1 
 






4.1 ILK localises to the focal adhesions in the presence and absence of Kindlin-1 in 
two different cancer models 
Because Kindlin-1 is known to bind to ILK in CHO cells (160), we first wanted to 
confirm that ILK binds Kindlin-1 in the Met-1 and SCC models. Models of Kindlin-1 
loss were previously generated in Met-1 (185) and SCC (210) cells. Similarly to 
generation of the Met-1 model previously described in chapter 3, WT-Kindlin-1 was 
re-expressed into SCC Kin1-Null cells to generate SCC Kindlin-1 WT cells (Kin1-WT) 
(210). Additionally, a mutant Kindlin-1, in which glutamine 611 and tryptophan 612 
was mutated to alanine, was re-expressed into SCC Kin-1 Null cells to generate SCC 
Kindlin-1 AA cells (Kin1-AA) (210). As explained in chapter 3, tryptophan 612 is critical 
for integrin binding and its mutation to alanine prevents Kindlin-1 binding to β-
integrin tails (145). The Kin-1 AA cell line enables the role of Kindlin-1 and integrin 
activation to be investigated in both cell lines. Immunoprecipitation using a Kindlin-
1-specific antibody was able to coimmunoprecipitate ILK confirming that Kindlin-1 
binds ILK in both the Met-1 and SCC models (Fig. 30). The loss of integrin binding 
(Kin1-AA) did not impact Kindlin-ILK binding in SCC cells (Fig. 30B). As Kindlin-1 binds 
ILK in both of these models, we next wanted to establish if loss of Kindlin-1 would 
impact the recruitment of ILK to FAs. In order to visualise FAs, we stained for the well-
characterised focal adhesion protein, FAK (282). In the absence of Kindlin-1, ILK is still 
recruited to FAs and colocalises with FAK in the Met-1 (Fig. 31) and SCC (Fig. 32) 
models. The loss of integrin binding (Kin1-AA) did not impact ILK localisation to FAs 
in the SCC cells (Fig. 32). It has previously been shown that the Kindlin-2-ILK 
interaction is necessary for FA localisation and so, as these cells also express Kindlin-
2, it is possible that Kindlin-2 can compensate for Kindlin-1 loss in these models and 
recruit ILK to FAs (281). It was not possible to stain for Kindlin-1 by 
immunofluorescence (IF) as we found both the Abcam Kindlin-1 antibody and the 




Figure 30. Kindlin-1 binds to ILK in two different cancer models. Western blot analysis demonstrating 
that immunoprecipitation using a Kindlin-1-specific antibody was able to co-immunoprecipitate ILK in 
(A) Met-1 and (B) SCC whole cell lysates.  
 
4.2 Identification of novel Kindlin-1 binding partners 
FAs provide a mechanical link between the ECM and the actin cytoskeleton through 
the interaction of the transmembrane proteins, integrins, with the ECM and with 
intracellular multi-protein assemblies that connect to the actin cytoskeleton (283). 
FAs are responsible for directing signalling from many proteins and inducing 
biochemical and mechanical outputs. Over sixty focal adhesion proteins have been 
discovered in vertebrates, which play catalytic and/or adaptor roles at focal 
adhesions (283). As very few Kindlin-1-focal adhesion protein binding partners have 
been determined (Fig. 7), immunoprecipitation with a Kindlin-1-specific antibody 




model and the human MDA-MB-231 cell model in order to identify novel Kindlin-1 




Figure 31. ILK is still able to localise at focal adhesions with Kindlin-1 loss in Met-1 cells. Confocal 
images of immunofluorescence staining of DAPI (blue), ILK (red) and FAK (green) in Met-1 cells. Scale 






















Figure 32. ILK is still able to localise at focal adhesions with Kindlin-1 loss in SCC cells. Confocal images 
of immunofluorescence staining of DAPI (blue), ILK (red) and FAK (green) in SCC cells. Scale bar: 50µm. 






4.2.1 Kindlin-1 binding partners in the Met-1 model  
Hierarchical clustering of the immunoprecipitated samples using Met-1 whole cell 
lysates demonstrated that samples from all of the three cell lines (Met-1 Kin1-Null, 
Kin1-WT and Kin1-AA) immunoprecipitated using the control IgG antibody, cluster 
together (Fig. 33). Samples using Met-1 Kin1-Null whole cell lysates 
immunoprecipitated with the Kindlin-1 antibody cluster alongside the control IgG 
samples demonstrating that immunoprecipitation with the Kindlin-1 antibody has 
enriched for Kindlin-1 associated proteins in the Met-1 Kin1-WT and Kin1-AA whole 
cell lysates (Fig. 33).  
 
Principal component analysis shows clusters of samples based on their similarity and 
demonstrates that samples from all cell lines immunoprecipitated with the control 
IgG antibody cluster together (Fig. 34A). Samples from the Kin1-WT and Kin1-AA cell 
lines that were immunoprecipitated with the Kindlin-1 antibody cluster together 
away from the Kin1-Null samples (Fig. 34B). Volcano plots show a clear difference in 
protein abundance between the Kin1-Null and Kin1-WT cell lines (Fig. 35A) and 
between the Kin1-Null and Kin1-AA cell lines (Fig. 35B). Samples from the Met-1 Kin1-
WT and Kin1-AA cell lysates immunoprecipitated with the Kindlin-1 antibody cluster 
together and the heat map shows that protein abundance is similar between the 
samples (Fig. 33). This was reaffirmed by the volcano plot, which shows that there is 
no significant difference in proteins binding to Kindlin-1 between the Kin1-WT and 
Kin1-AA cell lines (Fig. 35C).  
 
We decided to analyse the difference between the Kin1-Null and Kin1-WT cell lines 
only. A Students t-test identified that 70 proteins significantly bound to Kindlin-1 in 
Kin1-WT cells with an enrichment factor of 1.5-fold or greater (Fig. 36A), with 18 
proteins enriched greater than 2-fold (Table 11, Fig. 36B). As predicted, ILK was found 
amongst the list of genes binding to Kin1-WT, however, the two other members of 




analysis of the 70 proteins with an enrichment factor of 1.5-fold identified several 
hubs linked to the T-complex 1 (TCP1) protein-folding complex, components of the 
26S proteasome and proteins involved in the cell cycle and microtubule-based 
processes (Fig. 36A, 37C). The majority of these proteins have binding or catalytic 
activities (Fig. 37A) and are involved in cellular and metabolic processes (Fig. 37B).  
 
It has previously been shown that Kindlin-1 is involved in the cell cycle by regulating 
mitotic spindle assembly through phosphorylation of Plk1 (168). Kindlin-1 has also 
been shown to regulate microtubule function to enable mitosis (284), and four of the 
proteins identified through the proteomic analysis are involved in microtubule-based 
processes. These include: Tubulin Beta Class V (Tubb6), Valosin-containing protein 
(Vcp), Tubulin Beta 4B Class IVb (Tubb4b) and Dynein Cytoplasmic 1 Heavy Chain 1 
(Dync1h1). Interestingly, TUBB4B is known to regulate Plk1 at G2/M transition. 
Network analysis of the proteins involved in the cell cycle and microtubule-based 
processes identified in the data set may shed insight into how Kindlin-1 may be 
regulating cell cycle progression (Fig. 37D). Of significance, are the proteins of the 
mini-chromosome maintenance (MCM) family: Mcm6 and Mcm5. The MCM family 
of proteins are essential for initiating genome replication in eukaryotes and are key 
players of genome stability as they have been associated with DNA damage response, 
transcription and chromatin structure (285). Their expression is stable throughout 
the cell cycle and therefore, they are considered a sensitive marker of proliferation 
and high levels of these proteins are associated with tumour or precancerous cells  
(286).   
 
Other hits of interest include the eukaryotic translation elongation factor, eEF1A1, 
which is highly expressed in breast tumours and modulates the cytoskeleton (287) 
and proteins that are components of the 26S proteasome (Fig. 36), which is known 




Figure 33. Heat map with hierarchical clustering of label-free quantification (LFQ) values of proteins 
identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) that interact with 
Kindlin-1 from Met-1 whole cell lysates. “K” and “C” correspond to immunoprecipitation using either 
the Kindlin-1 or control IgG antibody and the numbers correspond to the technical replicates of each 
of the samples. The colours correspond to protein-relative abundance, using Z score normalised values 
(Kindlin-1 bait abundance is set to 1). On the bait-normalised scale, red and shades of red correspond 
to abundant interactions between Kindlin-1 and the hits, while white to blue colour indicates barely 





Figure 34. Principal component analysis (PCA) of samples from liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Samples are colour coded by cell line and condition. “K” and “C” 
correspond to immunoprecipitation using either the Kindlin-1 or control IgG antibody. (A) PCA of 
samples immunoprecipitated using either the Kindlin-1 or control IgG antibody (B) PCA of samples 






Figure 35. Volcano plots of the mass spectrometry data from the Met-1 model. Volcano plots of the 
mass spectrometry data demonstrate the magnitude and significance of the cellular proteins 
interacting with (A) Kindlin-1 WT (K_WT) and (B) Kindlin-1 AA (K_AA) compared to the negative control 
Kindlin-1 Null (K_Null). No difference was found between proteins interacting with K_WT compared 
to K_AA (C). The x-axis is the fold-change value (Kindlin-1 WT or Kindlin-1 AA/ Kindlin-1 Null) and the 





Figure 36. Met-1 Kindlin-1 WT interactome. A Students t-test (p<0.05) identified that 70 proteins (A) 
significantly bound to Kindlin-1 in WT cells with an enrichment factor of 1.5-fold or greater and 18 (B) 






Figure 37. Gene Ontology analysis of Kindlin-1 binding proteins. Pie charts show the (A) Molecular 
Functions, (B) Biological Processes and (C) Cellular Processes of the 70 proteins that significantly bound 
(p<0.05) to Kindlin-1 in WT cells with an enrichment factor of 1.5-fold or greater. (D) Network analysis 






Table 11. Functions of the 18 proteins identified by a Students t-test that significantly bound to 
Kindlin-1 in WT cells with an enrichment factor greater than 2-fold.  
Gene Name Function  
PSMC2 Proteasome 26S subunit, ATPase 2 (PSMC2) is an ATPase subunit of the 26S 
proteasome, which is a multiprotein complex that functions to degrade 
ubiquitinated proteins in an ATP-dependent manner. High expression of 
proteasome subunits has been found in different cancers including breast 
cancer and this correlates with the necessity of this complex for 
proliferation of tumour cells in tissues (289). 
NSUN2 NOP2/Sun RNA Methyltransferase 2 (NSUN2) is a tRNA methyltransferase 
that methylates mRNAs. It regulates the translation or turonover of mRNAs 
that are involved in processes such as cell proliferation, oxidative stress and 
replicative senescence (290–294). 
MTHFD1 Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and 
formyltetrahydrofolate synthetase 1 (MTHFD1) is a metabolic enzyme that 
catalyses tetrahydrofolate into substrates for de novo purine and 
pyrimidine synthesis (295). MTHFD1 is upregulated in several cancers and 
has been  associated with poor disease outcomes in breast cancer 
(296,297).   
PSMC1 Proteasome 26S subunit, ATPase 1 (PSMC1) is an ATPase subunit of the 26S 
proteasome (see above description for PSMC2). 
HADHA Alpha subunit of the mitochondrial enzyme, hydroxyacyl-CoA 
dehydrogenase trifunctional multi-enzyme (HADHA), which catalyses the 
last three reactions of mitochondrial beta-oxidation of long chain fatty acids 
(298). HADHA is downregulated in clear cell renal carcinoma and when 
overexpressed, has been shown to inhibit cancer growth by disrupting lipid 
metabolism (299).  
ACLY ATP-citrate lyase (ACLY) is an enzyme that cleaves citrate and coenzyme A 
to form oxaloacetate and acetyl-CoA. These molecules are essential to 
sustain pathways that support cancer cell growth (as reviewed in (300). 
PSMC3 Proteasome 26S subunit, ATPase 3 (PSMC3) is an ATPase subunit of the 26S 
proteasome (see above description for PSMC2). 
PSMC6 Proteasome 26S subunit, ATPase 6 (PSMC6) is an ATPase subunit of the 26S 
proteasome (see above description for PSMC2). 
PHGDH Phosphoglycerate dehydrogenase (PHGDH) is an enzyme involved in the 
initial step of the serine biosynthetic pathway. PHGDH is highly expressed 
in cancers including breast cancer (301). 
PSMC5 Proteasome 26S subunit, ATPase 5 (PSMC5) is an ATPase subunit of the 26S 
proteasome (see above description for PSMC2). 
TUFM Mitochondrial Tu translation elongation factor (TUFM) is a protein present 
in the mitochondria that that is involved in mitochondrial protein 
translation. Upregulation of TUFM has been reported in several cancers 
(302–306).  
PSMD2 Proteasome 26S subunit, non-ATPase 2 (PSMD2) is a non-ATPase subunit 




HSPH1 Heat shock protein family H member 1 (HSPH1) is a member of the heat 
shock protein 70 family. Heat shock proteins (HSPs) are chaperones 
involved in refolding of misfolded proteins and regulate other important 
cellular processes including secretion, transportation, translocation and 
protein degradation. They also regulate transcription factors. HSPs are 
overexpressed in a range of different cancers and many of the proteins they 
interact with are well known oncoproteins. (as reviewed in (307)) 
ALDH18A1 Aldehyde dehydrogenase 18 family member A1 (ALDH18A1) is a member 
of the aldehyde dehydrogenase family, which are a family of enzymes that 
detoxify intracellular aldehydes. High ALDH1 expression correlates with 
poor prognosis in breast cancer and has been linked to metastasis (51,308). 
In breast cancer, cells with high expression of members of the ALDH family 
have cancer stem cell properties (25,308).    
CCT8 Chaperonin containing t-complex polypeptide 1 subunit 8 (CCT8) is a 
subunit of the chaperonin, chaperonin containing t-complex polypeptide 1 
(CCT). Substrates for CCT are involved in protein folding and the subunits of 
the complex have been linked to different cancer types including breast 
cancer (309).  
ILK ILK is a FA protein that is required for effective integrin signalling and 
essential for development (161,310). It bind with PINCH and Parvin to 
form a mutiprotein complex that is necessary for its function (162,272–
276). Its functions include: adhesion, differentiation, survival, migration 
and polarity, proliferation and invasion (as reviewed in (280). 
MCM5 Minichromosome maintenance complex component 5 (MCM5) is a 
member of the minichromosome (MCM) family. The MCM family of 
proteins are involved in genome replication in eukaryotes and have roles 
in the DNA damage response, transcription and chromatin structure (285). 
Their expression is a marker of proliferation and therefore, their 
expression has been linked to cancer (286).   
CCT5 Chaperonin containing t-complex polypeptide 1 subunit 5 (CCT5) is a 
subunit of the chaperonin, chaperonin containing t-complex polypeptide 1 
(CCT). See above description for CCT8. 
 
We chose to follow up VCP and Dync1h1 from the Kindlin-1 binding hits in the Met-1 
model and verify these hits by co-IP. VCP appeared to be a contaminant in the data 
set based on co-IP experiments that were carried out (not shown). Western blot 
analysis showed that VCP was present in both Met-1 Kin1-Null and Kin1-WT cells 
immunoprecipitated with Kindlin-1. The CRAPome database (a contaminant 
repository for affinity purification coupled with mass spectrometry) also shows VCP 
as a contaminant in multiple  affinity purification experiments that have been coupled 
with mass spectrometry (311). Although an initial Dync1h1 co-IP experiment showed 




very variable upon repeat. There was not enough time to further optimise the 
conditions of the co-IP. For future experiments, different beads and different IP 
conditions could be tested. 
 
4.2.2 Kindlin-1 binding partners in the MDA-MB-231 model 
To look for common Kindlin-1 binding partners in different breast cancer models, 
immunoprecipitation with a Kindlin-1-specific antibody followed by mass 
spectrometry analysis was performed with the human MDA-MB-231 cell line. The 
experiment was carried out using a lung metastatic variant of the human MDA-MB-
231 cell line (MDA-MB-231-LM), alongside its parental counterpart (207). 
Hierarchical clustering of MDA-MB-231 whole cell lysates immunoprecipitated with 
the Kindlin-1-specific antibody cluster away from those immunoprecipitated with the 
control IgG antibody in both cell lines (Fig. 38A-B). Principal component analysis 
demonstrates that samples from cell lines immunoprecipitated with the control IgG 
antibody cluster together and away from the samples immunoprecipitated with the 
Kindlin-1 antibody (Fig. 39). 
 
More proteins were significantly differentially bound to Kindlin-1 with an enrichment 
factor of 2-fold in the lung metastatic variant (Fig. 40A,41B) compared to its parental 
counterpart (Fig. 40B,41B) when normalised against the IgG controls (51 compared 
to 35, respectively). Table 12 shows a list of genes only found in the lung metastatic 
cell line or the parental cell line. Similarly, to the mouse breast cancer model, gene 
ontology analysis showed that the majority of the proteins bound to Kindlin-1 in the 
parental and lung metastatic MDA-MB-231 cell lines have binding or catalytic 
activities (Fig. 42A,43A) and are involved in cellular and metabolic processes (Fig. 
42B,43B). Some of these proteins are also involved in the cell cycle and cell cycle 











Figure 38. Heat maps with hierarchical clustering of label-free quantification (LFQ) values of proteins 
identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) that interact with 
Kindlin-1 from MDA-MB-231 whole cell lysates. Cellular proteins interacting with Kindlin-1 compared 
to a negative IgG control in (A) Lung metastatic and (B) Parental MDA-MB-231 whole cell lysates. “K” 
and “C” correspond to immunoprecipitation using either the Kindlin-1 or control IgG antibody and the 
numbers correspond to the technical replicates of each of the samples. The colours correspond to 
protein-relative abundance, using Z score normalised values (Kindlin-1 bait abundance is set to 1). On 
the bait-normalised scale, red and shades of red correspond to abundant interactions between 






Figure 39. Principal component analysis (PCA) of samples from liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Samples are colour coded by cell line and condition. “K” and “C” 
correspond to immunoprecipitation using either the Kindlin-1 or control IgG antibody.  
 
 
Network analysis showed that the interactome of the lung metastatic variant was 
very similar to that of the parental cell line (Fig. 44,45). An interesting family of 
proteins that were found in both these data sets were proteins from the 14-3-3 
family, which mediate signal transduction by binding to phosphoserine-containing 
proteins and govern critical processes in cancer (312). β-catenin (CTNNB1) is also 
found in both cells lines and Kindlin-1 has previously been linked to increased 
canonical Wnt/β-catenin signalling (156). Notably, ILK was not present in the MDA-
MB-231 proteomic data sets (Fig. 44,45). However, all three data sets contained 
proteins from the MCM family (Fig. 36,44,45) and similarly to the Met-1 data set, the 
lung metastatic variant data set contained proteins that form the 26S proteasome 
(Fig. 36,44). Although we saw proteins from the same family of proteins, there were 
no common Kindlin-1 interactors found between the three cell lines (Fig. 41A). Only 
one common binder was found between the Met-1 Kin1-WT and the MDA-MB-231 




enzyme, hydroxyacyl-CoA dehydrogenase trifunctional multi-enzyme (HADHA) (Fig. 
36,44).  
 
Table 12. Proteins significantly differentially bound to Kindlin-1 in only the Lung metastatic or 
Parental cell lines with an enrichment factor of 2-fold or above.  




























Figure 40. Volcano plots of the mass spectrometry data from the MDA-MB-231 cell lines. Volcano 
plots of the mass spectrometry data demonstrate the magnitude and significance of the cellular 
proteins interacting with Kindlin-1 compared to the negative IgG control in the (A) Lung metastatic 
and (B) Parental cell lines. The x-axis is the fold-change value (Kindlin-1 Lung metastatic or Kindlin-1 






Figure 41. Venn diagrams of proteins significantly differentially bound to Kindlin-1 with an 
enrichment factor of 2-fold. The Met-1 Kin1-WT cell line was normalised against the Met-1 Kin1-Null 
cell line and the MDA-MB-231 cell lines were normalised against the IgG controls. (p<0.05 and 
enrichment factor was >2-fold) (A) Comparison of binders of Kindlin-1 in the Met-1 Kin1-WT cell line, 
lung metastatic variant MDA-MB-231 cell line and the parental counterpart. 18 proteins significantly 
differentially bound to Kindlin-1 in the Met-1 Kin1-WT cell line whilst 51 proteins significantly 
differentially bound to Kindlin-1 in the Lung metastatic cell line compared to 35 in the parental cell 
line. No common binders of Kindlin-1 were found between the three cell lines and only one common 




line. (B) Comparison of the lung metastatic variant MDA-MB-231 cell line and the parental 
counterpart. 31 proteins bound to Kindlin-1 in both the cell lines.  
 
Figure 42. Gene Ontology analysis of Kindlin-1 binding proteins in Lung metastatic MDA-MB-231 
cells. Pie charts show the (A) Molecular Functions, (B) Biological Processes and (C) Cellular Processes 
of the 51 proteins that significantly bound (p<0.05) to Kindlin-1 in Lung metastatic MDA-MB-231 cells 





Figure 43. Gene Ontology analysis of Kindlin-1 binding proteins in parental MDA-MB-231 cells. Pie 
charts show the (A) Molecular Functions, (B) Biological Processes and (C) Cellular Processes of the 35 
proteins that significantly bound (p<0.05) to Kindlin-1 in parental MDA-MB-231 cells with an 









Figure 44. Lung Metastatic MDA-MB-231 Kindlin-1 interactome. A Students t-test (p<0.05)  identified 
that 51 proteins significantly bound to Kindlin-1 with an enrichment factor of 2-fold or greater. 















Figure 45. Parental MDA-MB-231 Kindlin-1 interactome. A Students t-test (p<0.05) identified that 35 
proteins significantly bound to Kindlin-1 with an enrichment factor of 2-fold or greater. Network 













4.3 Discussion  
4.3.1 In the absence of Kindlin-1, ILK is still recruited to the FAs in Met-1 and SCC 
cancer models 
Consistent with studies using CHO cells, we found that ILK binds to Kindlin-1 in Met-
1 (Fig. 30A) and SCC cells (Fig. 30B). Unlike Kindlin-2, which has been previously 
shown to prevent localisation of ILK to FAs upon its depletion (134), Kindlin-1 loss was 
not found to affect localisation of ILK to the FAs of cells in Met-1 (Fig. 31) and SCC 
cells (Fig. 32). Although both Kindlin-1 and Kindlin-2 have been found to target to FAs 
in most expressing cells, Kindlin-2 has been shown to have a better ability to 
accumulate at FAs compared to Kindlin-1 (160). Kindlin-2 has also been found to bind 
with more affinity to ILK compared with Kindlin-1 (160) and loss of either Kindlin-2 or 
ILK results in similar cell spreading defects indicating that recruitment of ILK to FAs is 
necessary for the function of Kindlin-2 (161,281,313). This suggests that the Kindlin-
2-ILK interaction at focal adhesions may be more important compared with the 
Kindlin-1-ILK interaction and in the absence of Kindlin-1, presence of Kindlin-2 
enables ILK to be successfully recruited to FAs. Further work would be to investigate 
if loss of both Kindlin-1 and Kindlin-2 completely prevents recruitment of ILK to focal 
adhesions and to compare the differences in cell spreading between loss of Kindlin-2 
alone compared to Kindlin-1 and Kindlin-2 combined.  
 
4.3.2 Kindlin-1 binds to proteins that are involved in microtubule-based processes  
Our analysis has shed light on other proteins, which Kindlin-1 may also bind with to 
regulate microtubule-based processes. As Kindlin-1 is already known to regulate 
mitotic spindle assembly in breast cancer cells and promotes cellular survival (168), 
these results may provide a more detailed understanding of its role in regulating 
these processes. In mitosis, regulation of microtubules (MT) is important for bipolar 
spindle assembly, alignment of chromosomes and separation of sister chromatids. 
Loss of Kindlin-1 was shown to lead to abnormal spindle formation, a phenotype 




the Tubulin family, Tubulin Beta 6 and Tubulin Beta 4B Class IVb (TUBB4B) as potential 
Kindlin-1 binding partners in our proteomic analysis (Fig. 36A,37D). As the tubulin 
family proteins are components of the microtubule cytoskeleton and perform 
essential cellular functions through the cell cycle, it is unsurprising that we have 
identified proteins from this family. This finding is also consistent with previous 
research from the Brunton group, which identified α-tubulin in GFP-Kindlin-1 pull 
downs in MDA-MB-231 cells (284). 
 
Kindlin-1 is recruited to the centrosome through phosphorylation of threonine-30 by 
Plk1 and its concentration peaks during the G2/M phase (168). At the centrosome, 
Kindlin-1 subsequently mediates spindle formation through regulation of the 
cytoplasmic class II histone deacetylase 6, HDAC6, which is responsible for acetylating 
MTs (284). Acetylation of MTs is a direct readout of MT stability and depletion of 
Kindlin-1 was shown to reduce acetylated-tubulin levels, cause an increased 
incidence of toppled spindles and reduce cell proliferation, however, these defects 
could be reversed through inhibition of HDAC6 (284). Two other proteins identified 
in our analysis linked directly to microtubule-based processes were DYNC1H1 and 
VCP (Fig. 36A,37D). Cytoplasmic dynein is a highly conserved multi-subunit motor 
complex that moves towards the minus end of MTs and has housekeeping functions 
including orientation of the mitotic spindle, nuclear positioning, golgi maintenance, 
and endosomal dynamics (314). The complex consists of a heavy chain (DYNC1H1), 
an intermediate chain (DYNC1I1), a light intermediate chain (DYNLIC), and a light 
chain (DYNLC) (315). The complex has a long tail domain towards the N terminal of 
the protein that has docking sites for cargo, which includes mRNA, transcription 
factors, vesicles, growth factors and also adaptor proteins (314,316). The complex is 
transported from the cytoplasm into the nucleus, which may suggest a mechanism 
for the transport of Kindlin-1 to the nucleus (see next chapter – Fig. 46) (314). 
Cytoplasmic dynein been reported to promote tumour formation in several cancer 
types including colorectal, cervical and gastric cancer (316–318). In gastric cancer, 




upregulating IL-6 expression and increasing p65 nuclear translocation (a member of 
the NF-kB family) (316). As our group has previously shown differential expression of 
IL-6 in Met-1 Kin1-Null and Met-1 Kin1-WT cells (Fig. 25A), we would expect more 
expression of nuclear p65 in cells with increased IL-6 expression and nuclear p65 
translocation  has been followed up in chapter 5 (Fig. 52). Our validation experiments 
to confirm binding of Kindlin-1 to Dynch1h1 were inconclusive and further 
optimisation was required using different beads and conditions to confirm this 
interaction. 
 
We chose to follow up binding of Kindlin-1 to VCP in the Met-1 model as increased 
expression of VCP has been identified as a marker of poor prognosis in breast 
carcinoma as well as patients with cancer of the liver, stomach, prostate, colorectum, 
esophagus and lung (319–323). In HeLa cells, depletion of VCP prevented cell-cycle 
progression and was linked to mitotic abnormalities and apoptosis (324). VCP has also 
been shown to promote metastasis in osteosarcoma via an anti-apoptotic effect on 
cells (325). VCP expression lead to degradation of p-IKBα in the cytoplasm, enabling 
NF-kB to translocate into the nucleus and act as a protective factor against apoptosis 
leading to increased metastatic potential (325). In prostate cancer, IL-6 was shown to 
induce expression of VCP and lead to increased cell proliferation, migration, and 
invasion (326). As regulation of VCP is linked with IL-6 expression and our group has 
previously shown significantly different levels of IL-6 expression between the Met-1 
Kin1-Null and Kin1-WT cells, we used the co-immunoprecipitation to validate this 
interaction, however, VCP appeared to be a contaminant and not a real Kindlin-1 
interactor.  
 
4.3.3 Kindlin-1 binds to proteins that are important regulators of cell cycle 
progression  
Kindlin-1 has been reported to have a role in a number of different cellular 




localisation of Kindlin to FAs where it acts as an adaptor protein and helps to link the 
actin cytoskeleton to the ECM (118,177,327,328). Kindlin-1 loss has been reported to 
impair cell proliferation in vitro and in vivo, which has been linked to the phenotype 
of the skin in KS patients (149,177). In keratinocytes, Kindlin-1 has been shown to 
bind key regulators of cell cycle progression: CDK1 and CDK2 (137). In KS 
keratinocytes (which lack Kindlin-1), inhibition of CDK led to oxidative damage 
induced cell cycle arrest and DNA damage (137). In our analysis, we found Kindlin-1 
bound to MCM5 and MCM6 of the MCM family in Met-1 cells (Fig. 28A). As 
phosphorylation by kinases (including the CDK family) is imperative for tight 
regulation of the MCM family in DNA replication and cell cycle progression, these 
Kindlin-1 binding partners may be relevant to the Kindlin-1-CDK literature (329). 
Moreover, the adaptor protein, ILK, which we have shown to bind Kindlin-1 in the 
Met-1 model, interacts with MCM7 and suppresses cell growth (330). Kindlin-1 was 
found to bind to MCM proteins in both mouse and human models (Fig. 36A,44,45), 
suggesting that this family of proteins is universally important amongst these cell 
lines. Knockdown of the MCM proteins has already been shown to decrease cancer 
cell proliferation and the MCM proteins can also be inhibited by targeting their 
helicase activity (331,332), highlighting this family of proteins as potential cancer 
therapeutic targets. As an interaction with MCM proteins was identified in all 3 data 
sets (Fig. 36,44,45), IHC could be performed on tumours to look at expression of these 
proteins in future experiments. Notably, Met-1 cells do not appear to grow differently 
in vitro and we previously reported a difference in cell proliferation in vitro between 
the Met-1 cell lines but only at the final time point of a cell counting assay (211). An 
in vitro proliferation assay could be used to assess the effect of loss of Kindlin-1 in the 








4.3.4 Other relevant interactors of Kindlin-1   
In our analysis of the MDA-MB-231 data sets, we identified proteins from the 14-3-3 
family that are known to interact with multiple proteins that are involved in signal 
transduction, apoptosis, cell cycle and cell migration (Fig. 44,45) (333). The 14-3-3 
family are overexpressed in different cancer types and research has shown they may 
have a key role in regulation of pathways that are linked to cancer initiation and 
progression (334). The mechanism of regulation of target proteins is primarily 
through phosphorylation of serine and threonine residues (335) and research has 
also shown that they interact with α3β1 integrins in keratinocytes to promote cell 
adhesion and motility (333), which could be relevant to their interaction with Kindlin-
1 as a known binder of β1-integrin (Fig. 7). 
 
Another protein of interest that was identified in both MDA-MB-231 data sets was β-
catenin, a significant molecule in Wnt signalling (Fig. 44,45). It has already been 
reported that Kindlin-2 directly binds to active β-catenin, prevents its degradation 
and enables recruitment of TCF4 (170). This tripartite nuclear transcriptional complex 
promotes Wnt target gene expression, which enables tumour cell invasion (170). In 
contrast, Kindlin-1 supresses Wnt signalling, loss of Kindlin-1 was  shown to induce 
Wnt ligand transcription and expression of Wnt target genes (156). The mechanism 
of suppression on the Wnt pathway was thought to be through retention of 
transcriptional cofactors in the cytoplasm independent of integrin (171).  
 
Notably, we did not find common binders between all the three cell lines analysed 
(Fig. 33A) but we did find interactors from the same family of proteins (Fig. 36,44,45). 
HADHA was the only one common binder between the Met-1 Kin1-WT and the MDA-
MB-231 lung metastatic cell lines (Fig. 36,41A,44). Overexpression of this enzyme has 
an inhibitory effect on tumour growth in clear cell renal carcinoma mechanistically 





4.3.4 Summary and future work 
In summary, we have shown that loss of Kindlin-1 does not affect ILK recruitment to 
FAs and further research to investigate Kindlin-2 loss versus combined loss of Kindlin-
1 and Kindlin-2 are necessary in order to observe recruitment and compensatory 
mechanisms within the cell. Our findings suggest that Kindlin-1 is an adaptor protein 
in the cell that regulates a number of key signalling hubs, which control several 
cellular processes including metabolism, cell proliferation, cell migration (through 
regulation of MTs), apoptosis and signal transduction. Other approaches could be 
used to compliment the Kindlin-1 binding partner data here such as BioID, which is a 
technique that uses biotin ligase to biotinylate proteins based on proximity to the 
protein of interest in living cells (336). The ligase is coupled to the protein of interest 
and biotinylates proximal endogenous proteins that can then be selectively isolated 
and identified (336). Advantages of using this technique are that it can be used for 
insoluble proteins and can identify weak or transient protein interactions. BioID can 
also be used to identify interactions with proteins that are also only expressed at a 
certain time (336). Both immunoprecipitation and BioID can detect proteins that are 
not direct binders of the protein of interest but are part of multi-protein complexes. 
This could be the case for some of the tubulins we have identified as Kindlin-1 
interactors. It has been previously shown that Kindlin-1 does not directly bind α-
tubulin, Kindlin-1 binds to Plk1 directly and to alpha-tubulin as a part of a complex 
(284). In order to determine whether the interaction is direct, a pull down assay using 
a fusion tagged bait protein (such as a Glutathione-S-transferase pull down assay) 
would need to be used (337). Furthermore, to identify the functional significance of 
proteins that bind to Kindlin-1, the binding sites of direct Kindlin-1 interactors would 
need to be mapped through generation of Kindlin-1 mutants and intervention studies 
carried out to determine if loss of the interaction of Kindlin-1 to a binding partner has 





Chapter 5 The Role of Kindlin-1 in the 























A number of FA proteins are now recognised to have functions within the nucleus; 
Zyxin was the first focal adhesion that was shown to shuttle from the cytoplasm into 
the nucleus (338) and since, Paxillin (339), ILK (340), FAK (341) and Src (342–344) 
among others have been shown to have roles in the nucleus.  A characteristic of many 
FA proteins that shuttle to nucleus is the presence of LIM domains and this is also a 
structural feature of many nuclear proteins that control gene expression (345). By 
shuttling to the nucleus, FA proteins facilitate communication between two 
subcellular domains and it has been hypothesised that some FA proteins may have 
evolved to have scaffolding roles distinct from their adhesion functions. For example, 
nuclear FAK has a scaffolding role in the nucleus, which facilitates cell survival. 
Nuclear FAK inactivates p53 through binding to p53 via its FERM domain and this 
causes Mdm2-dependent p53 degradation (341). Several other FA proteins have also 
been shown to regulate hormone receptor signalling and impact gene transcription 
(346). 
 
To date, Kindlin-2 is the only Kindlin family member with a recognised NLS, which is 
located at amino acids 55-72 (117). Kindlin-2 has been shown to localise to the 
nucleus in leiomyosarcomas and leiomyomas (117,191) and in mouse muscle cells 
and breast cancer cells, promote the transcription of genes that activate Wnt 
signaling (169,170). Kindlin-2 has also been shown to repress microRNAs and 
promote breast cancer invasion (191). Mechanistically, nuclear Kindlin-2 binds DNA 
methyltransferase 3 alpha (DNMT3A) and forms a complex that occupies the 
promoter of miRNA-200b to repress its expression and this enables Zinc Finger E-box-
binding homeobox 1 (ZEB1) to accumulate, which leads to EMT and cell invasion 
(191). As Kindlin-1 has previously been found in the nucleus of  keratinocytes (118) 
and we have shown that Kindlin-1 regulates Tnc gene expression (185), we asked if 
Kindlin-1 has an important role in the nucleus to influence gene expression in breast 
cancer cells.  
 




1. Confirm the presence of Kindlin-1 in the nucleus of breast cancer and 
squamous cell carcinoma cell lines.  
2. Identify if loss of Kindlin-1 affects localisation of other focal adhesion proteins 
to the nucleus of breast cancer and squamous cell carcinoma cell lines. 
3. Generate a Kindlin-1 nuclear mutant that cannot localise to the nucleus for 
phenotypic analysis of the effect that loss of Kindlin-1 recruitment into the 
nucleus has in vivo.  

























5.1 Kindlin-1 and other focal adhesion proteins are found in the nucleus of Met1 
and SCC cells 
Cellular fractionation was performed in order to extract the nuclear proteins from 
the cell (Fig. 46A). In the fractionation protocol used, three fractions were collected; 
the cytoplasmic, perinuclear and nuclear fraction. Before blotting for proteins of 
interest, the fractions were checked for contaminating organelles by western using 
antibodies that were picked based on their compartmentalisation. GM130 was used 
as a marker of the perinucleus, α-tubulin was used as a cytoplasmic marker and 
Histone H4 was selected as a marker of the nucleus (Fig. 46A). Kindlin-1 was found in 
the nucleus of Met-1 Kin1-WT and Met1 Kin1-AA cells but as expected, not found in 
Kin1-Null cells (Fig. 46).  
 
In addition to Kindlin-1, the focal adhesion proteins: Kindlin-2, ILK and FAK were 
probed for in the nucleus of Met-1 cells (Fig. 47A). Western blotting confirmed that 
Kindlin-2 and ILK are present in the nucleus of all three cell lines, whereas FAK was 
only found in the perinuclear and cytoplasmic fractions (Fig. 47A). These focal 
adhesion proteins were also probed for in cellular fractions of SCC cells (Fig. 48). 
Western blotting confirmed that Kindlin-1 was present in the nucleus of SCC Kin1-WT 
and Kin1-AA cells but not Kin1-Null cells, and ILK was present in the nucleus of all 
three cell lines (Fig. 48). Kindlin-2 and FAK were found in the perinuclear and 
cytoplasmic fractions but not the nuclear fractions of the SCC cells (Fig. 48). Notably, 
the levels of ILK found in the nucleus of the SCC Kin1-WT and Kin1-AA cell lines were 
higher than the levels found in the Kin1-Null cells, however, due to time constraints 






Figure 46. Kindlin expression in the nucleus in cancer cells. (A) Kindlin-1 is expressed in the nucleus 
and localisation to the nucleus is independent of integrin binding in Met-1 cells. Western blot analysis 
for Kindlin-1 in the nucleus of Met-1 Kin1-Null, Kin1-WT and Kin1-AA cells. GM130 was used as a 
marker of the perinucleus, α-tubulin as a cytoplasmic marker and histone H4 was used as a nuclear 
marker. (B) Relative Kindlin-1 protein expression in the nucleus of Met-1 cells normalised to Histone 
H4 (*p<0.05). Values are mean ±SEM of 3 independent experiments.  P values were obtained by a one-






Figure 47. Focal adhesion protein expression in the nucleus of Met-1 cells. (A) Western blot analysis 
for Kindlin-1, Kindlin-2, FAK and ILK in the nucleus of Met-1 A1 Kin1-Null, Kin1-WT and Kin1-AA cells. 
Kindlin-2 and ILK are expressed in the nucleus and localisation to the nucleus is independent of 
presence of Kindlin-1. GM130 was used as a marker of the perinucleus, α-tubulin as a cytoplasmic 
marker and histone H4 was used as a nuclear marker. (B) ILK protein expression was analysed by Fiji; 
values are mean ± SEM of three replicates. Protein expression was normalised Kin1-WT cells. P values 





Figure 48. Focal adhesion protein expression in the nucleus of SCC cells. Western blot analysis for 
Kindlin-1, Kindlin-2, FAK and ILK in the nucleus of SCC Kin1-Null, Kin1-WT and Kin1-AA cells. ILK was 
expressed in the nucleus and localisation to the nucleus is independent of presence of Kindlin-1. 
GM130 was used as a marker of the perinucleus, α-tubulin as a cytoplasmic marker and histone H4 
was used as a nuclear marker. 
 
 
Kindlin-1 and Kindlin-2 have been shown to have both distinct and overlapping roles 
and examples of redundancy have been described in the literature (153–155). 
Overlapping functions in sustaining epithelial integrity have previously been reported 
with cells able to compensate for loss of Kindlin-1 through regulation of Kindlin-2 
gene expression and vice versa (154). Moreover, Kindlin-1 and Kindlin-2 were found 
to predominantly reside in different cellular locations, however, Kindlin-1 was shown 
to relocate in the absence of Kindlin-2 and compensate for its functions in vitro (155). 
Loss of Kindlin-1 had no effect on ILK expression in the Met-1 model (Fig. 47B), 
however, Kindlin-2 was found in the nucleus of the Met-1 model (Fig. 47A). This data, 




Kindlin-2, lead us to question whether presence of Kindlin-1 is important for the 
import of ILK into the nucleus in the SCC model because the SCC cells lack Kindlin-2 
in the nucleus (Fig. 48). We carried out preliminary experiments using Kindlin-2 siRNA 
in the Met-1 model to knockdown Kindlin-2 expression and establish if this impacted 
the amount of ILK found in the nucleus of Met-1 Kin1-Null cells compared to Kin1-WT 
cells, however, these experiments were inconclusive and required further 
optimisation.  
 
5.2 Generation of a Kindlin-1 NLS mutant that cannot localise to the nucleus 
In order to test the importance of localisation of Kindlin-1 to the nucleus of cancer 
cells, we generated a Kindlin-1 NLS mutant (Kin1-NLS) that sequesters Kindlin-1 in the 
cytoplasm (Fig. 49). The Kindlin-1 NLS mutant was generated using the Met-1 CRISPR-
cas9 Kindlin-1 knockout clone, clone 3B. This is a different Met-1 CRISPR-cas9 Kindlin-
1 knockout clone to the clone used for the experiments in chapters 3 and 4 (clone 
A1). The Kin1-NLS mutant was generated using the vector, pWZL, as this was the 
vector used to generate the Met-1 Kin1-WT and Kin1-AA cell lines. The Met-1 Kin-1 
Null Clone A1 had an empty vector pWZL re-expressed (as a control) and therefore, 
was resistant to the selection marker. The parental Met-1 Kin-1 Null Clone A1 was 
not present in frozen stocks and therefore, we infected the Met-1 3B Kin1-Null clone 
with the Kin1-NLS to keep the vectors containing the Kindlin-1 sequences consistent.  
 
An NLS typically consists of one or more short sequences of basic amino acids, such 
as lysine and arginine (12), and using NLS mapper (347), this allowed identification of 
a putative NLS in the Kindlin-1 sequence (Fig. 54A). Nuclear import requires 
importin α, which recognises and binds to the cargo containing an NLS in the 
cytoplasm (348). The cargo is then linked to β-karyopherin and importin-β, to form a 
tripartite complex, which can interact with the nuclear pore to enable translocation 
to the nucleus (348). NLS peptides bind to major and minor pockets of importin-α 




importin-α (349). Amino acids of the NLS sequence bind to the NLS-binding pockets 
of importin-α in an extended conformation and the main chains of the amino acids in 
the NLS run anti-parallel to the chain of importin-α (349). The binding pockets contain 
conserved tryptophans and a number of invariant asparagines four residues 
downstream (350,351). The lysine side chains of the NLS sequence sit in between 
stacked hydrophobic indole side chains of conserved tryptophans of importin-α and 
form salt bridges with negatively charged amino acids lining the binding pocket 
(350,351). The asparagine’s of importin-α form key chain contacts with the NLS 
sequence (350,351). Therefore, in order to abrogate localisation to the nucleus, two 
arginine and four lysine residues in the NLS sequence, which carry a positive charge 
were mutated to alanine, which has no charge (Fig. 49B). The Kindlin-1 NLS mutant 
sequence with six amino acid mutations (NLS-4) was successfully made and 
confirmed by cDNA sequencing, however, retroviral infection of Kin1-NLS into Met-1 
Kin1-Null cells using Phoenix-ECO cells was unsuccessful. The Met-1 Kin1-Null cells 
appeared unable to tolerate the amount of mutations made to the Kin1-WT sequence 
as the cells did not survive selection, whereas retroviral infection with Kin1-WT and 
Kin1-AA sequences that were performed alongside as controls were successful. The 
same result was found upon infection of cells with a mutant Kindlin-1 sequence 
containing five mutations (NLS-3) (Fig. 49B). Subsequently, mutant Kindlin-1 
sequences with three (Kin1-NLS1) and four (Kin1-NLS2) mutations to the NLS 
sequence were infected into Met-1 Kin1-Null cells (Fig. 49B) and these mutations 
successfully prevented localisation of Kindlin-1 to the nucleus and perinucleus of the 
cells (Fig. 49C). Loss of Kindlin-1 localisation to the nucleus of the cells did not change 














Figure 49. Generation of a Kindlin-1 nuclear localisation mutant. (A) The Kindlin-1 sequence with the 
predicted nuclear localisation signal (NLS) highlighted in blue (Dr Hitesh Patel) (B) Amino acids mutated 
to alanine in the predicted Kindlin-1 NLS sequence are shown in red. (C) Western blot analysis for 
Kindlin-1 in the nucleus of Met-1 clone 3B cells with genetic deletion of Fermt1 (Kin1-Null) and re-
expression of WT Kindlin-1 (Kin1-WT), Kindlin-1 nuclear localisation mutant 1 (NLS1) or Kindlin-1 
nuclear localisation mutant 2 (NLS2). Kindlin-1 was not present in the nucleus or perinucleus of Met-1 
3B Kin-1 Null, Kin1-NLS1 or Kin1-NLS2 cells. GM130 was used as a marker of the perinucleus, α-tubulin 
as a cytoplasmic marker and histone H4 was used as a nuclear marker. (D) Representative images of 
Met-1 clone 3B Kin1-Null, Kin1-WT, Kin1-NLS1 and Kin1-NLS2 cells. Objective magnification: 10x. Scale 
bar represents 100μm.  
 
5.3 Characterisation of the effect of a Kindlin-1 NLS mutant on tumour growth    
To investigate the effect that loss of Kindlin-1 localisation to the nucleus has in vivo, 
mice were inoculated subcutaneously with the Met-1 3B model (Fig. 50). The growth 
rate of tumours between the different cell lines did not differ until day 10 where the 
growth rate of Kin-1 NLS cells and Kin1-Null cells was significantly lower compared to 
Kin1-WT cells (Fig. 50). The growth rate of Kin1-NLS tumours was significantly lower 
than Kin1-WT tumours at each time point from day 10 (Fig. 50). Although the growth 




difference in growth rate at each time point did not reach significance (Fig. 50). Kin1-
NLS tumours had a consistently lower growth rate compared to Kin1-Null tumours 
from day 10 onwards but the growth rate was not significantly lower at each time 






Figure 50. Tumour growth with loss of Kindlin-1 localisation to the nucleus. (A) Mean (±SEM) tumour 
growth of mice inoculated with Met-1 3B Kin1-Null, Kin1-WT or Kin1-AA cells (n=16 tumours per 
group). (B) Table displaying results of a two-way ANOVA of growth rates of mice inoculated with Met-
1 Kin1-Null, Kin1-WT or Kin1-AA cells. Row number corresponds to each time point. (n=10 tumours 
per group, *p<0.05, **p<0.01, one-way ANOVA).  
 
5.4 General impact of a Kindlin-1 NLS mutant on the TNFα-p65-IL6 pathway 
It has been previously shown that DYNC1I1, a component of the dynein multi-protein 
complex, increases proliferation and migration of tumour cells in gastric cancer by 
increasing p65 nuclear translocation and the expression of IL-6 (316). As data 
suggested that Kindlin-1 binds a subunit of cytoplasmic Dynein, Dync1h1, in the Met-
1 Kin1-WT cell line (Fig. 36A,37D) and previous data showed an increase in IL-6 with 
the loss of Kindlin-1 (Fig. 25A), we firstly examined Il-6 expression in the Met-1 3B 
clone (Fig. 51). There was a small increase in Il-6 expression compared to Kin1-WT 
cells (Fig. 51) but this did not reach statistical significance, which was consistent with 
what we observed in previous experiments using the A1 clone (Fig. 25E). Gene 
expression analysis showed that Il-6 expression did not significantly differ between 
the Kin1-Null and Kin1-NLS cells (Fig. 51).  
As translocation of p65 to the nucleus is known to regulate IL6 expression, we also 
investigated nuclear p65 protein levels in these cell lines under basal conditions and 
after incubation with the inflammatory cytokine, Tumour Necrosis Factor alpha 
(TNFα), to stimulate p65 nuclear translocation. TNFα is a pro-inflammatory cytokine 
that stimulates the canonical NF-κB pathway, which leads to activation of p65 
(otherwise known as RelA) containing dimers (352,353). The dimer translocates to 
the nucleus once activated where it regulates pro-inflammatory and cell survival 
genes, which include IL-6 (352,353). There was little nuclear p65 under basal 
conditions but when stimulated with TNFα, Met-1 Kin1-WT cells had a higher level of 
nuclear p65 compared to Kin1-Null and Kin1-NLS2 cells (Fig. 52). There was a similar 
increase in p65 in the perinuclear fraction in all Met-1 cell lines suggesting that 




experiment was only carried out once due to time constraints and therefore, 
statistical analysis could not be performed.  
 
Figure 51. Fermt1 and Il-6 gene expression analysis in Met-1 Clone 3B cells. Fermt1 and Il-6 
expression in Met-1 clone 3B cells with genetic deletion of Fermt1 (Kin1-Null) and re-expression of WT 
Kindlin-1 (Kin1-WT), Kindlin-1 nuclear localisation mutant 1 (NLS1) or Kindlin-1 nuclear localisation 
mutant 2 (NLS2). Expression was analysed by qRT-PCR; values are mean ± SEM of triplicate 
experiments. The expression in Met-1 Kin1-Null cells was normalised to Met-1 Kin1-WT cells. 






Figure 52. Loss of Kindlin-1 reduces translocation of p65 to the nucleus after stimulation with TNFα 
and presence of Kindlin-1 that can not localise to the nucleus does not restore the phenotype to that 
of Kin1-WT cells. Western blot analysis for Kindlin-1 and p65 in the nucleus of Met-1 clone 3B Kin1-
Null, Kin1-WT and Kin1-NLS2 cells. Cells were stimulated with 100ng/mL TNFα for 5 hours before 
nuclear fractionation was performed. GM130 was used as a marker of the perinucleus, α-tubulin as a 
cytoplasmic marker and histone H4 was used as a nuclear marker. 
 
 
5.5 Discussion  
5.5.1 Kindlin-1 is found in the nucleus of two different cancer models  
To our knowledge, this is the first study to report Kindlin-1 in the nucleus of cancer 
cell lines (Fig. 46-48). Kindlin-1 has been identified in the nucleus of normal human 
keratinocytes using IF (118), however, a nuclear role for Kindlin-1 in these cells has 
not yet been established. This study confirms that Kindlin-1 is able to localise to the 
nucleus in breast cancer and squamous cell carcinoma cells (Fig. 51-53). We have also 
shown that mutation to certain amino acids in our predicted NLS sequence, 
sequesters Kindlin-1 in the cytoplasm and this confirms that like Kindlin-2, Kindlin-1 
has a functional NLS sequence (Fig. 49A-C). Interestingly, it was not possible to 
generate a Kindlin-1 nuclear localisation mutant containing five or six mutations to 
our predicted NLS. Despite several attempts at infecting Met-1 Kin1-Null cells with 




survive. As we were able to generate NLS mutants with three and four mutations to 
the NLS sequence (Fig. 49C), it is possible that mutating five or six amino acids of the 
sequence caused Kindlin-1 to misfold. Large expression of a misfolded protein could 
cause havoc in the cell through unspecific interactions and this may trigger apoptosis 
signalling. Another hypothesis is that the five and six amino acid mutant-Kindlin-1 
proteins may not be able interact with the same proteins as Kindlin-1 WT or could 
have more or less affinity for certain proteins. If the mutations to the NLS increased 
the affinity of Kindlin-1 for some proteins, this could make the interactions between 
Kindlin and an interactor much stronger and have a kidnapping mechanism, 
preventing these proteins from undergoing normal cellular interactions and/or roles. 
Notably, the levels of the Kin1-NLS that were expressed into Met-1 Kin1-Null cells 
were much lower than the Kin1-WT re-expressed protein levels, which suggests that 
the cells are not happy with high levels of the NLS mutant (Fig. 49C). 
Interestingly, the Kindlin-1 NLS mutants blocked localisation of Kindlin-1 to the 
perinucleus as well as the nucleus (Fig. 49C). NLS mutants strictly block importin-
mediated nuclear import as described above but whether these mutants affect 
localisation to other parts of the cell is not well reported. Many cell fractionation 
protocols extract the nucleus and cytoplasmic fractions only and do not isolate a 
perinuclear fraction. Therefore, the NLS mutant protein would need to be tagged 
with a fluorescent protein to observe by microscopy where in the cell the mutant 
protein accumulates. On one hand, it is possible that mutation of the NLS may cause 
a queue of proteins outside the nucleus i.e. accumulation at the perinuclear space - 
on the other hand, the cell may not even try to translocate the protein if there is no 
functional NLS present, which is possibly why we do not see Kindlin-1 in the 
perinuclear fraction with the NLS mutation (Fig. 49C). There may also be differences 
in accumulation of the protein in the perinuclear space due to structural changes that 
aren't related to nuclear trafficking. Furthermore, the "perinuclear fraction" isn't 
strictly the best name for the perinuclear fraction isolated in the protocol we have 
used here as the marker chosen for the perinuclear fraction (GM130), does not 




endosomes, for example. Data have shown (unpublished, Adam Byron) that some 
endosome subpopulations and some plasma membrane markers are present in this 
fraction and it is therefore more accurate to call this fraction a membrane region. As 
the perinuclear fraction represents vesicular structures, loss of Kindlin-1 in the 
perinuclear fraction could be related to transport back into the cytoplasm and 
because Kindlin-1 does not enter the nucleus in the first place, the protein is not 
transported back into the cytoplasm and is therefore, not present in vesicular 
structures for trafficking.  
 
In future experiments, a wider panel of antibodies should be used to check for 
contaminating organelles by western after carrying out cellular fractionation 
experiments. In addition, mRNA could be extracted from the nucleus and RT-qPCR 
performed to further confirm that there is no Kindlin-1 present in the nucleus in the 
Kin1-NLS cell line. The Kin1-WT and Kin1-NLS proteins could also be tagged with a 
fluorescent protein to observe by microscopy where Kindlin-1 is accumulating in the 
organelles of the different cell lines. 
 
5.5.2 Kindlin-1 and focal adhesion proteins in the nucleus  
We have shown that in Met-1 cells, the focal adhesion proteins: Kindlin-2 and ILK are 
detected at similar levels in the nucleus in the presence and absence of Kindlin-1 (Fig. 
47). Preliminary data in SCC cells showed that with loss of Kindlin-1, there was a lower 
level of ILK detected in the nucleus and we did not detect Kindlin-2 in the nucleus 
with the presence or absence of Kindlin-1 in this model (Fig. 48). ILK has a recognised 
NLS and is known to bind both Kindlin-1 and Kindlin-2 (117,354). Although the role of 
ILK in the nucleus is not well-known, ILK has been shown to shuttle to the nucleus 
after phosphorylation by PAK1 and regulate gene expression of the connector 
enhancer of kinase suppressor of Ras3 by interacting with gene regulatory chromatin 
(355). ILK has also been found to increase DNA synthesis in keratinocytes and was 




Maintenance 1, also known as Exportin 1 for translocation out of the nucleus and this 
is modulated by dephosphorylation by ILK Associated Serine/Threonine Phosphatase 
(ILKAP) (356). The binding of Kindlin-2 to ILK is necessary for Kindlin-2 localisation to 
FAs (354) and so, it is feasible that ILK and Kindlin-2 may get trafficked to the nucleus 
together from cell focal adhesions. As Kindlin-1 is also known to bind ILK, it is possible 
that the two proteins also get trafficked to the nucleus together. There is redundancy 
between the two proteins, which has been discussed in previous chapters and 
therefore, it is possible that the Kindlin-1-ILK interaction becomes more important in 
the absence of Kindlin-2 recruitment to the nucleus especially as ILK is known to have 
a stronger binding affinity for Kindlin-2 compared to Kindlin-1 (117). In SCC cells, we 
observed a lower level of ILK in the nucleus with loss of Kindlin-1 and we did not 
detect Kindlin-2 in the nucleus (Fig. 48). This suggests that when both Kindlin-1 and 
Kindlin-2 are absent or not recruited to the nucleus, this may result in less ILK 
trafficked to the nucleus. However, preliminary experiments using Kindlin-2 siRNA in 
Met-1 cells were inconclusive and the experiment needs further optimisation. There 
is already evidence for FA proteins shuttling to or from the nucleus as carrier 
complexes – Paxillin, which does not have a canonical NLS has been proposed to 
transport into the nucleus via a carrier complex and c-Abl, PABP-1 and FAK have been 
proposed as candidates (357–360).  Furthermore, Nakrieko et al. (356) suggested that 
when ILKAP binds ILK in the nucleus, it may modify ILK or another ILK-interacting 
protein and enhance nuclear export. Therefore, the importance of a Kindlin-ILK 
interaction for nuclear transport is not impossible. As ILK is also a focal adhesion 
protein with important roles in tumourigenesis and there is evidence for both Kindlin-
2 (169,170) and ILK (361,362) acting as transcriptional regulators in the nucleus, their 
interaction and the mechanism of trafficking to the nucleus is something that could 
be important to explore further.  
 
Notably, FAK has previously been detected in the nucleus of other SCC models but 
we did not detect FAK in the nucleus of the SCC cells used in this study (Fig. 48), or in 




have an immuno-modulatory role through the regulation of the transcription of 
inflammatory cytokines and chemokines including Ccl5 and TGFβ2 in a kinase-
dependent manner (363). Mechanistically, nuclear FAK associates with chromatin 
and interacts with a network of transcription factors and their regulators, which leads 
to modulation of Ccl5 expression (363). Ccl5 promotes recruitment of Tregs and 
supresses the CD8+T cell population, which supresses the anti-tumour response of 
the immune system enabling tumours cells to grow (363). Furthermore, the kinase 
activity of nuclear FAK has also been shown to control chromatin accessibility and 
control gene expression of the cytokine Il33, which like Ccl5, is also involved in anti-
tumour immunity (364). In addition, FAK has been shown to have adaptor functions 
in the nucleus, as previously mentioned, FAK associates with p53 and enhances its 
degradation to promote cell proliferation and survival (341). Nuclear FAK also 
regulates GATA4 in a kinase-independent manner – FAK binds to GATA4 via its FERM 
domain and regulates GATA4 through polyubiquitination (365). FAK has an NLS 
located in the F2 lobe of its FERM domain (341) and accumulates in the nucleus in 
many different cell types under conditions of cell stress (366–368), which is perhaps 
why we did not detect FAK in the nucleus of the SCC or Met-1 cells at basal conditions 
(Fig. 47,48). For future studies, the presence of focal adhesion proteins could be 
investigated in the cellular fractions of Kindlin-1-deficient cells under different 
conditions of cellular stress to observe whether their localisation to the nucleus is 
impacted.  
 
5.5.3 Loss of Kindlin-1 to the nucleus significantly reduces the growth rate of 
primary tumours 
To our knowledge, this is the first study to report a nuclear role for Kindlin-1 in 
tumour growth (Fig. 50). We showed that primary tumour growth is significantly 
reduced when Kindlin-1 is confined to the cytoplasm of cancer cells (Fig. 50). 
Interestingly, although the growth rate of cells with complete loss of Kindlin-1 was 
consistently lower than those expressing wild-type Kindlin-1, the growth rate was 




tumours from the Met-1 clone A1 model had completely regressed by day 16, 
whereas the growth rate of Kin1-Null tumours from the 3B clone was still 
exponentially increasing at day 16 (compare Fig. 24A with Fig. 50A). These models 
were generated from single cell clones and the data suggests that there are clonal 
differences. The in vivo study using the Met-1 3B clone needs to be repeated to 
establish if the Met-1 3B Kin1-Null and Kin1-NLS cells regress at a later time point or 
continue to grow at a reduced rate to Kin1-WT tumours.  
 
In the SCC model of tumour growth, loss of Kindlin-1 promotes tumorigenesis (210), 
which suggests that Kindlin-1 has differential roles in the cellular compartments of 
different cell types. As previously discussed, nuclear roles of other FA proteins have 
been established in tumorigenesis and Kindlin-2 already has a known role in breast 
cancer cells. We have not established the mechanism in which Kindlin-1 regulates 
tumour growth in the nucleus of breast cancer cells. Notably, Rognoni et al. (171) 
reported Kindlin-1 in the nucleus of keratinocytes by IF but excluded a nuclear role 
for Kindlin-1 in the nucleus in regulation of Wnt signaling in these cells by expressing 
Kindlin-1-GFP fused to two SV40 NLS in Kindlin-1 deficient keratinocytes. It would be 
interesting to investigate the nuclear binding partners of Kindlin-1 to establish if 
Kindlin-1 forms transcriptional complexes in the nucleus or binds to DNA 
methyltransferase, similarly to Kindlin-2 (169,170,191), to either prevent or promote 
transcription of genes.  
 
5.5.4 Regulation of p65 in the nucleus by Kindlin-1 
As data suggested that Kindlin-1 binds a subunit of cytoplasmic Dynein, Dync1h1, and 
cytoplasmic Dynein has been previously linked to regulation of nuclear p65, we 
investigated what the significance of this might be by investigating if loss of Kindlin-1 
impacted the amount of p65 in the nucleus. Preliminary data suggest that when 
stimulated with TNFα, Kindlin-1 regulates the amount of p65 in the nucleus (Fig. 52). 




nuclear p65 found in the NLS mutant and the amount of p65 found in the perinucleus 
was consistent between the cell lines (Fig. 52), it suggests Kindlin-1 may 
transcriptionally influence p65 levels. Many FAs are emerging as important regulators 
of gene expression by acting as adaptor proteins that bind transcription factors and 
as complexes, bind promoter regions of genes – as described for FAK (363) and 
Kindlin-2 (169,170,191). Therefore, a potential role for Kindlin-1 in the regulation of 
p65 in the nucleus warrants further investigation. 
 
TNFα activates canonical NF-κB signalling, a pathway which regulates and increases 
the expression of IL-6 (352,353,369). Therefore, with increased nuclear p65 in Met-1 
3B Kin1-WT cells, we would expect increased levels of IL-6 expression. IL-6 mRNA 
expression was not significantly different between the cell lines of the Met-1 3B clone 
(Fig. 51), and, similarly, mRNA levels did not significantly differ in the Met-1 A1 clone 
(Fig. 25E). As no significant difference was observed between IL-6 mRNA levels in the 
Met-1 cell lines, this suggests that Kindlin-1 is regulating IL-6 post-transcriptionally 
and therefore, we would not expect differences in the NF-κB pathway between the 
Met-1 Kin1-Null and Kin1-WT cells as this pathway regulates transcription of IL-6. In 
the Met-1 A1 clone, the protein levels of IL-6 were significantly increased with loss of 
Kindlin-1 (Fig. 25A) and data (not shown) from the Brunton lab has also demonstrated 
increased secretion of IL-6 with Kindlin-1 loss using the forward phase array. 
Collectively, this suggests that Kindlin-1 may affect protein stability or degradation of 
IL-6.  It is interesting that we have identified the NF-κB pathway as being regulated 
by Kindlin-1, as this is novel, however, the expression of other NF-κB gene targets 
need to be evaluated to obtain more evidence for a role for Kindlin-1 in the regulation 
of the NF-κB pathway. The NF-κB pathway regulates multiple cytokines and 







5.5.4 Summary and future work 
In summary, our data reveal a novel cellular location for Kindlin-1 in cancer cells. We 
show that Kindlin-1 is in the nucleus of breast cancer and squamous cell carcinoma 
cells and that Kindlin-1 has an NLS that can be altered to prevent protein localisation 
to the nucleus. We have performed preliminary analysis that suggests that nuclear 
Kindlin-1 is important for primary tumour growth and that Kindlin-1 may be 
important for p65 regulation in the nucleus.  
 
For future studies, it would be interesting to perform immunoprecipitation with a 
Kindlin-1-specific antibody followed by mass spectrometry analysis to compare the 
interactome of the Met-1 Kin1-NLS with the Kin1-WT cell line. It would also be 
valuable to extract the nuclear fraction from these cells and perform a Kindlin-1 
nuclear immunoprecipitation in order to focus on Kindlin-1 binding partners within 
the nucleus to drill down into its role and mechanism here, which is unknown. As 
phosphorylation and dephosphorylation has been shown to be important for the 
import or export of ILK to and from the nucleus, investigating modification of Kindlin-
1, would be useful in order to establish the mechanism of Kindlin-1 translocation to 
the nucleus.  
 
Immunophenotyping of the tumours from in vivo experiments would provide 
information on the status of the immune system and establish if T cells ratios are 
impacted by loss of localisation of Kindlin-1 to the nucleus. This would be important 
to establish if Kindlin-1 is transcriptionally controlling factors, which regulate the T 
cells. In addition, an IL-6 ELISA assay using the Met-1 3B clone would confirm if 
Kindlin-1 has the same effect on IL-6 protein levels in the Met-1 3B clone and whether 
a Kindlin-1 nuclear mutant impacts IL-6 levels. Further analysis on gene targets of the 
NF-κB pathway and investigation of the effect of Kindlin-1 on p65 in the nucleus of 
the different cell lines may also help elucidate whether Kindlin-1 has a wider role in 



























The mechanisms by which Kindlin-1 mediates metastasis to the lungs in breast cancer 
remain relatively unknown. The Brunton group previously demonstrated that Kindlin-
1 promotes lung metastasis by supporting cell adhesion in the lung endothelium 
through its interaction with β1-integrin and that β1 integrin is required for 
micrometastatic outgrowth (185). We hypothesised that additional effects may occur 
downstream of the adhesion defects that we observed with loss of Kindlin-1 and that 
Kindlin-1 may impact outgrowth or colonisation of tumour cells. This project aimed 
to investigate the role of Kindlin-1 in breast cancer and specifically: 
 
 Determine if Kindlin-1 regulates outgrowth of micrometastases. 
 Establish if Kindlin-1 affects breast cancer stem cell activity. 
 Identify binding partners of Kindlin-1 in different breast cancer cell models.  
 Explore a nuclear role for Kindlin-1 in breast cancer. 
 
The following findings of this study contribute to existing knowledge: 
 Kindlin-1 has an integrin-dependent role in tumour initiation. (Chapter 3) 
 The immune system impacts on the ability of Kindlin-1 to regulate tumour 
growth. (Chapter 3) 
 Loss of localisation of Kindlin-1 to the nucleus reduces primary tumour 
growth. (Chapter 5) 
 
The functions of Kindlin-1 that we have identified and how these roles may 







Figure 53. Summary of the mechanisms that Kindlin-1 may regulate primary tumour growth. (A) 
Integrin activation by Kindlin-1 is required for tumour initiation but Kindlin-1 has integrin-independent 
roles including within the nucleus for the promotion and progression of breast cancer. (B) Kindlin-1 
modulates T cell ratios through regulation of IL-6. Kindlin-1 inhibits production of IL-6 pushing the 
differentiation of naïve CD4+ T cells away from T helper 17 (Th17) and towards T regulatory (Tregs) 
cells, which suppresses the anti-tumour immune response and leads to tumour growth. (C) Nuclear 
Kindlin-1 increases levels of p65 in the nucleus, a protein that dimerises with NF-κB to form a complex 
that functions as a transcriptional activator of NF-κB target genes. As the NF-κB pathway has a role in 
stem cell signalling, this raises the question: does nuclear Kindlin-1 promote tumour growth by 
regulating stem cell signalling via the NF-κB pathway?  
 
6.1 A role in tumour initiation 
Consistent with previous reports (186), Kindlin-1 was found to affect primary tumour 
growth and this was demonstrated in a mouse and human model. The Brunton group 
previously reported that Kindlin-1 has a role in early pulmonary metastases (185) and 
interestingly, we found that Kindlin-1’s interaction with integrin affected early 




deficient Kindlin-1 mutant demonstrated that early primary tumour growth was 
integrin dependent, however, integrin binding was not required after this stage as 
tumours later reached the same growth rate as the Kindlin-1 WT tumours. Activation 
of integrin by Kindlin-1 was also important for tumour initiation in the PyMT 
spontaneous tumour mouse model (178). The importance of Kindlin-1 in the initial 
establishment of the tumour was also suggested in our human model of Kindlin-1 
loss. We found a reduction in tumour growth when MDA-MB-231 cells containing 
shRNA that targeted Kindlin-1 were inoculated in mice. However, we did not see a 
reduction in tumour growth after tumour fragments containing the shRNA Kin-1 cells 
were transplanted into mice. We propose that knockdown of Kindlin-1 did not impact 
tumour growth in the tumour fragment model as tumour fragments are established 
tumours that have bypassed the tumour initiation phase. Whereas in the cell 
inoculation model, tumour initiation was hindered with knockdown of Kindlin-1 and 
this led to significantly reduced tumour growth. As we have shown that Kindlin-1 is 
important in tumour initiation in the primary growth model, it would be interesting 
to establish if Kindlin-1 is equally important to establish micrometastases. The FA 
protein, FAK, is downstream of β1-integrin and has been associated with the 
regulation of initiation and progression in cancer cells. Deletion of β-integrin in a 
MMTV transgenic mouse model has been shown to reduce tumour burden 
mechanistically by reducing FAK phosphorylation and decreasing cell proliferation 
(239). Another in vivo study using mouse mammary cancer cell lines demonstrated 
that β1-integrin/FAK and the MAPK pathway was important for metastatic outgrowth 
(370). As Kindlin-1 has an important role in β1-integrin activation, the effect of 
Kindlin-1 on the outgrowth of micrometastases should be revisited. 
 
As the integrins have been implicated in stem cell regulation (235–238) and tenascin-
C expression was shown to be dependent on Kindlin-1-integrin interaction (185), we 
investigated a role for Kindlin-1 in stem cell signalling using the mammosphere assay. 
This assay quantifies breast stem cell activity, however, the results reported between 




also variable, suggesting that the mammosphere assay is not a robust assay and not 
suitable for this purpose. Other methods are required such as evaluation of a wider 
panel of stem cell markers, investigation of cell surface markers and use of in vivo 
methods such as transplantation paradigms or lineage tracing experiments. 
Regulation of stem cell signalling by Kindlin-1 could be important for tumour initiation 
and outgrowth of micrometastases. We found that Kindlin-1 regulates the protein 
levels of the cytokine IL-6, a protein that has been linked to NF-κB signalling. This 
suggests a relevant role for Kindlin-1 in potential stem cell signalling. Preliminary 
analysis suggested that Kindlin-1 may be important for regulation of a transcriptional 
activator of the canonical NF-κB pathway in the nucleus, p65. It would be useful to 
investigate this pathway in further detail and evaluate if loss of Kindlin-1 impacts 
other NF-κB gene targets. 
 
6.2 A role in the anti-tumour immune response 
We found evidence that suggests there may be a complex interplay with Kindlin-1 
and the immune system. One of the most significant questions in the cancer field is: 
how do cancer cells evade the immune system? Our data points towards a role in 
regulation of T cell populations by Kindlin-1 that enables tumour cells to avoid 
destruction by the immune system. Loss of Kindlin-1 in an immunocompetent mouse 
model resulted in complete clearance of the tumour, whereas loss of Kindlin-1 in an 
immunocompromised mouse model that has a reduced amount of T cells (229), did 
not result in complete clearance of the tumour by the immune system. We show that 
mechanistically, loss of Kindlin-1 post-transcriptionally upregulates production of the 
cytokine IL-6, which reduces the population of Tregs and increases the population of 
Th17 cells. High numbers of Tregs in cancer tissues has been connected with a pro-
tumour effect, disease progression and a worse prognosis in breast cancer (371). We 
propose that loss of Kindlin-1 leads to upregulation of IL-6 and this drives 
differentiation of naïve CD4+ T cells from Tregs into Th17 cells, which has a protective, 




IL-6 and leads to differentiation of naive CD4+ T cells into Tregs, which suppresses 
the anti-tumour immune response resulting in tumour growth. The regulation of T 
cell populations by Kindlin-1 could be relevant for the outgrowth of micrometastases 
as well as primary tumour growth demonstrated here. Metastasis-initiating cells 
need to develop mechanisms to evade the immune system in the target organ and 
the immune-related mechanisms operating at this level are largely unknown. 
Therefore uncovering the molecular details of Kindlin-1 and the regulation of T cells 
could help dissect the complex interactions between the immune population and 
disseminated cancer cells.  
 
We used a proteomics approach to identify novel binding partners of Kidlin-1 to 
address our third aim and followed up hits that possibly linked Kinlin-1 to regulation 
of IL-6. This included a subunit of cytoplasmic dynein, however, the results of these 
experiments were inconclusive. In the context of the immune system, a potential 
candidate that should be followed up in the future is ALDH18A1. ALDH18A1 is a 
member of the aldehyde dehydrogenase family and although we did not validate 
binding of Kindlin-1 to ALDH18A1, this could be relevant in our model of how Kindlin-
1 interacts with the immune system. Aldehyde dehydrogenase (ALDH) and its 
production of retinoic acid (RA) by different immune cells has been implicated in 
immune tolerance through the induction of Tregs from naïve CD4+ T cells (372,373). 
RA has also been shown to inhibit differentiation of naive CD4+ T cells into pro-
inflammatory Th17 cells (372,373). It is thought that ALDH inhibition may increase 
the ratio of effector T cells to Tregs and enhance T-cell mediated tumour elimination 
(374). Overexpression of ALDH has been associated with poor prognosis in various 
tumour types and its expression has also been found in CSCs and linked to metastasis, 
(375). Several ALDH inhibitors have been developed with some promise of treating 
cancer and therefore, if ALDH18A1 is shown to interact with Kindlin-1 it may 





6.3 A nuclear role that is important for primary tumour growth 
To our knowledge, this is the first study to report Kindlin-1 in the nucleus of cancer 
cell lines. As Kindlin-2 and other focal adhesion proteins have established nuclear 
roles in tumorigenesis as scaffolding proteins that form complexes with transcription 
factors, we hypothesised that Kindlin-1 may also play a similar role in breast cancer 
cells to regulate factors associated with metastasis. In order to address the final aim 
of this study, we generated a Kindlin-1 NLS mutant and identified that mutation of 
certain amino acids in our predicted NLS sequence, sequesters Kindlin-1 in the 
cytoplasm. This confirms that like Kindlin-2, Kindlin-1 has a functional NLS sequence. 
Loss of Kindlin-1 localisation to the nucleus significantly reduced primary tumour 
growth, however, the mechanism that nuclear Kindlin-1 regulates tumour growth has 
not been established. Immunophenotyping of the tumours from in vivo experiments 
would provide information on the status of the immune system and establish if T cell 
ratios are impacted with loss of nuclear Kindlin-1. This would be important to 
establish if Kindlin-1 is transcriptionally controlling factors, which regulate the T cells.  
 
We performed preliminary analysis that suggests that Kindlin-1 may be important for 
p65 regulation in the nucleus. We found increased levels of nuclear p65 with 
presence of nuclear Kindlin-1 when cells were stimulated with TNFα. IL-6 is regulated 
by the NF-κB pathway and nuclear NF-κB p65 induces IL-6 gene expression (369). 
With increased nuclear p65, we would expect increased expression of IL-6, however, 
we found that Kindlin-1 inhibits IL-6 expression. Our data suggests that Kindlin-1 does 
not regulate IL-6 expression via the NF-κB pathway and we propose that Kindlin-1 
post-transcriptionally regulates IL-6 by affecting the stability or degradation of the 
protein. Our finding that Kindlin-1 may the NF-κB pathway is novel and additional NF-
κB gene targets need to be evaluated to determine if Kindlin-1 regulates the NF-κB 






6.4 Wider implications 
The results presented in this thesis have focused on the role of Kindlin-1 in primary 
breast cancer growth. As described above, we believe that the roles that we have 
uncovered for Kindlin-1 in primary tumour growth, may be important for promoting 
pulmonary breast cancer metastasis and may also have wider implications in other 
cancer types and inflammatory disease.  
 
6.4.1 Implications in different tumour types  
As well as breast cancer, increased expression of Kindlin-1 has been found to promote 
colon (116) and pancreatic (184) cancers. Kindlin-1 may also have similar roles in 
these cancer types to the roles we have identified here. Intriguingly, Kindlin-1 
appears to have a tumour suppressor function in lung (186), oesophageal (182) and 
skin cancer (187). Patients with KS are predisposed to SCC and previous research by 
the Brunton group found that re-expression of WT Kindlin-1 in a mouse SCC model 
inhibited tumour growth (210). Our data showed that Kindlin-1 localises to the 
nucleus of the SCC WT Kindlin-1 re-expressed cells (Chapter 3). It is therefore possible 
that Kindlin-1 could have opposing nuclear roles in cancers where its expression 
inhibits tumour growth and regulates genes that inhibit rather than promote cancer. 
 
6.4.2 Implications in inflammatory disease  
Patients with Kindler syndrome also suffer from an ulcerative colitis-like condition 
(149,377). Ulcerative colitis (UC) is an inflammatory bowel disease that is a 
consequence of perturbed immune homeostasis. UC is stimulated by a misbalance in 
cytokine production and various types of immune cells have a crucial role in 
pathogenesis by regulation, suppression, and maintenance of inflammation. 
Importantly, Th17 cells have been shown to be important regulators of inflammatory 
bowel disease as antibody-mediated blockade of IL-6 (an important driver of 




chapter 3), reduced experimental colitis (378,379). Additionally, a number of 
polymorphisms in genes linked to Th17 cells have been connected with inflammatory 
bowel disease (380). The potential role that we have uncovered for Kindlin-1 in 
relation to IL-6 and T cell regulation could therefore be important for the UC-like 
symptoms of KS patients. IL-6 has also been linked to progressive fibrosis of the 
dermis in KS (180) and our findings could also be relevant here. 
 
6.5 Summary and conclusion  
In conclusion, the work presented here suggests that Kindlin-1 has an integrin-
dependent role in tumour initiation but once the tumour has been established, 
Kindlin-1 has roles independent of integrin activation that are important for tumour 
growth. We show that the immune system impacts on its ability to regulate tumour 
growth and our evidence suggests a potential role for Kindlin-1 in the regulation of T 
cell subset changes. Our data suggest that one mechanism by which Kindlin-1 may 
control the ratios of T cells is through the regulation of IL-6 protein levels. We propose 
that reduction of IL-6 drives differentiation of naïve CD4+ T cells into T regulatory 
cells, which suppresses the anti-tumour immune response and promotes 
tumorigenesis. We also found that nuclear Kindlin-1 is important for tumour growth 
and similar to Kindlin-2, Kindlin-1 also has an NLS that tags it for nuclear import. Given 
that Kindlin-1 is a well-established focal adhesion protein whose most researched 
role is in relation to integrin activation, it is interesting to find evidence that suggests 
Kindlin-1 has important functions in the nucleus. Questions stemming from this work 
include whether Kindlins’ nuclear function is also important for the regulation of the 
immune system and if Kindlin-1 regulates pathways linked to tumourigenesis through 
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